

11° CONGRESSO NAZIONALE



**Italian Conference on
AIDS and Antiviral Research**

5-7 GIUGNO 2019



UNIVERSITÀ DEGLI STUDI
DI MILANO



Presidenza del Congresso
Antonella Castagna
Antonella d'Arminio Monforte
Massimo Puoti
Giuliano Rizzardini

SCIENTIFIC
PROGRAMME



Promosso da



e da

INMI, Istituto Nazionale per le Malattie Infettive

ISS, Istituto Superiore di Sanità

AMCLI, Associazione Microbiologi Clinici Italiani

SIICA, Società Italiana di Immunologia, Immunologia Clinica e Allergologia

SIMaST, Società Interdisciplinare per lo Studio delle Malattie Sessualmente Trasmissibili

SITA, Società italiana per la Terapia Antinfettiva

SIV-ISV, Società Italiana di Virologia - Italian Society for Virology

ANLAIDS, Associazione Nazionale per la lotta all'AIDS

ARCIGAY, Associazione LGBT Italiana

ASA Onlus, Associazione Solidarietà AIDS Onlus

EpaC Onlus, Associazione EpaC Onlus

LILA, Lega Italiana per la lotta contro l'AIDS

MARIO MIELI, Circolo di Cultura Omosessuale

NADIR, Associazione Nadir Onlus

NPS Italia Onlus, Network Persone Sieropositive

PLUS Onlus, Persone LGBT sieropositive Onlus

Con il Patrocinio di





PROVIDER AND ORGANIZING SECRETARIAT



Via G.B. Giorgini, 16 - 20151 Milan, I
Phone +39 02 3343281 - Fax +39 02 33496370
icar2019@effetti.it
www.effetti.it

QUICK LINKS

Organizing Secretariat icar2019@effetti.it
Abstract Secretariat abstract.icar2019@effetti.it
ICAR Website www.icar2019.it



www.facebook.com/ICARcongress



twitter.com/ICARcongress



ICAR
2019

Download the ICAR App for free from the main markets (Apple Store and Google Play)

"Minimum system requirements required for the App: Android 6.0 and iOS 10"





11° CONGRESSO NAZIONALE
Italian Conference on
AIDS and Antiviral Research

5-7 GIUGNO 2019
UNIVERSITÀ DEGLI STUDI DI MILANO

Endorsements

Con il Patrocinio di

INSTITUTIONS



INSTITUTES



FOUNDATIONS

Aviralia, Fondazione Aviralia Onlus

Icna, Fondazione Icna

The Bridge, Fondazione The Bridge

Villa Maraini, Fondazione Villa Maraini

SCIENTIFIC SOCIETIES

AIMI, Associazione Infermieri Malattie Infettive

AISF, Associazione Italiana per lo Studio del Fegato

ASPE, Associazione Studio Patologie Epatiche

FeDerSerD, Federazione Italiana degli Operatori dei Dipartimenti e dei Servizi delle Dipendenze

SIM, Società Italiana di Microbiologia

SIMET, Società Italiana di Medicina Tropicale

SIMPIOS, Società Italiana Multidisciplinare per la Prevenzione delle Infezioni nelle Organizzazioni Sanitarie

SIMSPe, Società Italiana di Medicina e Sanità Penitenziaria

SIPaD, Società Italiana Patologie da Dipendenza

ASSOCIATIONS

Alessandro Rizzo Lari, Circolo Culturale TBIGL+

Arcobaleno AIDS

C.I.C.A. Coordinamento Italiano delle Case Alloggio per persone con HIV/AIDS

Gay Center

Milano Check Point

MIT, Movimento Identità Transessuale



Scientific Committee

Chairs



Antonella Castagna, Milano



Antonella d'Arminio Monforte, Milano



Massimo Puoti, Milano



Giuliano Rizzardini, Milano

Abstract and Pre-Conference Courses Coordinator

Franco Maggiolo, Bergamo

Scientific Secretariat

Chiara Agrati, Roma

Alessandra Bandera, Milano

Teresa Bini, Milano

Paolo Bonfanti, Lecco

Luca Butini, Ancona

Andrea Calcagno, Torino

Dario Cattaneo, Milano

Anna Maria Cattelan, Padova

Francesca Ceccherini-Silberstein, Roma

Stefania Cicalini, Roma

Antonella Cingolani, Roma

Paola Cinque, Milano

Nicola Coppola, Napoli

Maria Luisa Cosmaro, Milano

Andrea De Luca, Siena

Antonio Di Biagio, Genova

Massimo Farinella, Roma

Massimo Fasano, Foggia

Cristina Gervasoni, Milano

Nicola Gianotti, Milano

Enrico Girardi, Roma

Giovanni Guaraldi, Modena

Giuseppe Lapadula, Monza

Sergio Lo Caputo, Bari

Giordano Madeddu, Sassari

Giulia Marchetti, Milano

Alberto Matteelli, Brescia

Maria Cristina Moiola, Milano

Cristina Mussini, Modena

Tullio S. Prestileo, Palermo

Diego Ripamonti, Bergamo

Stefano Rusconi, Milano

Annalisa Saracino, Bari

Loredana Sarmati, Roma

Valentina Svicher, Roma

Camilla Tincati, Milano

Pre-Conference Courses Secretariat

Francesca Bai, Milano

Alba Bigoloni, Milano

Valeria Cento, Milano

Annalisa Mondì, Roma

Antonio Muscatello, Milano

Silvia Nozza, Milano

Viviana Picciotto, Milano

Carmela Pinnetti, Roma

Barbara Rossetti, Siena

Roberto Rossotti, Milano

Francesco Saladini, Siena

Vincenzo Spagnuolo, Milano

Annual Programme Committee

Michele Breveglieri, Bologna

Antonella Castagna, Milano

Antonella d'Arminio Monforte, Milano

Margherita Errico, Milano

Andrea Gori, Milano

Adriano Lazzarin, Milano

Carlo Federico Perno, Milano

Massimo Puoti, Milano

Giuliano Rizzardini, Milano



Government Bodies

ICAR Government

Coordinator

Andrea Antinori, Roma

Secretary

Antonella d'Arminio Monforte, Milano

Members

Massimo Andreoni, Roma

Giulio Maria Corbelli, Bologna

Massimo Galli, Milano

Adriano Lazzarin, Milano

Carlo Federico Perno, Milano

Massimo Puoti, Milano

Maurizio Zazzi, Siena

SPC

(Scientific Programme Committee)

Massimo Andreoni, Roma

Andrea Antinori, Roma

Guido Antonelli, Roma

Matteo Bassetti, Udine

Alberto Bignardi, Bologna

Paolo Bonfanti, Lecco

Stefano Bonora, Torino

Maria Rosaria Capobianchi, Roma

Antonella Castagna, Milano

Francesco Castelli, Brescia

Anna Maria Cattelan, Padova

Benedetto Maurizio Cesia, Catania

Antonella Cingolani, Roma

Massimo Clementi, Milano

Giulio Maria Corbelli, Bologna

Andrea Cossarizza, Modena

Antonella d'Arminio Monforte, Milano

Maria Grazia Di Benedetto, Catania

Antonio Di Biagio, Genova

Giovanni Di Perri, Torino

Massimo Di Pietro, Pistoia

Margherita Errico, Milano

Vincenzo Esposito, Napoli

Massimo Farinella, Roma

Massimo Galli, Milano

Ivan Gardini, Vimercate MB

Enrico Girardi, Roma

Andrea Gori, Milano

Giuseppe Ippolito, Roma

Sergio Lo Caputo, Bari

Paolo Maggi, Napoli

Franco Maggiolo, Bergamo

Michele Manfredini, Milano

Bruno Marchini, Roma

Claudio Maria Mastroianni, Roma

Giovanni Mazzola, Palermo

Cristina Mussini, Modena

Silvia Nozza, Milano

Giuseppe Nunnari, Messina

Giustino Parruti, Pescara

Carlo Federico Perno, Milano

Massimo Puoti, Milano

Maria Carla Re, Bologna

Giovanni Rezza, Roma

Giuliano Rizzardini, Milano

Stefano Rusconi, Milano

Filippo von Schloesser, Roma

Laura Sighinolfi, Ferrara

Guido Silvestri, Atlanta USA

Barbara Suligoj, Roma

Gloria Taliani, Roma

Marcello Tavio, Ancona

Carlo Torti, Catanzaro

Stefano Vella, Roma

Maurizio Zazzi, Siena

CsC

(Community sub-Committee)

Alberto Bignardi, Bologna

(ARCIGAY)

Giulio Maria Corbelli, Bologna

(PLUS onlus)

Maria Grazia Di Benedetto, Catania

(LILA)

Margherita Errico, Milano

(NPS Italia Onlus)

Massimo Farinella, Roma

(Circolo Mario Mieli)

Ivan Gardini, Vimercate MB

(EpaC onlus)

Michele Manfredini, Milano

(ASA onlus)

Bruno Marchini, Roma

(ANLAIDS)

Filippo von Schloesser, Roma

(NADIR onlus)



Faculty

Chiara Agrati, Roma
Massimo Andreoni, Roma
Gioacchino Angarano, Bari
Teresa Angelini Zucchetti, Milano
Andrea Antinori, Roma
Guido Antonelli, Roma
Giovanni Apolone, Milano
Bertrand Audoin, Paris (F)
Sergio Babudieri, Sassari
Lorenzo Badia, Bologna
Francesca Bai, Milano
Alessandra Bandera, Milano
Matteo Bassetti, Udine
Rita Bellagamba, Roma
Roberto Bernabei, Roma
Alberto Bignardi, Modena
Alba Bigoloni, Milano
Teresa Bini, Milano
Paolo Bonfanti, Lecco
Stefano Bonora, Torino
Marco Borderi, Bologna
Silvio Borrè, Vercelli
Luca Butini, Ancona
Andrea Calcagno, Torino
Valeria Calvino, Roma
Amedeo Capetti, Milano
Maria Rosaria Capobianchi, Roma
Giampiero Carosi, Brescia
Antonio Cascio, Palermo
Antonella Castagna, Milano
Dario Cattaneo, Milano
Anna Maria Cattelan, Padova
Roberto Cauda, Roma
Francesca Ceccherini - Silberstein, Roma
Benedetto Maurizio Ceslasia, Catania
Valeria Cento, Milano
Massimo Cernuschi, Milano
Antonella Cingolani, Roma
Paola Cinque, Milano
Daniela Cirillo, Milano
Massimo Clementi, Milano
Mario Clerici, Milano

Luigi Codecasa, Milano
Nicola Coppola, Napoli
Giulio Maria Corbelli, Bologna
Maria Luisa Cosmaro, Milano
Andrea Cossarizza, Modena
Antonio Craxi, Palermo
Marco Cusini, Milano
Gerardo D'Amico, Roma
Antonella d'Arminio Monforte, Milano
Gabriella d'Ettorre, Roma
Franco Dal Molin, Milano
Andrea De Maria, Genova
Giuseppe De Socio, Perugia
Steven G. Deeks, San Francisco (USA)
Mario Delpini, Milano
Antonio Di Biagio, Genova
Simona Di Giambenedetto, Roma
Giovanni Di Perri, Torino
Massimo A. Di Pietro, Pistoia
Margherita Errico, Milano
Vincenzo Esposito, Napoli
Massimo Farinella, Roma
Carlo Ferrari, Parma
Michele Formisano, Taranto
Giorgia Fracca, Milano
Elio Franzini, Milano
Giovanni Battista Gaeta, Napoli
Massimo Galli, Milano
Fiorenzo Galli, Milano
Jorge Garrido, Madrid (E)
Cristina Gervasoni, Milano
Vania Giacometti, Milano
Nicola Gianotti, Milano
Carlo Giaquinto, Padova
Noel Gill, London (UK)
Enrico Girardi, Roma
Andrea Gori, Milano
Giovanni Guaraldi, Modena
Alessio Guidotti, Roma
Maria Rosaria Iardino, Milano
Giuseppe Ippolito, Roma
Florian Klein, Cologne (D)
Loreta Kondili, Roma
Giuseppe Lapadula, Monza
Maria Agnese Latino, Torino

Adriano Lazzarin, Milano
Miriam Lichtner, Latina
Sergio Lo Caputo, Bari
Giordano Madeddu, Sassari
Paolo Maggi, Napoli
Franco Maggiolo, Bergamo
Donatella Mainieri, Milano
Pierfrancesco Majorino, Milano
Duilio Manara, Milano
Giulia Marchetti, Milano
Bruno Marchini, Roma
Renato Maserati, Pavia
Claudio Maria Mastroianni, Roma
Alberto Matteelli, Brescia
Sandro Mattioli, Bologna
Giovanni Mazzola, Palermo
Piergiorgio Mazzoli, Milano
Francesco Mazzotta, Firenze
Maria Cristina Moioli, Milano
Brian Moldt, San Francisco (USA)
Mario U. Mondelli, Pavia
Annalisa Mondì, Roma
Beatriz Mothe, Badalona (E)
Antonio Muscatello, Milano
Cristina Mussini, Modena
Luigi Naldini, Milano
Anna Nava, Milano
Corina Nicoara, Palermo
Silvia Nozza, Milano
Giuseppe Nunnari, Messina
Massimo Oldrini, Como
Maurizio Orso, Milano
Giorgio Palù, Padova
Saverio Parisi, Padova
Giustino Parruti, Pescara
Carlo Federico Perno, Milano
Nicola Petrosillo, Roma
Patrizio Pezzotti, Roma
Viviana Picciotto, Milano
Stefania Piconi, Milano
Guido Poli, Milano
Tullio Salvatore Prestileo, Palermo
Massimo Puoti, Milano
Laura Rancilio, Milano
Mario Raviglione, Milano



Bruce Richman, New York (USA)
Diego Ripamonti, Bergamo
Giuliano Rizzardini, Milano
Barbara Rossetti, Siena
Roberto Rossotti, Milano
Claudio Ruggieri, Milano
Stefano Rusconi, Milano
Francesco Saladini, Siena
Teresa Santantonio, Foggia
Maria Santoro, Roma
Annalisa Saracino, Bari
Loredana Sarmati, Roma
Gabriella Scarlatti, Milano
Laura Sighinolfi, Ferrara
Guido Silvestri, Atlanta (USA)
Vincenzo Spagnuolo, Milano
Maria Stagnitta, Firenze
Barbara Suligoj, Roma
Valentina Svicher, Roma
Gloria Taliani, Roma
Giuseppe Tambussi, Milano
Marcello Tavio, Ancona
Camilla Tincati, Milano
Carlo Torti, Catanzaro
Caterina Uberti Foppa, Milano
Luca Valenti, Milano
Stefano Vella, Roma
Mario Venditti, Roma
Pierluigi Viale, Bologna
Filippo von Schloesser, Roma
Maurizio Zazzi, Siena
Valentina Zuccaro, Pavia

Abstract Reviewers

Chiara Agrati, Roma
Claudia Alteri, Milano
Mauro Andreotti, Roma
Guido Antonelli, Roma
Francesca Bai, Milano
Alessandra Bandera, Milano
Marco Bartoli, Roma
Teresa Bini, Milano
Paolo Bonfanti, Lecco

Stefano Bonora, Torino
Marco Borderi, Bologna
Vanni Borghi, Modena
Luca Butini, Ancona
Andrea Calcagno, Torino
Anna Paola Callegaro, Bergamo
Leonardo Calza, Bologna
Maria Rosaria Capobianchi, Roma
Francesco Castelli, Brescia
Dario Cattaneo, Milano
Anna Maria Cattelan, Padova
Francesca Ceccherini - Silberstein, Roma
Benedetto Maurizio Celesia, Catania
Valeria Cento, Milano
Massimo Cernuschi, Milano
Stefania Cicalini, Roma
Antonella Cingolani, Roma
Paola Cinque, Milano
Mario Clerici, Milano
Laura Comi, Bergamo
Nicola Coppola, Napoli
Giulio Maria Corbelli, Bologna
Maria Luisa Cosmaro, Milano
Andrea Cossarizza, Modena
Alessandro Cozzi-Lepri, London (UK)
Gabriella d'Ettorre, Roma
Gianpiero D'Offizi, Roma
Andrea De Maria, Genova
Antonio Di Biagio, Genova
Giovanni Di Perri, Torino
Margherita Errico, Milano
Massimo Farinella, Roma
Massimo Fasano, Foggia
Micol Ferrara, Torino
Carlo Ferrari, Parma
Giovanni Battista Gaeta, Napoli
Laura Galli, Milano
Cristina Gervasoni, Milano
Nicola Gianotti, Milano
Enrico Girardi, Roma
Andrea Gori, Milano
Giovanni Guaraldi, Modena
Giuseppe Lepadula, Monza
Miriam Lichtner, Latina
Giuseppina Liuzzi, Roma

Sergio Lo Caputo, Bari
Giordano Madeddu, Sassari
Gaetano Maffongelli, Roma
Paolo Maggi, Napoli
Franco Maggiolo, Bergamo
Giulia Marchetti, Milano
Renato Maserati, Pavia
Claudio Maria Mastroianni, Roma
Alberto Matteelli, Brescia
Maria Cristina Moiola, Milano
Annalisa Mondì, Roma
Laura Monno, Bari
Antonio Muscatello, Milano
Cristina Mussini, Modena
Emanuele Nicastrì, Roma
Silvia Nozza, Milano
Giancarlo Orofino, Torino
Saverio Parisi, Padova
Stefania Piconi, Milano
Carmela Pinnetti, Roma
Tullio Salvatore Prestileo, Palermo
Vincenzo Puro, Roma
Diego Ripamonti, Bergamo
Barbara Rossetti, Siena
Roberto Rossotti, Milano
Stefano Rusconi, Milano
Francesco Saladini, Siena
Maria Santoro, Roma
Annalisa Saracino, Bari
Loredana Sarmati, Roma
Laura Sighinolfi, Ferrara
Alessandro Soria, Monza
Vincenzo Spagnuolo, Milano
Nicola Squillace, Monza
Valentina Svicher, Roma
Gloria Taliani, Roma
Lucia Taramasso, Milano
Marcello Tavio, Ancona
Elisabetta Teti, Roma
Camilla Tincati, Milano
Carlo Torti, Catanzaro
Daria Trabattoni, Milano
Francesca Vichi, Firenze



Dear Colleagues,

It is our great pleasure to welcome you to the **11th edition of ICAR, the Italian Conference on AIDS and Antiviral Research** which takes place this year at **University of Milan**.

ICAR 2019, strengthened by the path and the experience acquired in these years in proposing itself as an **abstract-driven Congress**, returns to Milan to discuss the suitable methodologies today and the crucial issues in the battle against HIV infection and other viral infections. It presents a congress characterized by a strong interaction between basic, translational and clinical research and inspired by the need for a common language between the scientific community, patients and civil society.

ICAR 2019 is aimed at young people to promote with determination the visibility of clinicians, basic researchers, nurses, social workers, volunteers in associations through **Young Investigators** and **Community Scholarships**. It is aimed at young people to listen to their voice with the **RaccontART** Contest and reward their merit by reconfirming the **ICAR-CROI Awards** event.

ICAR 2019 wants to address the population with the **HIV-HCV Rapid Test** offer and embrace the city from which it took its first steps.

Special thanks go to the **Scientific and Course Secretariats**, to the **Abstract Reviewers** for their commitment, to our **Faculty Members**, to the **ICAR Governing Board**, to **SIMIT, Institutions, Scientific Societies and Patient Associations**, to the **schools** and students, to the **Municipality of Milan** and to our **Sponsors** who enabled us to involve and host hundreds of young researchers and representatives of the Community of patient associations. We are greatly honored and pleased to welcome you in Milan and wish you a pleasant and interesting stay.

Welcome to ICAR 2019!

The Chairs

Antonella Castagna

Antonella d'Arminio Monforte

Massimo Puoti

Giuliano Rizzardini

11° CONGRESSO NAZIONALE



**Italian Conference on
AIDS and Antiviral Research**

Promosso da



5-7 GIUGNO 2019
UNIVERSITÀ DEGLI STUDI DI MILANO

Presidenza del Congresso
Antonella Castagna
Antonella d'Arminio Monforte
Massimo Puoti
Giuliano Rizzardini

PROGRAMME AT A GLANCE





MERCOLEDÌ
5 GIUGNO

PROGRAMME
AT A GLANCE

11° CONGRESSO NAZIONALE
**Italian Conference on
AIDS and Antiviral Research**

5-7 GIUGNO 2019
UNIVERSITÀ DEGLI STUDI DI MILANO

	AULA MAGNA	AULA 211	AULA 201	AULA MALLIANI	AULA CROCIERA	AULA 113
10.00 13.00	Secretariat Opening and Registration					
13.00 13.30	SPECIAL EVENT					
13.30 15.30	PTS (Patto Trasversale per la Scienza) Meeting <i>pag. 18</i>	PRE-CONFERENCE ADVANCED COURSE Viral reservoir as obstacle to cure <i>pag. 16</i>	INCONTRO CON LE SCUOLE FINALISTE RACCONTART QUARTA EDIZIONE CONCORSO HIV e Infezioni Sessualmente Trasmissibili <i>pag. 20</i>	PRE-CONFERENCE ADVANCED COURSE Ageing with HIV infection: new scenarios and new challenges <i>pag. 16</i>	PRE-CONFERENCE ADVANCED COURSE Prevention and treatment of sexually transmitted diseases (STDs) <i>pag. 17</i>	PRE-CONFERENCE ADVANCED COURSE HIV and chronic viral hepatitis: the strategic role of the nurse <i>pag. 17</i>
15.30 16.00						
16.00 16.45	SATELLITE SYMPOSIUM Towards cure programs in HIV and HBV <i>pag. 22</i>					
	AULA MAGNA					
17.00 20.45	ICAR 2019 Opening Session 17.00-17.30 Introducing ICAR 2019 <i>pag. 23</i> 17.30-17.50 RaccontART HIV contest Awards <i>pag. 23</i> 17.50-18.50 The centrality of the person between care and culture <i>pag. 23</i> 18.50-19.05 Il sorriso di Andrea <i>pag. 23</i> 19.05-20.05 Keynote Lectures <i>pag. 24</i> 20.05-20.30 ICAR-CROI Awards 2019 for young Italian HIV investigators <i>pag. 24</i> 20.30-20.45 Closing Remarks <i>pag. 24</i>					
20.45 23.00	ICAR 2019 Welcome Reception					



GIOVEDI' 6 GIUGNO **PROGRAMME AT A GLANCE**

AULA MAGNA				
09.00 10.00	Keynote Lectures Exploiting HIV for the gene therapy of inherited diseases and cancer Luigi Naldini, Milano Looking to a future management of HIV patients: key elements for transition Andrea Antinori, Roma <i>pag. 25</i>			
	AULA MAGNA	AULA 211	AULA 201	AULA MALLIANI
10.05 11.35	ANDREA DE LUCA SYMPOSIUM Facing Resistance in 2019 <i>pag. 25</i>	ORAL COMMUNICATION Challenges in HCV elimination <i>pag. 25</i>	ORAL COMMUNICATION Immunological insights of HIV infection <i>pag. 26</i>	
11.40 12.40	SYMPOSIUM New options for treating opportunistic infections in immunocompromised host <i>pag. 27</i>	ORAL COMMUNICATION A Healthy Brain in People Living with HIV <i>pag. 28</i>	ORAL COMMUNICATION New insights in HIV pathogenesis <i>pag. 29</i>	EXPERT MEETING The revolution of rapid molecular diagnosis "near patient" <i>pag. 30</i>
12.40 13.10				EXPERT MEETING Moving forward to tailored approaches: real life & future in virology <i>pag. 30</i>
13.15 14.00	SPONSORED SYMPOSIUM 2DR: from opportunity to change of paradigm <i>pag. 30</i>	POSTER DISCUSSION Social Science and management of HIV beyond antiretroviral therapy <i>pag. 31</i>	SATELLITE SYMPOSIUM The last mile towards HCV elimination <i>pag. 32</i>	
14.05 14.50			SATELLITE SYMPOSIUM Long-life individuality in caring for HIV <i>pag. 33</i>	EXPERT MEETING Recent advances in the management of Gram positive infections: the evolving role of long acting therapy <i>pag. 32</i>
14.55 16.25	SYMPOSIUM Critical issues in ART <i>pag. 33</i>	POSTER DISCUSSION Clinical HIV and Epidemiology <i>pag. 34</i>	ORAL COMMUNICATIONS Let's PrEP now: Italian experiences <i>pag. 35</i>	EXPERT MEETING Potency of drugs to overcome the challenges of micro-elimination <i>pag. 36</i>
16.30 17.30	RENATO DALLE NOGARE SYMPOSIUM Global Health: disease burden, migration and ageing <i>pag. 36</i>	ORAL COMMUNICATIONS Targeting 90-90-90 <i>pag. 37</i>	ORAL COMMUNICATIONS Cancers and bacterial infections <i>pag. 38</i>	EXPERT MEETING Hospital acquired and Gram negative-resistant pneumonia <i>pag. 36</i>
17.30 18.00				



VENERDI'
7 GIUGNO

PROGRAMME
AT A GLANCE

11° CONGRESSO NAZIONALE
Italian Conference on
AIDS and Antiviral Research

5-7 GIUGNO 2019
UNIVERSITÀ DEGLI STUDI DI MILANO

AULA MAGNA				
09.00 10.00	Keynote Lectures Community-based interventions on chemsex among MSM Jorge Garrido, Madrid E New perspectives for medical treatment of Hepatocellular Carcinoma Antonio Craxi, Palermo <i>pag. 39</i>			
	AULA MAGNA	AULA 211	AULA 201	AULA MALLIANI
10.05 10.30	SYMPOSIUM	ORAL COMMUNICATION	ORAL COMMUNICATION	
10.30 11.35	Getting to zero in HIV and HCV <i>pag. 39</i>	ART and long-term safety issues <i>pag. 39</i>	Resistance. Is it still a problem? <i>pag. 40</i>	EXPERT MEETING Innovation vs novelty <i>pag. 42</i>
11.40 12.25	SPONSORED SYMPOSIUM The beauty of what is possible <i>pag. 42</i>	ORAL COMMUNICATION From naive to highly treated subjects. Efficacy of cART <i>pag. 42</i>	ORAL COMMUNICATION Changing HIV epidemiology <i>pag. 44</i>	EXPERT MEETING Effects of vitamin D deficiency and respiratory infections' prevention in HIV population <i>pag. 45</i>
12.30 13.10	FERNANDO AIUTI SYMPOSIUM		POSTER DISCUSSION	POSTER DISCUSSION
13.15 14.00	New immune tools and targets towards an HIV cure <i>pag. 45</i>	SATELLITE SYMPOSIUM HIV: same day treatment in real life <i>pag. 48</i>	HIV co-morbidities <i>pag. 46</i>	Viral Hepatitis <i>pag. 47</i>
14.05 15.35	ORAL COMMUNICATION New challenges of viral hepatitis <i>pag. 48</i>	ORAL COMMUNICATION Social and PLWHIV related issues <i>pag. 50</i>	POSTER DISCUSSION Virology, Immunology and Basic science <i>pag. 51</i>	POSTER DISCUSSION HIV therapy and management <i>pag. 52</i>
AULA MAGNA				
15.40 16.45	Round Table "U=U" <i>pag. 54</i>			
16.45 17.00	ICAR and SIMIT Special Awards <i>pag. 54</i>			
17.00 17.15	ICAR 2019 Closing remarks <i>pag. 54</i>			



SCIENTIFIC
PROGRAMME

11° CONGRESSO NAZIONALE



**Italian Conference on
AIDS and Antiviral Research**

Promosso da



5-7 GIUGNO 2019
UNIVERSITÀ DEGLI STUDI DI MILANO

Presidenza del Congresso

Antonella Castagna
Antonella d'Arminio Monforte
Massimo Puoti
Giuliano Rizzardini

PRE-CONFERENCE ADVANCED COURSES

MERCOLEDÌ
5 GIUGNO





MERCOLEDÌ
5 GIUGNO

11° CONGRESSO NAZIONALE
Italian Conference on
AIDS and Antiviral Research

5-7 GIUGNO 2019
UNIVERSITÀ DEGLI STUDI DI MILANO

PRE-CONFERENCE ADVANCED COURSE 13.30-16.00

AULA 211

Viral reservoir as obstacle to cure

Chairs: F. Bai (Milano), F. Saladini (Siena)

The persistence of the viral reservoir is still the main obstacle to the eradication of HIV infection. The availability of new high-sensitivity techniques of investigation has allowed to increase the ability to characterize the reservoir, but leaving open questions about the reliability of the methods and the clinical significance of generated data. The course aims to present the current status of technologies potential aimed at the qualitative and quantitative assessment of reservoir in the patient follow-up, and deepen the current therapeutic strategies to limit the extent of viral reservoir as the first approach to HIV cure. Attendees will be involved with a questionnaire to evaluate the perception of the usefulness of some diagnostic tests or clinical markers for the patient's routine follow-up. The results of the survey will be discussed at the end of the course.

13.30-14.00	Measuring the reservoir today	Maria Santoro, Roma
14.00-14.30	Evolution of reservoir during the infection: immunological aspects	Alessandra Bandera, Milano
14.30-15.00	Evolution of reservoir during the infection: virological aspects	Francesca Ceccherini - Silberstein, Roma
15.00-15.30	Antiretrovirals distribution in sanctuaries	Andrea Calcagno, Torino
15.30-16.00	Discussion of survey results and conclusions	

PRE-CONFERENCE ADVANCED COURSE 13.30-16.00

AULA MALLIANI

Ageing with HIV infection: new scenarios and new challenges

Chairs: A. Mondì (Roma), V. Spagnuolo (Milano)

By 2030, 70% of HIV-infected patients will be 50 years of age or older and one third of people living with HIV will have at least three age-related comorbidities. In light of this changing epidemiology, HIV providers must recognize and manage this new picture of the disease. In addition to multiple comorbidities, the ageing HIV population is at risk for geriatric syndromes, such as frailty, falls, delirium and functional impairment. It is therefore necessary to adopt a multidisciplinary approach to the patient and a proactive management of comorbidities. Nevertheless, in the elderly subject with HIV infection, the personalization of antiretroviral therapy, which must be based on an in-depth knowledge of the characteristics of antiretroviral drugs, drug interactions with concomitant therapy and patient's clinical characteristics, is even more important.

Epidemiological data

13.30-14.00	Ageing with HIV: current and future size of an epidemic	Giordano Madeddu, Sassari
-------------	--	---------------------------

Pathogenetic bases

14.00-14.30	Immunosenescence and inflammaging: from basic research to clinic	Gabriella d'Ettore, Roma
-------------	---	--------------------------

Clinical aspects

14.30-15.00	Diagnosis and screening of frailty in ageing with HIV Infection	Giovanni Guaraldi, Modena
15.00-15.30	Diagnosis and screening of neurocognitive disease in HIV	Paola Cinque, Milano
15.30-16.00	Managing polypharmacy in elderly patient	Cristina Gervasoni, Milano



MERCOLEDÌ
5 GIUGNO

11° CONGRESSO NAZIONALE
Italian Conference on
AIDS and Antiviral Research

5-7 GIUGNO 2019
UNIVERSITÀ DEGLI STUDI DI MILANO

PRE-CONFERENCE ADVANCED COURSE 13.30-16.00

AULA CROCIERA

Prevention and treatment of sexually transmitted diseases (STDs)

Chairs: A. Muscatello (Milano), S. Nozza (Milano), R. Rossotti (Milano)

Sexually transmitted diseases (STDs) are infections that are passed from one person to another through sexual contact. Antibiotics can treat STDs caused by bacteria, yeast, or parasites; for this correct diagnosis and treatment are crucial.

PrEP (pre-exposure prophylaxis) has been shown to reduce the risk of HIV infection in people who are at high risk by up to 92% when taken consistently. Italian regulatory agency approved use of PrEP. This course is focused on STDs diagnosis and treatment and on PrEP request and management in clinical practice.

13.30-13.50	The current management of sexually transmitted diseases	Marco Cusini, Milano
13.50-14.10	The support of the laboratory in STDs early diagnosis	Maria Agnese Latino, Torino
14.10-14.30	Indications and clinical implications of vaccinations against STDs	Maurizio Orso, Milano
14.30-14.45	The role of counselor and cultural mediator in prevention	Giorgia Fracca, Milano
14.45-15.00	The PrEP clinic in hospital	Rita Bellagamba, Roma
15.00-15.15	The PrEP clinic in check points	Lorenzo Badia, Bologna
15.15-16.00	Discussion on Course issues	

PRE-CONFERENCE ADVANCED COURSE 13.30-16.00

AULA 113

HIV and chronic viral hepatitis: the strategic role of the nurse

Chairs: A. Bigoloni (Milano), V. Picciotto (Milano), C. Uberti Foppa (Milano)

The current management of HIV-HCV co-infected patient in the clinic today requires more than ever, due to the characteristics of complexity, a management based on close medical-nurse collaboration and team-based approach to the patient.

We will therefore define the role of the nurse in relation to the patient's helping relationship with new disease response and support for adherence to therapy, knowledge of HIV and HCV drugs and the role of the nurse in clinical research.

13.30-14.00	Communication of diagnosis and management of disease chronicity: the point of view of the patient and the operator	Claudio Ruggieri, Milano
14.00-14.30	New anti-HIV and HCV drugs: interactions and undesirable effects	Teresa Angelini Zucchetti, Milano
14.30-15.00	Health counseling and adherence to therapy	Viviana Picciotto, Milano
15.00-15.30	Role of the nurse in clinical trial	Duilio Manara, Milano
15.30-16.00	Discussion on Course issues	



MERCOLEDÌ
5 GIUGNO

11° CONGRESSO NAZIONALE
Italian Conference on
AIDS and Antiviral Research

5-7 GIUGNO 2019
UNIVERSITÀ DEGLI STUDI DI MILANO

PATTO TRASVERSALE PER LA **SCIENZA** La Salute basata sulle Evidenze

Presentazione del Patto e dell'Associazione

Mercoledì 5 giugno 2019
Aula Magna

Conduce Gerardo D'Amico, conduttore RAI NEWS24, divulgatore scientifico

13.00 **PRIMA PARTE: LA SCIENZA A SERVIZIO DELLA SOCIETÀ'**

IL PATTO TRASVERSALE PER LA SCIENZA: come è nato e perché

Roberto Burioni Professore Ordinario di Microbiologia e Virologia Università Vita e Salute San Raffaele

Guido Silvestri Professore Ordinario di Patologia, Emory University, Atlanta

La testimonianza di Romina Scaloni, vittima del negazionismo dell'AIDS

L'ASSOCIAZIONE PATTO TRASVERSALE PER LA SCIENZA: finalità e obiettivi

Pier Luigi Lopalco, Professore Ordinario di Igiene e Medicina Preventiva – Università di Pisa

Andrea Cossarizza, Professore Ordinario di Patologia Generale e Immunologia – Università di Modena e Reggio Emilia

La testimonianza di Andrea Lanfri, Atleta paralimpico e Lara Redditi #ioVaccino

14.00 **SECONDA PARTE: POLITICA E INFORMAZIONE PER LA TUTELA E LA PROMOZIONE DELLA SCIENZA**

Elena Fattori (Senatore, Movimento 5 Stelle), **Maria Stella Gelmini** (Capogruppo Forza Italia, Camera dei Deputati), **Andrea Gnassi** (Sindaco di Rimini), **Beatrice Lorenzin** (Deputato Civica e Popolare), **Enrico Mentana** (Direttore Tg La 7), **Giorgio Trizzino** (Deputato Movimento 5 Stelle), **Roberto Burioni** e **Guido Silvestri**.

15.00 **L' IMPEGNO DEL PATTO PER IL FUTURO**

Roberto Burioni, Guido Silvestri, Pier Luigi Lopalco, Andrea Cossarizza

11° CONGRESSO NAZIONALE



Italian Conference on
AIDS and Antiviral Research

Promosso da



5-7 GIUGNO 2019
UNIVERSITÀ DEGLI STUDI DI MILANO

Presidenza del Congresso
Antonella Castagna
Antonella d'Arminio Monforte
Massimo Puoti
Giuliano Rizzardini

SCIENTIFIC PROGRAMME

MERCOLEDÌ
5 GIUGNO

GIOVEDÌ
6 GIUGNO

VENERDÌ
7 GIUGNO





MERCOLEDÌ
5 GIUGNO

11° CONGRESSO NAZIONALE
Italian Conference on
AIDS and Antiviral Research

5-7 GIUGNO 2019
UNIVERSITÀ DEGLI STUDI DI MILANO

ARTISTIC CONTEST "RACCONTART HIV" 13.30-16.00 INCONTRO CON LE SCUOLE FINALISTE

AULA 201

Moderatori: A. Di Biagio (Genova), M. Errico (Milano), D. Mainieri (Milano)

13.30-13.40 **Benvenuto dei Presidenti ICAR**

A. Castagna (Milano), A. d'Arminio Monforte (Milano), M. Puoti (Milano), G. Rizzardini (Milano)

13.40-14.00 **Introduzione, obiettivi dell'incontro, presentazione della Giuria Artistica e Scientifica**

A. Di Biagio (Genova), M. Errico (Milano), D. Mainieri (Milano)

La Giuria Artistica

- **Alessandro Castellano**, Architetto e designer
- **Maria Fratelli**, Assessorato Cultura, Unità Case Museo e Progetti Speciali, Comune di Milano
- **Alessandro Gottardo**, (alias Shout), Illustratore
- **Paola Manfrin**, Direttore Creativo indipendente
- **Enzo Porcelli**, Produttore cinematografico
- **Francesco Suriano**, Scrittore di teatro, sceneggiatore e regista
- **Rocco Toscani**, Fotografo e videomaker

La Giuria Scientifica

- **Antonella Castagna**, IRCCS Ospedale San Raffaele, Università Vita-Salute, Milano
- **Francesca Ceccherini-Silberstein**, Università degli Studi di Roma Tor Vergata
- **Antonella Cingolani**, Fondazione Policlinico Universitario Agostino Gemelli, Roma
- **Paola Cinque**, IRCCS Ospedale San Raffaele, Università Vita-Salute, Milano
- **Maria Luisa Cosmaro**, LILA, Milano
- **Antonella d'Arminio Monforte**, ASST Santi Paolo e Carlo, Università degli Studi di Milano
- **Giovanni Del Bene**, ANLAIDS, Milano
- **Antonio Di Biagio**, Ospedale Policlinico San Martino, Genova
- **Margherita Errico**, NPS Italia, Milano
- **Massimo Farinella**, Circolo di Cultura Omosessuale Mario Mieli, Roma
- **Donatella Mainieri**, ANLAIDS, Milano
- **Silvia Nozza**, IRCCS Ospedale San Raffaele, Università Vita-Salute, Milano
- **Massimo Puoti**, ASST Grande Ospedale Metropolitano Niguarda, Milano
- **Giuliano Rizzardini**, ASST Fatebenefratelli Sacco, Ospedale Luigi Sacco, Milano
- **Roberto Rossotti**, ASST Grande Ospedale Metropolitano Niguarda, Milano



MERCOLEDÌ
5 GIUGNO

11° CONGRESSO NAZIONALE
Italian Conference on
AIDS and Antiviral Research

5-7 GIUGNO 2019
UNIVERSITÀ DEGLI STUDI DI MILANO

14.00-15.50 **Presentazione delle Opere finaliste al Concorso a cura degli Istituti Scolastici**

Gli Istituti Scolastici

- **AFOL Metropolitana – CFP** Cormano (MI)
- **Galileo-Luxemburg** Milano
- **I.I.S. Falcone-Righi** Corsico (MI)
- **I.I.S. Gadda** Paderno Dugnano (MI)
- **I.I.S. Luigi Einaudi** Ferrara
- **I.S. Puecher-Olivetti** Rho (MI)
- **I.T.I.S. Galileo-Galilei** Milano
- **I.I.S. Via dei Papareschi** Roma
- **I.P.S. Ciro Pollini** Mortara (PV)
- **Istituto Professionale Marignoni-Polo** Milano
- **Istruzione Superiore E. Majorana** San Lazzaro di Savena (BO)
- **Liceo Artistico** Latina
- **Liceo Artistico Istituto MK Gandhi** Besana (MB)
- **Liceo Artistico-I.S.Francesco Orioli** Viterbo
- **Liceo Artistico-IIS Luigi Einaudi** Magenta (MI)
- **Liceo Brera** Milano
- **Liceo Virgilio** Milano

15.50-16.00 **Conclusioni**

A. Di Biagio (Genova), M. Errico (Milano), D. Mainieri (Milano)



MERCOLEDÌ
5 GIUGNO

11° CONGRESSO NAZIONALE
Italian Conference on
AIDS and Antiviral Research

5-7 GIUGNO 2019
UNIVERSITÀ DEGLI STUDI DI MILANO

SATELLITE SYMPOSIUM 16.00-16.45

Con la sponsorizzazione non condizionante di Gilead Sciences

Towards cure programs in HIV and HBV

Chairs: A. Gori (Milano), G. Tambussi (Milano)

There were approximately 36.9 million people living with HIV at the end of 2017 with 1.8 million people becoming newly infected in 2017 globally. There is no cure for HIV infection but effective ARV drugs can control the virus and help prevent transmission. An estimated 257 million people are living with HBV infection around the world. Similarly, current HBV treatments suppress HBV viral replication but do not completely clear the virus. Today researchers are committed to develop innovative therapies to achieve functional cure for patients: the symposium will address the expectancies of the scientific community and the update of the ongoing projects in HIV and HBV cure research.

- | | |
|-------------|---|
| 16.00-16.05 | Introduction |
| 16.05-16.15 | The expectations from the point of view of the clinician |
| 16.15-16.35 | The scientific efforts in cure programs |
| 16.35-16.45 | Discussion on Symposium issues |

Andrea Gori, Milano
Giulia Marchetti, Milano
Brian Moldt, San Francisco USA



MERCOLEDÌ
5 GIUGNO

11° CONGRESSO NAZIONALE
Italian Conference on
AIDS and Antiviral Research

5-7 GIUGNO 2019
UNIVERSITÀ DEGLI STUDI DI MILANO

ICAR 2019 OPENING SESSION

AULA MAGNA

Introducing ICAR 2019 17.00-17.15

A. Castagna (Milano), A. d'Arminio Monforte (Milano), M. Puoti (Milano), G. Rizzardini (Milano)

Welcome addresses 17.15-17.30

Elio Franzini, Magnifico Rettore, Università degli Studi di Milano, Milano

RaccontART HIV contest Awards 17.30-17.50

Chairs: M. Errico (Milano), M. Galli (Milano)

The centrality of the person between care and culture 17.50-18.50

Chairs: A. Castagna (Milano), A. d'Arminio Monforte (Milano), M. Puoti (Milano), G. Rizzardini (Milano)

17.50-17.55 **Introduction by Chairs**

17.55-18.10 **The commitment of the city of Milan**

Introduced by Maria Rosaria Iardino, Milano

Piefrancesco Majorino,
Assessore alle Politiche sociali e Cultura della salute, Comune di Milano

18.10-18.30 **Lecture of his most reverend excellence,
the Archbishop of Milan Monsignor Mario Delpini**

Monsignor Mario Delpini,
Arcivescovo metropolitano di Milano

18.30-18.50 **The contemporaneity of Leonardo da Vinci**

Fiorenzo Galli,
Direttore Generale del Museo Nazionale Scienza e Tecnologia Leonardo da Vinci, Milano

Il sorriso di Andrea 18.50-19.05

Chairs: R. Cauda (Roma), M. Zazzi (Siena)

This special session is dedicated to the memory of Andrea De Luca through the testimonies of his colleagues.

Simona Di Giambenedetto (Roma), Massimiliano Fabbiani (Pavia), Roberta Gagliardini (Roma), Sara Modica (Siena),
Barbara Rossetti (Siena)



MERCOLEDI'
5 GIUGNO

11° CONGRESSO NAZIONALE
Italian Conference on
AIDS and Antiviral Research

5-7 GIUGNO 2019
UNIVERSITÀ DEGLI STUDI DI MILANO

Keynote Lectures 19.05-20.05

Chairs: G. Ippolito (Roma) A. Lazzarin (Milano), F. von Schloesser (Roma)

19.05-19.15	Introduction	Giuseppe Ippolito, Roma and Adriano Lazzarin, Milano
19.15-19.40	Mauro Moroni Memorial Lecture "HIV Cure"	Steven G. Deeks, San Francisco USA
19.40-19.45	Introduction	Filippo von Schloesser, Roma
19.45-20.05	The Fourth Decade in HIV: new challenges	Valeria Calvino, Roma

ICAR-CROI Awards 2019 for young Italian HIV Investigators 20.05-20.30

Chairs: G. Angarano (Bari), A. Antinori (Roma), G. Silvestri (Atlanta USA)

Selected Italian Investigators

- INI-resistance dynamics from 2007 to 2017 in Italian clinical isolates
- GSS of NRTI-backbone predicts time to virological failure of INI-based regimens
- Quantification of CD64: a predictive biomarker for progression to active tuberculosis
- Subclinical tubular impairment is common in ART-treated HIV+ patients in Uganda
- Evolution and reversibility of renal function after switch from TDF to TAF regimens
- Impact of HBCAB+ on advanced liver fibrosis development in HIV-HBV infected patients
- Metabolomic profiling of HIV patients with and without HIV-associated dementia
- Extracellular vesicle-associated cytokines in HIV-infected human ex vivo tonsils
- HCV late relapse in patients with directly acting antiviral-related SVR 12
- Effectiveness of single- vs multiple-tablet regimens as 1st-line ART in ICONA cohort
- Modulation of gut microbiota improves mucosal permeability in HIV+ patients
- Interferon-free regimens improve renal function in patients with chronic Hepatitis C
- Genotypic and phenotypic susceptibility to fostemsavir in multidrug-resistant HIV-1
- In vitro activity of DTG/BIC/E/CAB on first-generation INSTI-resistant HIV-1
- ERAP2 administration reduces in vitro PBMC susceptibility to HIV-1-infection
- Time to undetectable viral load achievement after ART start and risk of mortality
- Increased SAMHD1 correlates with ISGs in HIV-1-infected patients
- Alzheimer's dementia cerebrospinal fluid biomarkers in HIV-positive patients on cART
- Relapse of symptomatic CSF HIV escape upon previously optimized cART regimen changes
- Low performance of the oraquick HCV rapid antibody test in HIV/HCV-infected people

Daniele Armenia, Roma
Alberto Borghetti, Roma
Cristina Ceriani, Legnano (MI)
Cecilia Costa, Torino
Roberta Gagliardini, Roma
Vincenzo Malagnino, Roma
Andrea Mastrangelo, Milano
Vincenzo Mercurio, Milano
Carmine Minichini, Napoli
Annalisa Mondì, Roma
Claudia Pinacchio, Roma
Federica Portunato, Napoli
Francesco Saladini, Siena
Francesco Saladini, Siena
Irma Saulle, Milano
Vincenzo Spagnuolo, Milano
Maura Statzu, Roma
Mattia Trunfio, Torino
Filippo Turrini, Milano
Serena Vita, Latina

Closing Remarks 20.30-20.45

A. Castagna (Milano), A. d'Arminio Monforte (Milano), M. Puoti (Milano), G. Rizzardini (Milano)

ICAR 2019 Welcome Reception 20.45-23.00

CORTILE D'ONORE





KEYNOTE LECTURES 09.00-10.00

Chairs: A. Cossarizza (Modena), M. Galli (Milano), B. Suligoi (Roma)

- 09.00-09.30 **Exploiting HIV for the gene therapy of inherited diseases and cancer**
09.30-10.00 **Looking to a future management of HIV patients: key elements for transition**

AULA MAGNA

Luigi Naldini, Milano

Andrea Antinori, Roma

ANDREA DE LUCA SYMPOSIUM 10.05-11.35

Facing Resistance in 2019

Chairs: M. Andreoni (Roma), B. Rossetti (Siena), M. Zazzi (Siena)

Back in 1996 drug resistance was a terrible occurrence and the few pharmaceutical options we had at that time were fading away with just some codon changes. Nowadays, the picture has dramatically changed and multiple therapeutic strategies have been developed combining antivirals, immunological therapies, and vaccines. Nevertheless, there is still an occasion to think globally about Drug Resistance, in the recent past with some fundamental mutations, with newer approaches, and with a deeper look into reservoirs.

- 10.05-10.20 **Global epidemiology of HIV resistance and clinical relevance**
10.20-10.35 **Remembering M184V**
10.35-10.50 **Overcoming resistance: the role of monoclonal antibodies**
10.50-11.05 **Drug resistance in sanctuary sites**
11.05-11.35 **Discussion on Symposium issues**

Carlo Federico Perno, Milano

Stefano Rusconi, Milano

Nicola Gianotti, Milano

Stefano Bonora, Torino

AULA MAGNA

ORAL COMMUNICATIONS 10.05-11.35

Challenges in HCV elimination

Chairs: N. Coppola (Napoli), C. Ferrari (Parma), T. Santantonio (Foggia)

- 10.05-10.20 **Diagnosis and management of NASH/NAFLD**

Luca Valenti, Milano

AULA 211

OC 1 10.20-10.30 Screening strategies for hepatitis C virus elimination in Italy

*L.A. Kondili¹, M.G. Quaranta¹, A. Marcellusi², A. Craxi³, M. Puoti⁴, I. Gamkrelidze⁵, S. Blach⁵, H. Razavi⁵, F.S. Mennini², and PITER Collaborating Group**

¹Istituto Superiore di Sanità, Rome, Italy, ²University of Rome Tor Vergata, Rome, Italy, ³University of Palermo, Palermo, Italy, ⁴Niguarda Hospital, Milan, Italy, ⁵Center for Disease Analysis Foundation, Lafayette, United States, *available at www.progettoper.it/rete.aspx

OC 2 10.32-10.42 Prevalence of HBV, HCV and HIV virus infections in a cohort of migrants in southern Italy

C. Monari^{1,2}, L. Onorato^{2,3,4}, L. Alessio^{1,3,4}, G. Di Caprio^{2,3,4}, L. Surace⁵, M. Starace², C. Sagnelli^{2,3,6}, L. Gualdieri⁷, M. Pisaturo^{2,3,4}, G. Scotto⁸, S. Curto⁹, M. Macera^{2,3,4}, N. Coppola^{1,2}

¹Infectious Diseases Unit, AORN Sant'Anna and San Sebastiano, Caserta, ²Department of Mental Health and Public Medicine, Section of Infectious Diseases, University of Campania Luigi Vanvitelli, Naples, ³Medical Center, Caserta, ⁴Medical Center, "Abraham's Tent", Caserta, ⁵Medical Center Lamezia Terme - Catanzaro Lido - Soverato, ⁶Medical Center, "Charity Nuns", Naples, ⁷ASL Napoli 1, Ascalesi Hospital, Naples, ⁸Infectious Diseases Unit, Foggia, ⁹Medical Center, Potenza

OC 3 10.44-10.54 HCV test and treat in two Milan prison institutions: an effective strategy to achieve micro-elimination

R. Giuliani¹, T. Sebastiani¹, V. Casigliani², G. Arzilli², G. Scardina², E. Freo¹, L. Tavoschi², R. Ranieri¹

¹Infectious Diseases Service, Penitentiary Health System, San Paolo University Hospital, Milano, Italy, ²Department of Translational Research and New Technologies in Medicine and Surgery, University of Pisa, Pisa, Italy



GIOVEDÌ
6 GIUGNO

11° CONGRESSO NAZIONALE
Italian Conference on
AIDS and Antiviral Research

5-7 GIUGNO 2019
UNIVERSITÀ DEGLI STUDI DI MILANO

OC 4 10.56-11.06 Efficacy and tolerability of DAAs in HCV-monoinfected and HCV/HIV-coinfected patients with psychiatric disorders

N. de Gennaro, L. Diella, E. Milano, L. Monno, G. Angarano, M. Milella, A. Saracino
Clinica Malattie Infettive, Università di Bari

OC 5 11.08-11.18 Road to HCV elimination in HIV/HCV coinfected patients by screening and universal access to DAA: baseline data from the first screening of NoCo (No Coinfection) study

A. d'Arminio Monforte¹, A. Tavelli², A. Cozzi-Lepri³, S. Cicalini⁴, A. Calcagno⁵, R. Rossotti⁶, E. Grilli⁴, F. Bai¹, E. Quiros-Roldan⁷, E. Girardi⁸, A. Antinori⁴, M. Puoti⁶ for the NoCo Study of the Icona cohort

¹ASST Santi Paolo e Carlo, University of Milan, Clinic of Infectious and Tropical Diseases, Dept of Health Sciences, Milan, Italy, ²Icona Foundation, Milan, Italy, ³Institute for Global Health, University College of London, London, UK, ⁴Clinical Division of HIV/AIDS, INMI "L. Spallanzani" IRCCS, Rome, Italy, ⁵Unit of Infectious Diseases, Department of Medical Sciences, Amedeo di Savoia Hospital, University of Torino, Torino, Italy, ⁶ASST Grande Ospedale Metropolitano Niguarda Division of Infectious Diseases, Milan Italy, ⁷Department of Infectious and Tropical Diseases, University of Brescia, ASST Spedali Civili Hospital, Brescia, Italy, ⁸Clinical Epidemiology Unit, INMI "L. Spallanzani" IRCCS, Rome, Italy

OC 6 11.20-11.30 Analysis of baseline factors associated with treatment outcome in HCV-infected patients starting a first-line DAA-treatment containing a NS5A inhibitor: particular focus on natural resistance

S. Barbaliscia¹, V.C. Di Maio¹, E. Teti², M. Aragri¹, S. Paolucci³, C. Masetti⁴, R. D'Ambrosio⁵, E. Degasperis⁶, E. Polilli⁶, V. Pace Palitti⁷, G. Fiorentino⁸, L. Foroghi², V. Cento⁹, R. Scutari¹, B. Bruzzone¹⁰, V. Calvaruso¹¹, N. Coppola¹², G.B. Gaeta¹², G. Morsica¹³, T. Ruggiero¹⁴, V. Ghisetti¹⁴, A. Bertoli¹, M. Milana⁴, L.A. Nicolini¹⁵, W. Gennari¹⁶, S. Galli¹⁷, C.F. Magni¹⁸, V. Micheli¹⁹, A. Lleo²⁰, A. Aghemo²⁰, R. Maserati²¹, S. Bonora²², N. Iapadre²³, F. Morisco²⁴, M. Siciliano²⁵, V. Guarneri²⁶, B. Rossetti²⁷, M. Lichtner²⁸, V. Borghi²⁹, T. Pollicino³⁰, C. Caudai³¹, L. Sarmati², M. Puoti³², A. Pellicelli³³, S. Babudieri³⁴, G. Rizzardini¹⁸, G. Taliani³⁵, G. Parruti⁶, M. Zazzi³⁶, P. Lampertico⁵, G. Raimondo³⁰, C. Pasquazzi⁸, M. Angelico⁴, F. Baldanti³, M. Andreoni², C.F. Perno³⁷, A. Craxi¹¹, F. Ceccherini-Silberstein¹ on behalf of HCV Virology Italian Resistance Network (Vironet C)

¹Department of Experimental Medicine, University of Rome "Tor Vergata", Rome, Italy, ²Infectious Diseases Unit, University of Rome "Tor Vergata", Rome, Italy, ³Molecular Virology Unit, Microbiology and Virology Department, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy, ⁴Hepatology Unit, University Hospital of Rome "Tor Vergata", Rome, Italy, ⁵A.M. e A. Migliavacca" Center for Liver Diseases, Division of Gastroenterology and Hepatology, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, University of Milan, Milan, Italy, ⁶Infectious Diseases Unit, Pescara General Hospital, Pescara, Italy, ⁷Hepatology Unit, Pescara General Hospital, Pescara, Italy, ⁸Infectious Diseases Unit, Sant'Andrea Hospital—"Sapienza" University, Rome, Italy, ⁹Residency program in Microbiology and Virology, Università degli Studi di Milano, Milan, Italy, ¹⁰Hygiene Unit, IRCCSAOU San Martino-IST, Genoa, Italy, ¹¹Gastroenterology, "P.Giaccone" University Hospital, Palermo, Italy, ¹²Infectious Diseases Unit, Department of Mental and Physical Health and Preventive Medicine, University of Campania L. Vanvitelli, Naples, Italy, ¹³Division of Infectious Diseases, IRCCS, Ospedale San Raffaele, Milan, Italy, ¹⁴Laboratory of Microbiology and Virology, "Amedeo di Savoia" Hospital, ASL, Città di Torino, Turin, Italy, ¹⁵Infectious Diseases Unit, IRCCSAOU San Martino-IST, Genoa, Italy, ¹⁶Microbiology and Virology Unit, University Hospital Policlinico of Modena, Modena, Italy, ¹⁷Microbiology and Virology Unit, Sant'Orsola-Malpighi Hospital, Bologna, Italy, ¹⁸1st Division of Infectious Diseases, ASST Fatebene fratelli Sacco, Milan, Italy, ¹⁹Clinical Microbiology, Virology and Bioemergencies, ASST Fatebenefratelli Sacco, Milan, Italy, ²⁰Department of Internal Medicine, Humanitas Research Hospital, Rozzano, Milan, Italy, ²¹Institute of Infectious Diseases, University of Pavia, Pavia, Italy, ²²Unit of Infectious Diseases, Department of Medical Sciences, University of Torino, Torino, Italy, ²³Infectious Diseases Unit, S.Salvatore Hospital, L'Aquila, Italy, ²⁴Gastroenterology, «Federical» University, Naples, Italy, ²⁵Gastroenterology, Catholic University of Rome, Rome, Italy, ²⁶Department of Medical and Surgical Sciences, University of Bologna, Bologna, Italy, ²⁷Infectious Diseases Unit, AOU Senese, Siena, Italy, ²⁸Infectious Diseases Unit, "Sapienza" University, Polo pontino, Latina, Italy, ²⁹Department of Biomedical Sciences, University of Modena School of Medicine, Italy, ³⁰Department of Internal Medicine, University Hospital of Messina, Messina, Italy, ³¹Department of Medical Biotechnology, University of Siena, Siena, Italy, ³²Hospital Niguarda Ca'Granda, Milan, Italy, ³³Hepatology Unit, San Camillo Forlanini Hospital, Rome, Italy, ³⁴Medical, Surgical and Experimental Sciences, University of Sassari, Sassari, Italy, ³⁵Infectious and Tropical Diseases Unit, Department of Clinical Medicine, "La Sapienza" University of Rome, Rome, Italy, ³⁶Department of Medical Biotechnology, University of Siena, Siena, Italy, ³⁷Department of Oncology and Oncohematology, University of Milan, Milan, Italy

ORAL COMMUNICATIONS 10.05-11.35

AULA 201

Immunological insights of HIV infection

Chairs: M. Lichtner (Latina), G. Tambussi (Milano), C. Tincati (Milano)

OC 7 10.05-10.15 Interleukin 32: a new marker of chronic immune activation in HIV patients receiving antiretroviral therapy

M. Statzu¹, L. Santinelli¹, C. Pinacchio², F. Frasca¹, C.M. Mastroianni², G. Antonelli¹, G. d'Ettore², C. Scagnolari¹

¹Department of Molecular Medicine, Laboratory of Virology affiliated to Istituto Pasteur Italia - Fondazione Cenci Bolognietti, Sapienza University, Rome, Italy; ²Department of Public Health and Infectious Diseases, Sapienza University, Rome, Italy

OC 8 10.17-10.27 Efficient anti-HPV specific T cell response after vaccination in HIV patients

M. Nasi¹, S. De Biasi², E. Bianchini¹, A. Neroni³, M. Digaetano⁴, D. Lo Tartaro⁵, M. Pinti², L. Gibellini¹, D. Pavia⁶, A. Bignardi⁷, C. Mussini^{1,4}, A. Cossarizza³

¹Department of Surgery, Medicine, Dentistry and Morphological Sciences, University of Modena and Reggio Emilia, Modena, Italy, ²Department of Life Sciences, University of Modena and Reggio Emilia, Modena, Italy, ³Department of Medical and Surgical Sciences for Children and Adults, University of Modena and Reggio Emilia, Modena, Italy, ⁴Infectious Diseases Clinics, Azienda Ospedaliero-Universitaria Policlinico di Modena, Modena, Italy, ⁵Department of Biomedical, Metabolic and Neural Sciences; University of Modena and Reggio Emilia, Modena Italy, ⁶Arcigay Modena "Matthew Shepard", Modena, Italy, ⁷Arcigay - Associazione LGBTI Italiana, Bologna, Italy



SCIENTIFIC
PROGRAMME



GIOVEDÌ
6 GIUGNO

11° CONGRESSO NAZIONALE
Italian Conference on
AIDS and Antiviral Research

5-7 GIUGNO 2019
UNIVERSITÀ DEGLI STUDI DI MILANO

- OC 9 10.29-10.39 Innate immune and epigenetic modulators reactivate latent HIV-1 T cell reservoirs**
E. Palermo¹, C. Acchioni², D. Di Carlo³, A. Zevini¹, M. Muscolini¹, M. Ferrari¹, L. Castiello¹, S. Virtuoso⁴, A. Borsetti⁴, G. Antonelli³, O. Turriziani³, M. Sgarbanti², J. Hiscott¹
¹Istituto Pasteur - Fondazione Cenci Bolognietti, Rome, ²Department of Infectious, Parasitic and Immune-Mediated Diseases, Istituto Superiore di Sanità, Rome, ³Department of Molecular Medicine, "Sapienza" University of Rome, Rome, ⁴National HIV/AIDS Research Center, Istituto Superiore di Sanità, Rome
- OC 10 10.41-10.51 Phenotypical Recovery of the T-cell Pool Following Switch to Dual INSTI-based cART**
C. Tincati, D. Mondatore, A. Tavelli, L. Nekrasova, M. Sala, A. d'Arminio Monforte, G. Marchetti
Department of Health Sciences, Clinic of Infectious Diseases, ASST Santi Paolo e Carlo, University of Milan, Italy
- OC 11 10.53-11.03 Sex-related differences in immune activation markers during HIV-1 infection**
L. Santinelli¹, C. Borrazzo², G.P. Innocenti², C. Pinacchio², M. Statzu¹, G. Ceccarelli², C. Scagnolari¹, G. Antonelli^{1,3}, C.M. Mastroianni², V. Vullo², G. d'Ettore²
¹Laboratory of Virology, Department of Molecular Medicine, Affiliated to Istituto Pasteur Italia - Cenci Bolognietti Foundation, Sapienza University of Rome, Rome, Italy, ²Department of Public Health and Infectious Diseases, Sapienza University of Rome, Rome, Italy, ³Microbiology and Virology Unit, Sapienza University Hospital, Rome, Italy
- OC 12 11.05-11.15 Stable Microbial Function Despite Shifts in the Faecal Microbiota Composition According to Third-Drug Class in Antiretroviral-Naive Individuals Introducing cART**
G. Ancona¹, C. Tincati¹, E. Merlini¹, A. Calcagno², A. d'Arminio Monforte¹, G. Marchetti¹
¹Department of Health Sciences, Clinic of Infectious Diseases, ASST Santi Paolo e Carlo, University of Milan, Italy, ²Unit of Infectious Diseases, Department of Medical Sciences, University of Torino
- OC 13 11.17-11.27 No association between patterns of 179-181tripeptide of the V2 domain binding the gut-homing 4 7 integrin and levels of bacterial translocation markers in HIV-1 infected patients naïve to antiretrovirals**
F. Balena, D.F. Bavarò, C. Fabrizio, A. Volpe, A. Lagioia, G. Angarano, L. Monno, A. Saracino
Department of Biomedical Sciences and Human Oncology, Clinic of Infectious Diseases, University of Bari Medical School, Bari, Italy

SYMPOSIUM 11.40-13.10

AULA MAGNA

New options for treating opportunistic infections in immunocompromised host

Chairs: G. Carosi (Brescia), R. Cauda (Roma), D. Cirillo (Milano)

Advanced HIV patients have with significant frequency "classical" opportunistic infections but also healthcare-related infections caused by multiresistant bacteria or yeasts. In the recent years healthcare-related and opportunistic infections in HIV-negative population had triggered the need to expand the therapeutic armamentarium with new drugs, characterized by a broader spectrum of action and/or less toxicity and more convenience. The indication for these drugs and the new perspectives offered by the anti-infective drugs pipelines must be part of the cultural background of the clinician who takes care of HIV patients.

- | | | |
|-------------|---|--------------------------|
| 11.40-11.55 | Innovation in diagnosis and treatment of CMV infection | Loredana Sarmati, Roma |
| 11.55-12.10 | Difficult to treat bacterial infections and immunodeficiencies | Mario Venditti, Roma |
| 12.10-12.25 | Fungal infections: latest in prevention and management | Pierluigi Viale, Bologna |
| 12.25-12.40 | Facing Mycobacteria in 2019 | Luigi Codecasa, Milano |
| 12.40-13.10 | Discussion on Symposium issues | |

Lunch from 12.30 to 14.30 - Porticato San Nazaro

SCIENTIFIC PROGRAMME

ORAL COMMUNICATIONS 11.40-13.10

AULA 211

A Healthy Brain in People Living with HIV

Chairs: A.M. Cattelan (Padova), G. Lapadula (Monza), R. Maserati (Pavia)

- OC 14 11.40-11.50 Comparative neuropsychiatric toxicity profile of dolutegravir (DTG)-based versus efavirenz (EFV)-based versus other recommend first-line antiretroviral therapies (ART): data from Icona Foundation Study Cohort**
A. Mondì¹, A. Cozzi-Lepri², A. Cingolani³, A. Tavelli⁴, M. Puoti⁵, V. Barocci⁶, A. Londero⁷, F. Bai⁸, C. Pinnetti¹, P. Cinque⁹, A. d'Arminio Monforte⁸, A. Antinori¹ on behalf of the Icona Foundation Study Group
¹HIV/AIDS Department, National Institute for Infectious Diseases "Lazzaro Spallanzani" IRCCS, Rome, Italy, ²Centre for Clinical Research, Epidemiology, Modelling and Evaluation (CREME), Institute for Global Health, UCL, London, UK, ³Infectious Diseases Unit, Catholic University of Sacred Heart, Rome, Italy, ⁴Icona Foundation, Milan, Italy, ⁵Infectious Diseases Department, ASST Grande Ospedale Metropolitano Niguarda, Milano, Italy, ⁶Clinic of Infectious Diseases, Dept. of Biomedical Sciences and Public Health, Polytechnic University of Marche, Ancona, Italy, ⁷Infectious Diseases Clinic, Department of Medicine University of Udine and Azienda Sanitaria Universitaria Integrata di Udine, Udine, Italy, ⁸Clinic of Infectious and Tropical Diseases, Department of Health Sciences, ASST Santi Paolo e Carlo, University of Milan, Milan, Italy, ⁹Department of Infectious Diseases, San Raffaele Hospital, Vita-Salute University, Milan, Italy
- OC 15 11.52-12.02 Neurocognitive Impairment (NCI) is not associated with Integrase Strand Transfer Inhibitors (INSTIs) use in HIV positive persons (PLWH)**
A. Mondì, A.C. Brita, P. Lorenzini, A. Vergori, R. Gagliardini, V. Mazzotta, S. Cicalini, R. Bellagamba, A. Antinori, C. Pinnetti
 HIV/AIDS Department, National Institute for Infectious Diseases "Lazzaro Spallanzani", IRCCS, Rome Italy
- OC 16 12.04-12.14 Central Nervous System Efficacy of Dual versus Triple Antiretroviral Therapy in a real-life setting**
M. Trunfio¹, D. Vai², E. Borgogno¹, V. Pirriatore¹, M.C. Tettoni¹, D. Imperiale², G. Di Perri¹, S. Bonora¹, A. Calcagno¹
¹Unit of Infectious Diseases, Amedeo di Savoia hospital, University of Torino, Torino, Italy, ²Unit of Neurology, Maria Vittoria hospital, Torino, Italy
- OC 17 12.16-12.26 Mini-Addenbrooke's Cognitive Examination versus International HIV-Dementia Scale for current HIV-Associated Neurocognitive Disorders**
M. Trunfio¹, D. Vai², M. Milesi¹, A. Trentalange¹, S. Audagnotto¹, G. Orofino³, D. Imperiale², S. Bonora¹, G. Di Perri¹, A. Calcagno¹
¹Unit of Infectious Diseases, Amedeo di Savoia hospital, Department of Medical Sciences, University of Turin, Turin, Italy, ²Unit of Neurology, Maria Vittoria hospital, ASL Città di Torino, Turin, Italy, ³Unit of infectious Diseases, Amedeo di Savoia hospital, Divisione A, Turin, Italy
- OC 18 12.28-12.38 Neuropsychological performance improves in fully virologically suppressed HIV-positive individuals**
A.C. Brita¹, B. Milanini², P. Lorenzini¹, A. Mondì¹, A. Vergori¹, S. Menichetti¹, R. Gagliardini¹, A. Giannetti¹, R. Bellagamba¹, S. Cicalini¹, A. Antinori¹, C. Pinnetti¹
¹HIV/AIDS Clinical Unit, INMI, Lazzaro Spallanzani, Rome, Italy, ²Memory and Aging Center, Department of Neurology, University of California, San Francisco, California
- OC 19 12.40-12.50 Frailty index (FI) and age predict neurocognitive functioning in a real life large prospective HIV+ cohort**
G. Guaraldi¹, J. Milic¹, L. Cysique², A. Malagoli¹, M.G. Corni¹, E. Bardi¹, F. Carli¹, I. Franconi¹, C. Mussini¹, M. Bloch³
¹Modena HIV Metabolic Clinic, University of Modena and Reggio Emilia, ²Neuroscience Research Australia, School of Medical Sciences, Faculty of Medicine, The University of New South Wales, Sydney, NSW, Australia, ³Holdsworth House Medical Practice, Sydney, NSW, Australia
- OC 20 12.52-13.02 Changes over time in clinical and laboratory features and correlates of survival of HIV-associated Progressive Multifocal Leukoencephalopathy**
I. Mainardi¹, A.G. Tarantino², R. Caccia³, F. Turrini³, F. Ferretti¹, A. Bestetti¹, A. Lazzarin¹, P. Cinque^{1,3}
¹Department of Infectious Diseases, San Raffaele Scientific Institute, Milano, ²Department of Research, Manima, Assistance and Healthcare Organization, Milano, ³Neurovirology Unit, Division of Immunology, Transplantation and Infectious Diseases, San Raffaele Scientific Institute, Milano





GIOVEDÌ
6 GIUGNO

11° CONGRESSO NAZIONALE
Italian Conference on
AIDS and Antiviral Research

5-7 GIUGNO 2019
UNIVERSITÀ DEGLI STUDI DI MILANO

ORAL COMMUNICATIONS 11.40-13.10

AULA 201

New insights in HIV pathogenesis

Chairs: D. Cattaneo (Milano), S. Parisi (Padova), G. Scarlatti (Milano)

OC 21 11.40-11.50 Analytical treatment interruption does not alter size but might cause genetic diversification of the HIV-1 peripheral reservoir

C. Alteri¹, R. Scutari², L. Galli³, M.C. Bellocchi², L. Carioti², V. Costabile⁴, A. Poli³, A. Galli³, F. Ceccherini-Silberstein², C.F. Perno¹, M.M. Santoro², A. Castagna^{3,5}, V. Spagnuolo⁵

¹Department of Oncology and Hemato-oncology, University of Milan, Milan, Italy, ²Department of Experimental Medicine, University of Rome Tor Vergata, ³Infectious Diseases, San Raffaele Scientific Institute, Milan, Italy, ⁴Department of Pathophysiology and Transplantation, University of Milan, Milan, Italy, ⁵Università Vita-Salute San Raffaele, Milan, Italy

OC 22 11.52-12.02 HIV mediated insertional mutagenesis induces a viral reservoir in T-regulatory cells

E. Bruzzesi^{1,3}, L. Rudilosso², P. Gallina², A. Calabria², S. Nozza¹, G. Tambussi¹, A. Castagna^{1,3}, E. Montini², D. Cesana²

¹Department of Infectious Diseases, San Raffaele Scientific Institute, Italy, ²San Raffaele Telethon Institute for Gene Therapy (SR-TIGET), San Raffaele Scientific Institute, Italy, ³Faculty of Medicine and Surgery, Vita-Salute San Raffaele University, Milan

OC 23 12.04-12.14 Highly Active Antiretroviral Therapy and osteogenic differentiation: new hints into drug-induced osteopenia

A. Cazzaniga, S. De Rose, V. Romeo, JAM Maier, S. Rusconi

¹General Pathology Laboratory, DIBIC Luigi Sacco, University of Milan, ²Infectious Diseases Unit, DIBIC Luigi Sacco, University of Milan

OC 24 12.16-12.26 Aging and hemato-lymphopoiesis in HIV infection: role of Per2 in the regulation of hematopoietic progenitor cells functions

V. Bordoni¹, E. Tartaglia¹, A. Sacchi¹, R. Casetti¹, E. Cimini¹, G. Grassi¹, O. Forini¹, A. Antinori², C. Agrati¹

¹Laboratorio di Immunologia Cellulare e Farmacologia, INM-HRCCS L.Spallanzani, Roma, ²Dipartimento Clinico INM-HRCCS L.Spallanzani, Roma

OC 25 12.28-12.38 DNA damage response genes: analysis of mRNA expression in naive and ART-treated HIV positive patients

D. Di Carlo¹, F. Falasca¹, E. Panzini², I. Sciandra¹, T. Melengu¹, O. Turriziani¹, G. Antonelli¹

¹Department of Molecular Medicine "Sapienza" University of Rome, Rome, ²University Hospital Policlinico Umberto I, Rome

OC 26 12.40-12.50 Endoplasmic reticulum associated aminopeptidases 2 (ERAP2) is released in the secretome of activated MDMs and reduces in vitro HIV-1 infection

I. Saulle¹, S.V. Ibba¹, E. Torretta², C. Vittori¹, C. Fenizia³, F. Piancone⁴, D. Minisci⁵, E.M. Lori¹, D. Trabattoni¹, C. Gelfi², M. Clerici^{3,4}, M. Biasin¹

¹Department of Biomedical and Clinical Sciences L. Sacco, University of the study Milan, Milan, Italy, ²Department of Biomedical Science for Health, University of the study Milan, Milan, Italy, ³Department of Pathophysiology Medical-Surgery and Transplantation, University of the study of Milan, Milan, Italy, ⁴Don C. Gnocchi Foundation ONLUS, IRCCS, Milan, Italy, ⁵Department of Infectious Disease, ASST Fatebenefratelli Sacco, Milan, Italy

OC 27 12.52-13.02 Interferon-inducible TRIM22 interacts with histone deacetylase (HDAC)-1 to maintain HIV-1 proviral latency

E. Vicenzi¹, F. Turrini^{1,2}, G. Forlani³, S. Ghezzi¹, R.S. Accolla³, G. Poli^{2,4}

¹Unit of Viral Pathogens and Biosafety, Division of Immunology, Transplantation and Infectious Diseases, IRCCS San Raffaele Scientific Institute, Milan, Italy, ²Vita-Salute San Raffaele University, School of Medicine, Milan, Italy, ³Laboratories of General Pathology and Immunology "Giovanna Tosi", Department of Medicine and Surgery, University of Insubria, Varese, Italy, ⁴AIDS Immunopathogenesis Unit, Division of Immunology, Transplantation and Infectious Diseases, San Raffaele Scientific Institute, Milano, Italy

Lunch from 12.30 to 14.30 - Porticato San Nazaro

SCIENTIFIC
PROGRAMME 



GIOVEDÌ
6 GIUGNO

11° CONGRESSO NAZIONALE
Italian Conference on
AIDS and Antiviral Research

5-7 GIUGNO 2019
UNIVERSITÀ DEGLI STUDI DI MILANO

EXPERT MEETING 11.40-12.40

Con la sponsorizzazione non condizionante di Cepheid

The revolution of rapid molecular diagnosis “near patient”

Discussants: M. Cernuschi (Milano), S. Mattioli (Bologna)

The aim of the workshop is to illustrate the advantages of rapid molecular diagnosis in the virology field. Different healthcare professionals (HCP) will provide an explanation of the technology and the impact of tests in different setting such as hospitals or alternative sites.

AULA MALLIANI

- 11.40-12.00 **The impact of molecular technology on HIV**
- 12.00-12.20 **The impact of molecular technology on HCV**
- 12.20-12.40 **Discussion on Expert Meeting issues**

Andrea Gori, Milano
Carlo Federico Perno, Milano

EXPERT MEETING 12.45-13.45

Con la sponsorizzazione non condizionante di MSD Italia

Moving forward to tailored approaches: real life & future in virology

Chair: G. Rizzardini (Milano)

Treatment personalization, based on patients' features, is becoming in HIV and HCV increasingly important. Efficacy, extremely high tolerability, as well as low DDI are now crucial treatment imperatives. Starting from real world clinical evidences going through innovative new treatment options, personalization is essential to ensure patients' high QoL and treatment effectiveness.

AULA MALLIANI

- 12.45-13.00 **DAA in clinical real life**
- 13.00-13.15 **Real world evidences: QD INSTI based strategies**
- 13.15-13.30 **HIV-1 infection: time to drive safely**
- 13.30-13.45 **Discussion on Expert Meeting issues**

Loreta Kondili, Roma
Simona Di Giambenedetto, Roma
Antonella Castagna, Milano

SPONSORED SYMPOSIUM 13.15-14.00

Con il supporto di ViiV Healthcare

2DR: from opportunity to change of paradigm

Chair: A. d'Arminio Monforte (Milano)

PLHIV are aware of the potential long-term risks of current ART therapies that in any case allow a control of viremia and a normal life expectancy. Dolutegravir represented a breakthrough therapy in HIV, demonstrated by 5 studies of superiority and by the recognition of an innovative product by the Italian regulatory agency, offering PLVWH valid therapeutic options. Thanks to the results obtained in triple therapies, dolutegravir was subsequently studied in robust 2-drug studies that allows to question the current twenty-year paradigm of the 3 drug regimens. Today, 2-Drug regimens have been proposed, ensuring the same efficacy and safety of a 3 drug regimen to reduce patient exposure to ARVs and potential associated toxicities since from naïve patient.

AULA MAGNA

- 13.15-13.30 **The effectiveness of dolutegravir: From the three drugs regimen to the two drug regimen**
- 13.30-13.45 **Dolutegravir: the importance of the high barrier to resistance**
- 13.45-14.00 **Discussion on Symposium issues**

Andrea Antinori, Roma
Maurizio Zazzi, Siena



SCIENTIFIC
PROGRAMME

Lunch from 12.30 to 14.30 - Porticato San Nazaro

POSTER DISCUSSION 13.15-14.45

AULA 211

Social Science and management of HIV beyond antiretroviral therapy

Chairs: A. Bignardi (Modena), B.M. Celesia (Catania)

- PD 1 13.15-13.20 Educational projects in schools: a retrospective analysis of a 15-year activity**
E. Mozzo¹, V. Ortolan¹, C. Novello¹, F. Batterman², N. Gatti², M. Crimardo², C. Giaquinto¹
¹Fondazione Penta, Padova, ²Associazione C.A.S.A., Padova
- PD 2 13.23-13.28 A survey as a chance of education on U=U in PLWHIVA**
G. Orofino¹, S. Patrucco², P. Altini³, G.L. Ciperò², A. Perziano², C. Owen², M. Gay⁴
¹Ospedale Amedeo di Savoia, Torino, ²Associazione Arcobaleno AIDS, Torino, ³Dipartimento di Scienze della Sanità Pubblica e Pediatriche, Torino, ⁴Ospedale SS. Antonio e Biagio e Cesare Arrigo, Alessandria
- PD 3 13.31-13.36 Testing MSM in cruising venues**
D. Zagato, A. Andolina, L. Beltrami, A. Bianchi, C. Ferrara, E. Garavaglia, V. La Monica, S. Lollo, L. Londei, F. Maddaloni, M. Manfredini, V. Nicotera, D. Pennisi, A. Pezzotti, M. Pierini, F. Poletti, F. Riili, C. Romero, J. Scalisi, P. Testoni, L. Valpreda, P. Vinti, A. Ünlü, M. Zoia, M. Cernuschi
ASA Associazione Solidarietà AIDS, Milan
- PD 4 13.39-13.44 Not only MSM: women and HIV test in a community-based site**
A. Bianchi, F.M. Esposito, A. Antonino, G. Fracca, M. Lanza, F. Rossi, J.G. Scalisi, R. Repposi, P. Testoni, D. Zagato, M. Cernuschi
ASA, Associazione Solidarietà AIDS Onlus, Milan, Italy
- PD 5 13.47-13.52 Clinical research integrated with narrative-based research to understand living and managing HIV: TMC114FD1HTX4011 - DIAMANTE study**
A. Antinori¹, A. Vergori¹, M. Camici¹, V. Esposito², M.A. Carleo², P. Rosario², M. Andreoni³, V. Malagnino³, L. Campogiani³, A. Cascio⁴, M. Trizzino⁴, G. Mazzola⁴, D. Ripamonti⁵, D. Valenti⁵, E. Manzillo⁶, T. Pizzella⁶, L. Aprea⁶, E. Focà⁷, A. Celotti⁷, A. Cappuccio⁸, L. Reale⁸, A. Uglietti⁹, D. Mancusi⁹, R. Termini⁹
¹HIV/AIDS Unit, National Institute for Infectious Diseases L. Spallanzani, IRCCS, Rome, Italy, ²General Infectious Diseases Unit, Department of Infectious Disease and Infectious Emergencies, Cotugno Hospital, Naples, Italy, ³Infectious Diseases Clinic, Foundation Policlinico Tor Vergata University Hospital, Rome, Italy, ⁴Infectious Diseases Clinic, AOU Policlinico "P.Giaccone", Palermo - Italy, ⁵Infectious Diseases Clinic, Papa Giovanni XXIII Hospital, Bergamo - Italy, ⁶UOS Infectious Disease and Infectious Emergencies, Azienda Ospedaliera dei Colli, Naples, Italy, ⁷Tropical and Infectious Diseases Clinic, ASST Spedali Civili di Brescia, University of Brescia, Brescia - Italy, ⁸ISTUD Foundation, Milan, Italy, ⁹Janssen-Cilag SpA, Cologno Monzese, Italy
- PD 6 13.55-14.00 "Integrated Protection for People Living with HIV in Angola" (PIPSA) a "Test/Treat/ Prevent HIV Program". Preliminary data**
L. Verzotti^{1,2}, T. Baldoni^{1,2}, S. Guedes¹, E. Braganha de Nascimento¹, J.C.G. Da Costa³, T. Chilumbo⁴, S.V. Loa⁵, G. Pellizzer⁶, Nigro^{1,6} for PIPSA Activists
¹Proteção integral para o Paciente Seropositivo Angola (PIPSA), Luanda, Angola, ²Unione Medico Missionaria Italiana (UMMI), Verona, Italia, ³Repartição Municipal de Saúde do Município de Kilamba Kixi, Luanda, Angola, ⁴Direcção Provincial da Saúde de Luanda, Luanda, Angola, ⁵Hospital Divina Providência, ⁶Medici con l'Africa-Cuamm, Padova, Italia
- PD 7 14.03-14.08 Retention in HAART among youth accessing SAAJ (Serviços Amigos dos Adolescentes e Jovens) in Beira, Mozambique**
C. Vitali¹, G. Prensusi², E. Namarime³, D. Pizzol⁴, G. Putoto⁵, L. Praticò⁶
¹University of Pavia, Pavia, ²University of Pavia, Pavia, ³Doctors with Africa CUAMM, Beira, ⁴Doctors with Africa CUAMM, Padova, ⁵Doctors with Africa CUAMM, Padova, ⁶Doctors with Africa CUAMM, Padova
- PD 8 14.11-14.16 Implementation of HIV patients care through personalized exercise program**
P. Vassalini, E.N. Cavallari, L. Santinelli, C. Borrazzo, L. Celani, G.P. Innocenti, G. Ceccarelli, G. Tancredi, C. Mastroianni, V. Vullo, G. d'Ettore
Sapienza University of Rome, Rome
- PD 9 14.19-14.24 In-hospital vaccination program for HIV positive patients: who are the unvaccinated individuals**
D. Barbanotti, L. Gazzola, A. De Bona, G. Ancona, F. Bai, S. Cianciola, K. Reister, P. Tognetti, C. Tincati, G. Marchetti, T. Bini, A. d'Arminio Monforte
Department of Health Sciences, Clinic of Infectious Diseases, ASST Santi Paolo e Carlo, University of Milan, Italy
- PD 10 14.27-14.32 Non-occupational Post-Exposure Prophylaxis: how everyday clinical practice complies with Guidelines recommendation?**
R. Rossotti, M. Cantone, L.G. Chianura, M.C. Moiola, S. Chiappetta, F. Crippa, M. Merli, D. Motta, C. Orcese, A. Pazzi, G. Travi, B.P. Vigo, M. Puoti
Department of Infectious Diseases, ASST Grande Ospedale Metropolitano Niguarda, Milan



SATELLITE SYMPOSIUM 13.15-14.00

Con la sponsorizzazione non condizionante di Gilead Sciences

AULA 201

The last mile towards HCV elimination

Chairs: G.B. Gaeta (Napoli) M. Puoti (Milano)

Synergy within institutions, clinicians and network systems has been the basis to develop integrated strategies for the management of chronic liver disease due to HCV infection. The challenge now is to screen and diagnose all in need of treatment. It means to identify and engage the critical mass of the many unaware of their condition or the difficult-to-reach high-risk populations, ensuring a wide-scale treatment. The high efficacy and the excellent safety of the new pangenotypic therapy show evidence of a reduced need for intensive treatment monitoring and simplify screening, diagnosis and care in few visits. An effective streamline approach that can make elimination of HCV in Italy by 2030 a feasible goal.

- 13.15-13.30 **Strategies for HCV control beyond network models**
- 13.30-13.45 **Test and treat approach: the next step to eradication**
- 13.45-14.00 **Discussion on Symposium issues**

Antonio Craxì, Palermo
Nicola Coppola, Napoli

EXPERT MEETING 14.00-15.00

Con la sponsorizzazione non condizionante di Angelini

AULA MALLIANI

Recent advances in the management of Gram positive infections: the evolving role of long acting therapy

Chair: M. Tavio (Ancona)

Gram positive infections are a continuing challenge for clinicians: while "classic" pathogens still persist and evolve acquiring new mechanisms of resistance, new pathogens emerge with intrinsic multiple antibiotics resistance profiles, causing life-threatening infections as nosocomial pneumonia and intravascular device associated bloodstream infections. Not less important, the population at risk, i.e. elderly with multiple comorbidities or recipients of various foreign bodies, is increasing. New therapy options are required, with increased bactericidal activity and antibacterial spectrum that includes multiple resistant pathogens. Finally, oral or long acting agents might be critical in order to reduce hospital costs with outpatient therapy feasible even for serious infections as bone and joint infections or endocarditis. In recent years the antimicrobial armamentarium has been enriched by "very long" acting anti Gram positive agents approved for the therapy of ABSSI, as oritavancin and dalbavancin. In particular, pharmacokinetic profile and convenient single dosing make dalbavancin an interesting option for other serious Gram positive infections requiring prolonged treatment courses, for example bone infections, endocarditis and intravascular line associated infections. The aim of this workshop is to critically review all available experiences with long acting agents in order to provide an up-to-date of the actual and potential future role of this options for serious Gram positive infections.

- 14.00-15.00 **Recent advances in the management of Gram positive infections: the evolving role of long acting therapy**

Silvio Borrè, Vercelli
Mario Venditti, Roma





**GIOVEDÌ
6 GIUGNO**

**11° CONGRESSO NAZIONALE
Italian Conference on
AIDS and Antiviral Research**

**5-7 GIUGNO 2019
UNIVERSITÀ DEGLI STUDI DI MILANO**

SATELLITE SYMPOSIUM 14.05-14.50

Con la sponsorizzazione non condizionante di Janssen

Long-life individuality in caring for HIV

Chair: M. Andreoni (Roma)

Nowadays challenges in caring for HIV are both the management of long-term antiretroviral therapy and the unmet needs of every single HIV-positive patient. Today antiretroviral drugs are easy to take, powerful and well tolerated. HIV-positive patients require long-life treatments and maintaining durability and tolerability of antiretroviral regimen in association with other co-administered drugs for incoming comorbidities. The aim of the symposium is to examine how current antiretroviral agents may be better incorporated into management strategies in daily practice to benefit patients now and to preserve the future. This is the most important goal: taking into account increasing age of HIV population and concomitant diseases and therapies that are now the challenge for Infectivologists.

AULA 201

- 14.05-14.20 **The challenge of focusing on the right patient**
- 14.20-14.35 **Tolerability: the long-life issue**
- 14.35-14.50 **Tailored Daily Practice**

- Cristina Mussini, Modena
- Sergio Lo Caputo, Bari
- Antonio Di Biagio, Genova

SYMPOSIUM 14.55-16.25

Critical issues in ART

Chairs: G. Angarano (Bari), T. Bini (Milano), G. Di Perri (Torino)

Despite the evident success of ART, with almost all patients attaining virological suppression, many issues remain only partially addressed. For instance, too many patients withdraw from treatment and can thus transmit HIV infection and adolescents that have been infected vertically must face HIV infection and its management in a very critical phase of their lives. Furthermore, there are still some shadow areas about the long-term efficacy of two-drugs regimens, and, while the toxicity of new ART regimens is certainly lower from that of the "old" ones, new regimens may not be free from not yet well defined adverse effects.

AULA MAGNA

- 14.55-15.10 **Lost in follow-up**
- 15.10-15.25 **Growing with ART**
- 15.25-15.40 **Toxicity: one step forward, one step back**
- 15.40-16.00 **2DR – 3DR: two points of view**
- 16.00-16.25 **Discussion on Symposium issues**

- Enrico Girardi, Roma
- Vania Giacomet, Milano
- Paolo Bonfanti, Lecco
- Simona Di Giambenedetto, Roma
- Sergio Lo Caputo, Bari

Lunch from 12.30 to 14.30 - Porticato San Nazaro





GIOVEDÌ
6 GIUGNO

11° CONGRESSO NAZIONALE
Italian Conference on
AIDS and Antiviral Research

5-7 GIUGNO 2019
UNIVERSITÀ DEGLI STUDI DI MILANO

POSTER DISCUSSION 14.55-16.25

AULA 211

Clinical HIV and Epidemiology

Chairs: A. De Maria (Genova), N. Petrosillo (Roma)

- PD 11 14.55-15.00 Dolutegravir-based antiretroviral regimens for HIV liver transplant patients in real life**
D. Cattaneo, S. Sollima, P. Meraviglia, L. Milazzo, D. Minisci, M. Fusi, C. Gervasoni
ASST Fatebenefratelli Sacco University Hospital, Milano
- PD 12 15.03-15.08 High incidence and prevalence of syphilis among HIV-infected MSM in Thailand**
C. Muccini^{1,2}, S. Pinyakorn^{3,4}, C.J Kolsteeg⁵, E. Kroon², C. Sacdalan², P. Prueksakaew², P. Phanuphak², J. Ananworanich^{2,3,4}, N. Phanuphak², D. Colby²
¹Vita-Salute San Raffaele University, Milan, Italy, ²SEARCH, The Thai Red Cross AIDS Research Centre, Bangkok, Thailand, ³U.S Military HIV Research Program, Walter Reed Army Institute of Research, Silver Spring, USA, ⁴Henry M. Jackson Foundation for the Advancement of Military Medicine, Bethesda, USA, ⁵Utrecht University, Utrecht, The Netherlands
- PD 13 15.11-15.16 Is HIV Sorted? Survey – Results Highlights for Italy**
B. Audoin¹, R. Caldera², M. Carlevari², S. Head³, C. Zocchetti², J. M. Zuniga⁴
¹International Association of Providers of AIDS Care (IAPAC), Paris, ²Gilead Sciences srl, Milan, ³Gilead Sciences Europe Ltd, Stockley Park, Uxbridge, ⁴International Association of Providers of AIDS Care (IAPAC), Washington DC
- PD 14 15.19-15.24 Impact of HIV self-test (HIVST) implementation on new HIV diagnoses in Italy**
G. Chiradia¹, A. Navarra¹, S. Pittalis¹, G. De Carli², N. Orchi², V. Puro², E. Girardi¹
¹Clinical Epidemiology Unit - National Institute for Infectious Diseases "L. Spallanzani" - IRCCS, Rome, ²AIDS Reference Center- National Institute for Infectious Diseases "L. Spallanzani" - IRCCS, Rome
- PD 15 15.27-15.32 "Test and treat": state of the art. Data from an Italian multicenter cohort**
G. Baldin¹, A. Ciccullo¹, S. Rusconi², V. Borghi³, A. Giacomelli⁴, S.T. Kiro⁵, M. Colafigli⁶, A. Lanari^{7,8}, L. Celani⁹, A. De Vito¹⁰, A. Giacomelli², C. Mussini³, G. Sterrantino⁵, S. Di Giambenedetto^{1,11}
¹Istituto di Malattie Infettive, Università Cattolica del Sacro Cuore, Roma, Italy, ²Infectious Diseases Unit, DIBIC Luigi Sacco, University of Milan, Milan, Italy, ³Azienda Ospedaliero Universitaria di Modena, Clinica Malattie Infettive e Tropicale, Modena, Italy, ⁴Clinic of Infectious Diseases, Dept. of Biomedical Sciences and Public Health, Polytechnic University of Marche, Ancona, Italy, ⁵Division of Tropical and Infectious Diseases, 'Careggi' Hospital, Florence, Italy, ⁶Infectious Dermatology and Allergology Unit, IFO S. Galliciano Institute (IRCCS), Rome, Italy, ⁷Infectious Diseases Unit, AOU Senese, Siena, Italy, ⁸Department of Medical Biotechnologies, University of Siena, Siena, Italy, ⁹Department of Public Health and Infectious Diseases, Azienda Policlinico Umberto I, Rome, Italy, ¹⁰Department of Clinical, Surgical and Experimental Sciences, University of Sassari, Sassari, Italy, ¹¹Fondazione Policlinico Universitario Agostino Gemelli IRCCS, UOC Malattie Infettive, Roma, Italy
- PD 16 15.35-15.40 Tracing the first HIV-1 epidemics in the Milan area**
A. Lai¹, A. Bergna¹, G. Zehender¹, A. Giacomelli¹, M. Ciccozzi², C. Balotta¹, M. Galli¹
¹Department of Biomedical and Clinical Sciences "Luigi Sacco", University of Milan, Milan, Italy, ²Unit of Clinical Pathology and Microbiology, University Campus Bio- Medico of Rome, Rome, Italy
- PD 17 15.43-15.48 Phylogenetic analysis of HIV-1 in foreign patients followed at San Martino Hospital, Genoa**
B. Bruzzone², A. Lai⁴, L. Magnasco³, P. Caligiuri¹, S. Varesano¹, N. Nigro², A. Di Biagio³
¹Hygiene Unit, Department of Health Sciences, University of Genoa, IRCCS San Martino - IST, Genoa, Italy, ²Hygiene Unit, IRCCS San Martino - IST, Genoa, Italy, ³Infectious Diseases, Department of Internal Medicine, University of Genoa, IRCCS San Martino - IST, Genoa, Italy, ⁴Department of Biomedical and Clinical Sciences, University of Milan, Milan Italy
- PD 18 15.51-15.56 Factors associated with being on treatment with a DRV-based regimen among adults with HIV-1 infection in real life**
L. Galli¹, A. Castagna^{1,2}, A. Poli¹, S. Bossolasco¹, G. Gaiera¹, M. Guffanti¹, M. Maillard¹, A. Andolina², A. Lazzarin¹, R. Termini³, M. Palma³, D. Mancusi³
¹Clinic of Infectious Diseases, Istituto Scientifico San Raffaele, Milano, Italy, ²Clinic of Infectious Diseases, Vita-Salute San Raffaele University, Milano, Italy, ³Janssen-Cilag SpA, Medical Affairs, Infectious Diseases; Cologno Monzese, Milano, Italy
- PD 19 15.59-16.04 Influence of Sexually Transmitted Infections on seminal HIV levels among patients on ART: preliminary data of a case-control study**
C. Stingone¹, R. Scutari², E. Teti¹, L. Piermatteo², V. Malagnino¹, M. Brugnati², M. Compagno¹, A. Bertoli², V. Svicher², C. Cerva¹, M. Santoro², C.F. Perno³, C. Alteri³, L. Sarmati¹, M. Andreoni¹, F. Ceccherini-Silberstein²
¹Clinical Infectious Diseases, Department of System Medicine, Tor Vergata University, Rome, Italy, ²Department of Experimental Medicine, Tor Vergata University, Rome, Italy, ³Department of Oncology and Hemato-oncology, University of Milan, Italy



SCIENTIFIC
PROGRAMME



GIOVEDÌ
6 GIUGNO

11° CONGRESSO NAZIONALE
Italian Conference on
AIDS and Antiviral Research

5-7 GIUGNO 2019
UNIVERSITÀ DEGLI STUDI DI MILANO

ORAL COMMUNICATIONS 14.55-16.25

AULA 201

Let's PrEP now: Italian experiences

Chairs: M. Errico (Milano), B. Marchini (Roma), L. Sighinolfi (Ferrara)

OC 28 14.55-15.05 PrEP services in Italy: how many people access them and what kind of services are offered?

G.M. Corbelli¹, L. Badia², E. Barchi³, F. Bonvicini³, F. Caselli⁴, B.M. Celesia⁵, M. Cernuschi⁶, A. Cingolani⁷, M. Cordiali⁸, G. Cuomo⁹, I. Dal Conte¹⁰, G. De Carli¹¹, A. Degli Antoni¹², F. Di Lorenzo¹³, M. Errico¹⁴, F.M. Fusco¹⁵, S. Mattioli¹, V. Mazzotta¹¹, A. Muscatello¹⁶, S. Nozza¹⁷, T. Prestileo¹³, A. Raimondi¹⁰, R. Rossotti¹⁸, A. Ruggieri¹⁹, L. Sighinolfi²⁰, C. Stingone²¹, S. Venturelli²², V. Puro¹¹

¹Plus onlus/BLQ Checkpoint, Bologna, ²Policlinico S. Orsola-Malpighi - Ambulatorio PrEP Bologna, ³Arcispedale Santa Maria Nuova - Spazio Sessualità salute, Reggio Emilia, ⁴Ospedale Infermi - UO Malattie Infettive, Rimini, ⁵Università di Catania ARNAS Garibaldi - UOC Malattie Infettive, Catania, ⁶Asa/Checkpoint Milano, ⁷Fondazione Policlinico "A. Gemelli", IRCCS Roma, ⁸AOUI Ospedale Policlinico "G.B. Rossi" - UOC Malattie Infettive e Tropicali, Verona, ⁹Policlinico di Modena - Malattie Infettive - ambulatorio PrEP, Modena, ¹⁰Ospedale Amedeo di Savoia - Ambulatorio IST, Torino, ¹¹INMI L. Spallanzani - Ambulatorio PrEP, Roma, ¹²U.O. Malattie Infettive Azienda Ospedaliero-Universitaria - Ambulatorio PrEP, Parma, ¹³A.R.N.A.S. Ospedale Civico - Malattie Infettive, Palermo, ¹⁴Network Persone Sieropositive, Milano, ¹⁵Ospedale Santa Maria Annunziata - SOC Malattie infettive, Bagno a Ripoli, ¹⁶Fondazione IRCCS Ca' Granda - Osp. Maggiore Policlinico - Ambulatorio di Malattie Infettive, Milano, ¹⁷Ospedale San Raffaele - Dipartimento di Malattie Infettive, Milano, ¹⁸Ospedale Niguarda - SC Malattie Infettive, Milano, ¹⁹Ospedale "Guglielmo da Saliceto" - UOC Malattie Infettive, Piacenza, ²⁰Azienda Ospedaliero-Universitaria - U.O. Malattie Infettive, Ferrara, ²¹Policlinico di Tor Vergata - Ambulatorio di Malattie Infettive, Roma, ²²Ospedale di Bergamo - Ambulatorio PrEP

OC 29 15.07-15.17 Getting toward a Checkpoint: experience of a PrEP service by our association

A. Bianchi¹, A. Tavelli¹, M. Lanza¹, D. Delelegni¹, V. Bertino², A. De Bona², E. Suardi², S. Negri³, M. Bagnato³, P.L. Vinti¹, A. Antonino¹, G. Fracca¹, M. Cernuschi¹

¹ASA. Associazione Solidarietà AIDS, Milan, Italy, ²San Paolo Hospital, Milan, Italy, ³Anlaidis Sezione Lombardia, Milan, Italy

OC 30 15.19-15.29 Pre-exposure prophylaxis: very first epidemiological data and clinical outcomes of the Modena outpatient clinic users

A. Raimondi¹, G. Cuomo¹, C. Rogati¹, A. Bianchi¹, B. Beghetto¹, E. Roncaglia¹, G. Nardini¹, V. Borghi¹, G. Guaraldi¹, M. Coppini², C. Mussini¹

¹Clinica di Malattie Infettive, Azienda Ospedaliero-Universitaria di Modena - Modena, ²Clinica Dermatologica, Università di Modena e Reggio Emilia - Modena

OC 31 15.31-15.41 Preliminary introduction of Pre-exposure Prophylaxis (PrEP) with emtricitabine/tenofovir disoproxil (F/TDF) in MSM population in Rome

F. De Zottis¹, V. Mazzotta¹, G. De Carli¹, R. Bellagamba¹, A. Cingolani², S. Nappi², C. Stingone³, M. Farinella⁴, G.M. Corbelli⁵, M. Andreoni³, V. Puro¹, A. Antinori¹

¹Istituto Nazionale per le Malattie Infettive Lazzaro Spallanzani IRCCS, Roma, ²Clinica Malattie Infettive, Fondazione Policlinico A. Gemelli IRCCS, Università Cattolica S. Cuore, Roma, ³Clinica Malattie Infettive, Università di Roma Tor Vergata, Roma, ⁴Circolo di Cultura Omosessuale Mario Mieli, Roma, ⁵PLUS Onlus, Bologna

OC 32 15.43-15.53 Pre-Exposure Prophylaxis: overall perception and discouraging factors among a cohort of MSM – data from the SEX-CHECK study

A. Maccaro¹, L. Badia¹, V. Guardigni¹, P. Malosso¹, R. Pascale¹, S. Coladonato¹, B. Tazza¹, E. Rosselli Del Turco¹, G.M. Corbelli², G. Verucchi¹, P. Viale¹, S. Mattioli²

¹Infectious Diseases Unit, Sant'Orsola-Malpighi Hospital, University of Bologna, ²PLUS Onlus, Bologna

OC 33 15.55-16.05 PrEP and risky behaviour: preliminary data from the Milano Checkpoint

M. Cernuschi, A. De Bona, D. Tesoro, E. Suardi, A. Tavelli, S. Negri, S. Bossolasco, A. Bianchi, A. Borrelli, D. Calzavara, D. Maineri, P. Vinti, L. Cosmaro, A. d'Arminio Monforte for the Milano Checkpoint association

ASST Santi Paolo e Carlo, Milano, Checkpoint Milano, Milano

OC 34 16.07-16.17 Assessment of the trough concentrations of tenofovir in HIV-negative subjects on pre-exposure prophylaxis: a single center, real-life experience

D. Cattaneo¹, C. Gervasoni¹, S. Baldelli¹, P. Vinti², M. Fusi¹, D. Zagato², A. De Bona³, E. Suardi³, S. Bossolasco⁴, M. Cernuschi^{2,4}

¹ASST Fatebenefratelli Sacco University Hospital, Milan, Italy, ²Associazione Solidarietà AIDS (ASA) Onlus, Milan, Italy, ³ASST Santi Paolo e Carlo, Milan, Italy, ⁴IRCCS San Raffaele Scientific Institute, Milan, Italy



EXPERT MEETING 15.15-16.15

Con la sponsorizzazione di AbbVie

Potency of drugs to overcome the challenges of micro-elimination

Chair: G. Rizzardini (Milano)

Italy is among the European countries with the greatest number of people exposed to the hepatitis C virus. Socially speaking, it exist an important need to treat HCV infections as quick as possible particularly in special populations (i.e., hemodialysis, liver transplantation, HIV co-infection). In this context the Inhibitory Quotient plays a relevant role in view of the growing demand for anti-HCV therapies in populations with a greater risk of variable therapeutic adherence and a complex therapeutic management. This last aspect will be a pharmacological parameter presented during the expert meeting, contextualized in the area of HCV therapy to highlight the potency of new DAAs and its possible role in the short therapeutic choice.

- | | | |
|-------------|--|--------------------------|
| 15.15-15.25 | Introduction | |
| 15.25-15.45 | Inhibitory Quotient of DAAs in HCV: pharmacokinetics and clinical relevance | Valentina Zuccaro, Pavia |
| 15.45-16.05 | The importance of Short Therapy for the treatment of special populations with HCV | Gloria Taliani, Roma |
| 16.05-16.15 | Discussion on Expert Meeting issues | |

AULA MALLIANI

EXPERT MEETING 16.30-17.30

Con la sponsorizzazione non condizionante di MSD Italia

Hospital acquired and Gram negative-resistant pneumonia

Chair: G. Di Perri (Torino)

The objective of the meeting is to have a clear picture of the nosocomial pneumonia related burden and patient outcome and provide clinicians with updates on the management of MDR Gram negative infections in the hospital setting.

- | | | |
|-------------|--|------------------------|
| 16.30-17.30 | Hospital acquired and Gram negative-resistant pneumonia | Matteo Bassetti, Udine |
|-------------|--|------------------------|

AULA MALLIANI

RENATO DALLE NOGARE SYMPOSIUM 16.30-18.00

Global Health: disease burden, migration and ageing

Chairs: S. Babudieri (Sassari), C. Giaquinto (Padova), T.S. Prestileo (Palermo)

HIV, the virus that causes AIDS, is one of the world's most serious public health challenges. According to UNAIDS, there were approximately 36.9 million people worldwide living with HIV/AIDS in 2017. In 2017, 21.7 million people living with HIV (59%) were accessing anti-retroviral therapy globally, an increase of 2.3 million since 2016 and up from 8 million in 2010. AIDS-related deaths have been reduced by more than 51% since the peak in 2004. This unprecedented global response to the AIDS pandemic can serve as a paradigm for the response to other global health threats. The aim of this symposium is to describe how "AIDS invented Global Health".

- | | | |
|-------------|---|--------------------------|
| 16.30-16.45 | The global answer to HIV: how to win the war | Stefano Vella, Roma |
| 16.45-17.00 | Ageing as global health challenge | Roberto Bernabei, Roma |
| 17.00-17.15 | Migrant as global health challenge | Corina Nicoara, Palermo |
| 17.15-17.30 | End TB globally | Mario Raviglione, Milano |
| 17.30-18.00 | Discussion on Symposium issues | |

AULA MAGNA





GIOVEDÌ
6 GIUGNO

11° CONGRESSO NAZIONALE
Italian Conference on
AIDS and Antiviral Research

5-7 GIUGNO 2019
UNIVERSITÀ DEGLI STUDI DI MILANO

ORAL COMMUNICATIONS 16.30-18.00

AULA 211

Targetting 90-90-90

Chairs: G. Mazzola (Palermo), F. Mazzotta (Firenze), A. Saracino (Bari)

16.30-16.45 **Different HIV screening strategies and their possible impact on HIV epidemics** Giustino Parruti, Pescara

OC 35 16.45-16.55 **The UNAIDS 90-90-90 target is achievable: a fast track City experience**

F. Maggiolo, L. Comi, R. Teocchi, E. Di Filippo, A.P. Callegaro, M. Rizzi
ASST Papa Giovanni XXIII, Bergamo

OC 36 16.57-17.07 **High HIV Prevalence following Screening of Subjects with HIV Indicator Conditions in a Hospital Setting**

C. Tincati¹, D. Barbanotti¹, T. Bini¹, A. Tavelli¹, M. Ravizza², A.M. Marconi², M. Cattaneo³, D.A. Chiumello⁴, A. Cerri⁵, A. Priori⁶, D. Ferrari⁷, A. d'Arminio Monforte¹

¹Department of Health Sciences, Clinic of Infectious Diseases, ASST Santi Paolo e Carlo, University of Milan, Italy, ²Department of Health Sciences, Clinic of Gynecology and Obstetrics, ASST Santi Paolo e Carlo, University of Milan, Italy, ³Department of Health Sciences, Clinic of Internal Medicine and Hematology, ASST Santi Paolo e Carlo, University of Milan, Italy, ⁴Department of Health Sciences, Clinic of Anaesthesia and Intensive Care Medicine, ASST Santi Paolo e Carlo, University of Milan, Italy, ⁵Department of Health Sciences, Clinic of Dermatology, ASST Santi Paolo e Carlo, University of Milan, Italy, ⁶Department of Health Sciences, Clinic of Neurology, ASST Santi Paolo e Carlo, University of Milan, Italy, ⁷Clinic of Oncology, ASST Santi Paolo e Carlo, San Paolo Hospital, Milan, Italy

OC 37 17.09-17.19 **Time to Linkage to Care (LtC) in the ICONA COHORT: 2010-2018**

P. Piselli¹, A. Tavelli², C. Cimaglia¹, G. Chiaradia¹, L. Rancilio³, M. Oldrini⁴, A. Cingolani⁵, M.E. Quiros Roldan⁶, V. Rizzo⁷, S. Rusconi⁸, A. Caraglia⁹, A. d'Arminio Monforte¹⁰, E. Girardi¹ for the ICONA Foundation Study Group and for the Working Group of the project "Linkage to Care in HIV: a further piece to the analysis of continuum of care in HIV in Italy"

¹INMI L. Spallanzani IRCCS, Rome, ²Icona Foundation, Milan, ³Caritas Ambrosiana, Milan, ⁴LILA, Milan, ⁵Cattolica University, Rome, ⁶University of Brescia, Brescia, ⁷AORN dei Colli, PO D. Cotugno, Naples, ⁸ASST FBF-Sacco, University of Milan, Milan, ⁹Minister of Health, Rome, ¹⁰ASST Santi Paolo e Carlo, University of Milan, Milan

OC 38 17.21-17.31 **Is time from HIV diagnosis to ART initiation predictive of virological outcome and of retention in care?**

A. d'Arminio Monforte¹, A. Tavelli², A. Cozzi-Lepri³, A. Castagna⁴, S. Passerini⁵, D. Francisci⁶, A. Saracino⁷, F. Maggiolo⁸, G. Lapadula⁹, E. Girardi¹⁰, C.F. Perno¹¹, A. Antinori¹² for the Icona Foundation Study Group

¹ASST Santi Paolo e Carlo, University of Milan, Clinic of Infectious and Tropical Diseases, Dept of Health Sciences, Milan, Italy, ²Icona Foundation, Milan, Italy, ³Institute for Global Health, University College of London, London, UK, ⁴Division of Infectious Diseases, IRCCS San Raffaele Scientific Institute, Vita-Salute San Raffaele University, Milan, Italy, ⁵III Division of Infectious Diseases, Luigi Sacco Hospital, ASST Fatebenefratelli Sacco, Milan, Italy, ⁶Unit of Infectious Diseases, University of Perugia, Perugia, Italy, ⁷Department of Infectious Diseases, Policlinic Hospital, University of Bari 'Aldo Moro', Bari, Italy, ⁸Division of Infectious Diseases, ASST Papa Giovanni XXIII, Bergamo, Italy, ⁹Clinic of Infectious Diseases, ASST Monza San Gerardo Hospital, University Milano-Bicocca, Monza, Italy, ¹⁰Clinical Epidemiology Unit, INMI "L. Spallanzani" IRCCS, Rome, Italy, ¹¹Haematology and Oncohematology Department, University of Milan, Milan, Italy, ¹²Clinical Division of HIV/AIDS, INMI "L. Spallanzani" IRCCS, Rome, Italy

OC 39 17.33-17.43 **Continuum of care among new diagnosed vs chronically followed HIV patients. Retention in care analysis in a single center cohort**

A. Comelli¹, I. Izzo², F. Donato³, A. Celotti¹, E. Focà¹, C. Pezzoli², F. Castelli¹, E. Quiros-Roldan¹

¹University Department of Infectious and Tropical Diseases, University of Brescia and ASST Spedali Civili, Brescia, Italy, ²Department of Infectious and Tropical Diseases, ASST Spedali Civili, Brescia, Italy, ³Unit of Hygiene, Epidemiology and Public Health, University of Brescia, Brescia, Italy

OC 40 17.45-17.55 **Lost to follow up: ten years challenge**

M. Polisenò, D.F. Bavaro, F. Di Gennaro, G. De Vita, A. Saracino, L. Monno, G. Angarano, S. Lo Caputo
Infectious Diseases Department University of Bari, Bari, Italy



GIOVEDÌ
6 GIUGNO

11° CONGRESSO NAZIONALE
Italian Conference on
AIDS and Antiviral Research

5-7 GIUGNO 2019
UNIVERSITÀ DEGLI STUDI DI MILANO

ORAL COMMUNICATIONS 16.30-18.00

AULA 201

Cancers and bacterial infections

Chairs: G. Guaraldi (Modena), S. Piconi (Milano)

OC 41 16.30-16.40 Latent Tuberculosis Prevalence at HIV Diagnosis: a Multicenter SIMIT Study

D. Goletti¹, A. Navarra¹, C. Cimaglia¹, E. Petruccioli¹, G. Cuzzi¹, A. Giannetti¹, V. Mazzotta¹, A. Spolti², C. Mastroianni³, P. Pavone³, M. Galli⁴, F. Franzetti⁴, E. Pontali⁵, M. Lichtner⁶, L. Sarmati⁷, M. Compagno⁷, D. Piacentini⁸, V. Pirriatore⁹, G. Lapadula², A. Gori¹⁰, E. Tacconelli⁸, E. Girardi¹, A. Antinori¹, A. Calcagno⁹

¹INMI Lazzaro Spallanzani IRCCS, Rome, ²Ospedale San Gerardo, Monza, ³Policlinico Umberto I, Università Sapienza, Rome, ⁴Ospedale Luigi Sacco Hospital - Polo Universitario, Milan, ⁵Ospedali Galliera, Genoa, ⁶Ospedale Santa Maria Goretti, Latina, ⁷Policlinico Universitario Università Tor Vergata, ⁸Università degli studi di Verona, Verona, ⁹Università degli studi di Torino, Turin, ¹⁰Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan

OC 42 16.42-16.52 Evaluation of the effect of HIV infection on quantiferon plus results in patients with active tuberculosis and latent infection

E. Petruccioli¹, T. Chiacchio¹, V. Vanini¹, G. Cuzzi¹, C. Cimaglia², A. Navarra², N. Riccardi^{3,4}, C. Pinnetti⁵, V. Mazzotta⁵, L.R. Codecasa^{4,6}, E. Girardi², A. Antinori⁵, D. Goletti¹

¹Translational Research Unit, National Institute for Infectious Diseases Lazzaro Spallanzani IRCCS, Rome, Italy, ²Epidemiology Unit, National Institute for Infectious Diseases Lazzaro Spallanzani IRCCS, Rome, Italy, ³Clinic of Infectious Diseases, Policlinico San Martino Hospital, University of Genoa, Genoa, Italy, ⁴StopTB Italia Onlus, Milan, Italy, ⁵Clinical Department, National Institute for Infectious Diseases Lazzaro Spallanzani IRCCS, Rome, Italy, ⁶Regional Tb Reference Centre-Villa Marelli Inst/Niguarda Hosp Milano

OC 43 16.54-17.04 Syphilis reinfection in HIV patients: the experience of a large clinical center in Rome

C. Picarelli¹, F. Lombardi¹, S. Belmonti¹, A. Ciccullo¹, A. Emiliozzi¹, D. Farinacci¹, D. Moschese¹, G. Baldin¹, S. Lamonica¹, A. Borghetti^{1,2}, A. Cingolani^{1,2}, S. Di Giambenedetto^{1,2}

¹Institute of Clinical Infectious Diseases, Catholic University of the Sacred Heart, Rome, Italy, ²Fondazione Policlinico Universitario A.Gemelli, IRCCS, Rome, Italy

OC 44 17.06-17.16 Predictors of Ureaplasma urealyticum urinary colonization in HIV+ pregnant women: a pilot study

I. Franconi, C. Puzzolante, A. Bianchi, N. Riva, A. Raimondi, M. Digaetano, A. Santoro, V. Borghi, G. Guaraldi, C. Mussini
Infectious Diseases Unit, University of Modena and Reggio Emilia

OC 45 17.18-17.28 CD4/CD8 ratio predicts the onset of virus-related cancers in HIV-positive patients on effective cART

E. Suardi¹, A. Cozzi Lepri², G. Madeddu³, V. Spagnuolo⁴, S. Vita⁵, V. Manfrin⁶, A. Bandera⁷, A. Cingolani⁸, A. Antinori⁹, C. Mussini¹⁰, G. Marchetti¹, A. d'Arminio Monforte¹, for the Icona Foundation Study Group

¹Clinic of Infectious Diseases, San Paolo Hospital-ASST Santi Paolo e Carlo, University of Milano, Milano, Italy, ²Institute for Global Health, University College of London, London, UK, ³Department of Medical, Surgical and Experimental Sciences, Division of Infectious Diseases, University of Sassari, Sassari, Italy, ⁴Division of Infectious Diseases, IRCCS San Raffaele Scientific Institute, Vita-Salute San Raffaele University, Milan, Italy, ⁵Department of Public Health and Infectious Diseases, University Sapienza of Rome, ⁶Department of Infectious and Tropical Diseases, St. Bortolo Hospital, Vicenza, Italy, ⁷Infectious Diseases Unit, Department of Internal Medicine, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, University of Milan, Milan, Italy, ⁸Institute of Clinical Infectious Diseases, Catholic University of Sacred Heart, Policlinico Gemelli, Rome, Italy, ⁹Clinical Division of HIV/AIDS, INMI "L. Spallanzani" IRCCS, Rome, Italy, ¹⁰Infectious Diseases Clinic, University of Modena and Reggio Emilia, Modena, Italy

OC 46 17.30-17.40 Persistence of high peripheral activated CD8+ T-cells and not a low CD4/CD8 ratio predict hpv-related dysplasia in cART-treated, HIV-infected subjects

C. Tincati¹, F. Bai¹, D. Mondatore¹, A. Vasile Baja¹, E. Suardi¹, M. Giovenzana², A. Pisani Ceretti², A. d'Arminio Monforte¹, G. Marchetti¹

¹Department of Health Sciences, Clinic of Infectious Diseases, ASST Santi Paolo e Carlo, University of Milan, Italy, ²Department of Health Sciences, Unit of Hepatobiliarypancreatic and Digestive Surgery, ASST Santi Paolo e Carlo, University of Milan, Italy

OC 47 17.42-17.52 Two-drugs regimens do not increase the risk of tumour in HIV+ patients

A. Borghetti¹, S. Bellino², F. Lombardi³, D. Moschese³, A. Ciccullo³, N. Ciccarelli⁴, G. Baldin³, A. Dusina³, A. Emiliozzi³, S. Lamonica³, S. Belmonti³, A. Cingolani³, P. Pezzotti², S. Di Giambenedetto^{1,2}

¹IRCCS Fondazione Policlinico Gemelli, Rome, Italy, ²Department of Infectious Diseases, Istituto Superiore di Sanità, Rome, Italy, ³Catholic University of Sacred Heart, Rome, Italy, ⁴Dipartimento di Psicologia, Catholic University of Sacred Heart, Milano, Italy



SCIENTIFIC
PROGRAMME



KEYNOTE LECTURES 09.00-10.00

Chairs: M. Cernuschi (Milano), M. Mondelli (Pavia), M. Puoti (Milano)

- 09.00-09.30 **Community-based interventions on chemsex among MSM**
09.30-10.00 **New perspectives for medical treatment of Hepatocellular Carcinoma**

Jorge Garrido, Madrid E
Antonio Craxì, Palermo

AULA MAGNA

SYMPOSIUM 10.05-11.35

Getting to zero in HIV and HCV

Chairs: M.L. Cosmaro (Milano), P. Pezzotti (Roma), C. Torti (Catanzaro)

Achievement of the ambitious HIV and HCV elimination targets is put at risk by the challenges encountered in reaching out to key populations. This session aims to highlight best practices and suggests how to overcome existing barriers and move forward to get to Zero.

- 10.05-10.20 **Ending HIV in England by 2030 – issues and actions**
10.20-10.35 **Getting to zero in Italian MSM**
10.35-10.50 **Gender identity and sexual health issues**
10.50-11.05 **Getting to zero in people using drugs**
11.05-11.20 **Fast Track in every city**
11.20-11.35 **Discussion on Symposium issues**

Noel Gill, London UK
Giulio Maria Corbelli, Bologna
Massimo Farinella, Roma
Michele Formisano, Taranto
Alessio Guidotti, Roma
Bertrand Audoin, Paris F

AULA MALLIANI

ORAL COMMUNICATIONS 10.05-11.35

ART and long-term safety issues

Chairs: A. Capetti (Milano), A. Matteelli (Brescia), M.C. Moioli (Milano)

- 10.05-10.20 **Lifestyle changes (stop smoking)**

Giuseppe De Socio, Perugia

OC 48 10.20-10.30 Overall tolerability of Integrase Inhibitors in clinical practice: results from a multicenter Italian cohort
A. Ciccullo¹, G. Baldin¹, V. Borghi², G. Sterrantino³, A. Latini⁴, G. d'Ettore⁵, A. Lanari^{6,7}, M. Mazzitelli⁸, A. De Vito⁹, M. Colafigli⁴, A. Capetti¹⁰, L. Oreni¹¹, F. Lagi³, S. Rusconi¹¹, S. Di Giambenedetto^{1,12}

¹Istituto di Malattie Infettive, Università Cattolica del Sacro Cuore, Roma, Italy, ²Azienda Ospedaliero Universitaria di Modena, Clinica Malattie Infettive e Tropicali, Modena, Italy, ³Dipartimento di Medicina Sperimentale e Clinica, Università di Firenze, Firenze, Italy, ⁴Infectious Dermatology and Allergology Unit, IFO S. Galliciano Institute (IRCCS), Rome, Italy, ⁵Department of Public Health and Infectious Diseases, Azienda Policlinico Umberto I, Rome, Italy, ⁶Infectious Diseases Unit, AOU Senese, Siena, Italy, ⁷Department of Medical Biotechnologies, University of Siena, Siena, Italy, ⁸Department of Medical and Surgical Sciences, Unit of Infectious and Tropical Diseases, Magna Graecia University, Catanzaro, Italy, ⁹Department of Clinical, Surgical and Experimental Sciences, University of Sassari, Sassari, Italy, ¹⁰Division of Infectious Diseases, Department of Infectious Diseases, Luigi Sacco University Hospital, Milan, Italy, ¹¹Infectious Diseases Unit, DIBC Luigi Sacco, University of Milan, Milan, Italy, ¹²Fondazione Policlinico Universitario Agostino Gemelli IRCCS, UOC Malattie Infettive, Roma, Italy

OC 49 10.32-10.42 Dolutegravir safety in a real-life setting: results from the SCOLTA cohort

G. Madeddu¹, M.S. Mameli¹, N. Squillace², B. Menzaghi³, R. Gulminetti⁴, G.V. De Socio⁵, A. Di Biagio⁶, G.C. Orofino⁷, G. Pellicano⁸, B.M. Celasia⁹, L. Calza¹⁰, C. Martinelli¹¹, S. Rusconi¹², A. Cascio¹³, F. Vichi¹⁴, G. Cenderello¹⁵, L. Valsecchi¹⁶, P. Maggi¹⁷, G. Angioni¹⁸, C. Dentone¹⁹, K. Falasca²⁰, E. Ricci²¹, P. Bonfanti²², on Behalf of CISA study group

¹Unit of Infectious Diseases, Department of Medical, Surgical and Experimental Sciences, University of Sassari, Sassari, ²Infectious Diseases Unit, Milano-Bicocca University, San Gerardo Hospital, Monza, ³Infectious Diseases Unit, ASST della Valle Olona, Busto Arsizio, ⁴Department of Medical Sciences and Infectious Diseases, Fondazione IRCCS Policlinico San Matteo-University of Pavia, ⁵Infectious Diseases Unit, Santa Maria Hospital, Perugia, ⁶Infectious Diseases Clinic, Policlinico Hospital San Martino, Genova, ⁷Division 1 of infectious and Tropical Diseases, ASL Città di Torino, ⁸Department of Human Pathology of the Adult and the Developmental Age "G. Barresi", Unit of Infectious Diseases, University of Messina, ⁹Unit of Infectious Diseases University of Catania ARNAS Garibaldi Catania, ¹⁰Infectious Diseases Unit, S. Orsola Malpighi Hospital, Bologna, ¹¹SOD Malattie Infettive e Tropicali AOU Careggi, Florence, ¹²Infectious Diseases Unit, DIBIC "Luigi Sacco", University of Milan, ¹³Infectious Diseases Unit, Policlinico P. Giaccone Hospital, Palermo, ¹⁴Infectious Diseases Unit, Santa Maria Annunziata Hospital, Usl centro, Florence, ¹⁵Infectious Diseases Unit, Galliera Hospital, Genova, ¹⁶Infectious Diseases Unit, ASST Fatebenefratelli Sacco, Milano, ¹⁷Infectious Diseases Clinic University of Campania "Luigi Vanvitelli", Naples, Italy, ¹⁸Infectious Diseases Unit, SS Trinità Hospital, Cagliari, ¹⁹Infectious Diseases Unit, Sanremo Hospital, Sanremo, ²⁰Clinic of Infectious Diseases, Department of Medicine and Science of Aging, University "G. d'Annunzio" Chieti-Pescara, ²¹Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milano, ²²Infectious Diseases Unit, Ospedale A. Manzoni, Lecco

OC 50 10.44-10.54 Screening for inducible myocardial ischemia in asymptomatic HIV subjects: final results from CORDIS study

V. Spagnuolo^{1,2}, L. Galli², A. Poli², C. Godino³, N. Gianotti², S. Nozza², C. Muccini¹, E. Bruzzesi¹, A. Lazzarin², A. Margonato^{1,3}, A. Castagna^{1,2}

¹Faculty of Medicine and Surgery, Vita-Salute San Raffaele University, Milan, ²Infectious Diseases Department, San Raffaele Scientific Institute, Milan, ³Division of Clinical Cardiology, Cardiothoracovascular Department, San Raffaele Scientific Institute, Milan

OC 51 10.56-11.06 Lipid profile changings after switching from rilpivirine/tenofovir disoproxil fumarate/emtricitabine to rilpivirine/tenofovir alafenamide/emtricitabine: different effects in different patients populations. Results from a large observational study

L. Taramasso^{1,2}, A. Di Biagio³, N. Riccardi^{2,4}, F. Briano², E. Di Filippo⁵, L. Comi⁵, S. Mora⁶, M. Giacomini⁶, A. Gori⁷, F. Maggiolo⁵

¹Infectious Diseases Unit, Department of Internal Medicine, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy, ²Department of Health Sciences (DISSAL), University of Genoa, Genoa, Italy, ³Infectious Diseases Clinic, Policlinico San Martino Hospital, Genoa, Italy, ⁴Infectious Diseases Department, San Raffaele Scientific Institute, Milan, Italy, ⁵Infectious Disease Unit, ASST Papa Giovanni XXIII, Bergamo, Italy, ⁶Department of Informatics Bioengineering, Robotics, and Systems Engineering (DIBRIS), University of Genova, Genoa, Italy, ⁷Infectious Diseases Unit, Department of Internal Medicine, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, University of Milan, Milan, Italy

OC 52 11.08-11.18 Advanced machine learning systems in HIV-1 infected patients: a promising tool to predict renal impairment

E. Grossi¹, L. Galli², A. Poli², S. Salpietro², L. Fumagalli², A. Castagna^{2,3}, A. Lazzarin²

¹Centro Ricerche Semeion, Roma, Italy, ²Clinic of Infectious Diseases, Istituto Scientifico San Raffaele, Milano, Italy, ³Clinic of Infectious Diseases, Vita-Salute San Raffaele University, Milano, Italy

OC 53 11.20-11.30 Uncovering EGFR profiles in HIV-infected patients: an alternative statistical approach

C. Brombin¹, C. Di Serio¹, L. Galli², A. Poli², L. Fumagalli², A. Castagna^{1,2}

¹Vita-Salute San Raffaele University, Milan, Italy, ²Infectious Diseases, IRCCS San Raffaele Scientific Institute, Milan, Italy

ORAL COMMUNICATIONS 10.05-11.35

AULA 201

Resistance. Is it still a problem?

Chairs: G. Antonelli (Roma), G. Palù (Padova), G. Poli (Milano)

OC 54 10.05-10.15 Dynamics of HIV-1 drug resistance over the years 1999-2017 in isolates from perinatally infected individuals followed in Italy

D. Armenia^{1,2}, B. Yagai², A. Bertoli², L. Palandri³, H. Tchidjou Kuekou⁴, F. Forbici⁵, R. Gagliardini⁵, M. Lichtner⁶, M. Andreoni⁷, A. Antinori⁵, F. Ceccherini-Silberstein², S. Bernardi⁴, C.F. Perno^{5,8}, M.M. Santoro²

¹Unicamillus, Saint Camillus International University of Health Sciences, ²University of Rome "Tor Vergata", Rome, ³University of Parma, Parma, ⁴Children's Hospital Bambino Gesù, Rome, ⁵National Institute for Infectious Diseases L. Spallanzani, IRCCS, Rome, ⁶La Sapienza University Polo Pontino, Latina, ⁷University Hospital of Rome Tor Vergata, Rome, ⁸University of Milan, Milan



- OC 55 10.17-10.27 Evaluation of resistance profile and virological response in drug-naïve patients who start a first-line regimen containing an integrase inhibitor**
D. Armenia^{1,2}, S. Nozza³, M.M. Santoro², M.R. Parisi³, F. Maggiolo⁴, E. Focà⁵, C. Cervà⁶, S. Rusconi⁷, L. Gazzola⁸, F. Ceccherini-Silberstein², C.F. Perno⁹, A. Lazzarin¹⁰, on behalf of the INIMAGE Study Group
¹UniCamillus, Saint Camillus International University of Health Sciences, Rome, Italy, ²University of Rome "Tor Vergata", Rome, Italy, ³Clinic of Infectious Diseases, Istituto Scientifico San Raffaele, Milano, Italy, ⁴Azienda Ospedaliera Papa Giovanni XXIII, Bergamo, Italy, ⁵Division of Infectious Diseases, University of Brescia, Brescia, Italy, ⁶Infectious Diseases Unit, University Hospital of Rome "Tor Vergata", Rome, Italy, ⁷Infectious Diseases Unit, DIBIC "Luigi Sacco", University of Milan, Milan, Italy, ⁸Clinic of Infectious Diseases, San Paolo Hospital, Milan, Italy, ⁹University of Milan, Milan, Italy
- OC 56 10.29-10.39 Impact of previous NRTIs resistance in HIV positive patients switched to DTG+2NRTIs under virological control**
A. Giacomelli^{1,2}, A. Lai¹, M. Franzetti³, F. Maggiolo⁴, S. Di Giambenedetto⁵, V. Borghi⁶, D. Francisci⁷, G. Magnani⁸, M. Pecorari⁹, L. Monno¹⁰, I. Vicenti¹¹, L. Lepore¹², F. Lombardi⁵, S. Paolucci¹³, S. Rusconi^{1,2} on behalf of ARCA collaborative group
¹III Infectious Disease Unit, ASST-FBF-Sacco, Milan, Italy, ²DIBIC L.Sacco, University of Milan, Milan, Italy, ³UOC Infectious Disease Unit, ASST-Lecco, Lecco, Italy, ⁴Department of Infectious Diseases, Azienda Ospedaliera Papa Giovanni XXIII, Bergamo, Italy, ⁵Institute of Clinical Infectious Diseases, Catholic University of Sacred Heart, Policlinico Gemelli, Rome, Italy, ⁶Infectious Diseases Clinic, Azienda Ospedaliero-Universitaria Policlinico, Modena, Italy, ⁷Clinical Infectious Diseases, University of Perugia, Perugia, Italy, ⁸Infectious Disease Unit, Reggio Emilia, Italy, ⁹Unit of Microbiology and Virology, Modena University Hospital, Modena, Italy, ¹⁰Department of Biomedical Sciences and Human Oncology, Clinic of Infectious Diseases, University of Bari, Italy, ¹¹Department of Medical Biotechnology, University of Siena, Siena, Italy, ¹²Department of Biomedical Sciences and Human Oncology, Clinic of Infectious Diseases, University of Bari, Italy, ¹³Molecular Virology Unit, Microbiology and Virology Department, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy
- OC 57 10.41-10.51 Impact of resistance mutations on virological efficacy of DTG-based maintenance two-drug regimens: an ARCA cohort study**
R. Gagliardini¹, B. Rossetti², D. Redi^{2,3}, S. Modica³, F. Montagnani^{2,3}, G. Zanelli^{2,3}, S. Di Giambenedetto⁴, F. Lombardi⁴, M. Pecorari⁵, V. Borghi⁶, A. Callegaro⁷, V. Micheli⁸, M. Annovazzi Lodi⁹, A. De Luca^{2,3}, M. Zazzi³
¹Lazzaro Spallanzani National Institute for Infectious Diseases IRCCS, Rome, Italy, ²Infectious Diseases Unit, AOU Senese, Siena, Italy, ³Department of Medical Biotechnologies, University of Siena, Siena, Italy, ⁴Clinic of Infectious Diseases, Catholic University of Sacred Heart, Rome, Italy, ⁵Unit of Microbiology and Virology, Modena University Hospital, Modena, Italy, ⁶Infectious Diseases Unit, Modena Hospital, Modena, Italy, ⁷Microbiology and Virology Unit, ASST Papa Giovanni XXIII, Bergamo, Italy, ⁸Unit of Clinical Microbiology and Virology, Luigi Sacco Hospital, ASST FBF-Sacco, Milan, Italy, ⁹Virologia Molecolare, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy
- OC 58 10.53-11.03 In vitro analysis of doravirine activity on HIV-1 clones harboring multiple NNRTI resistance mutations**
F. Saladini¹, F. Giammarino¹, A. Giannini¹, A. Boccuto¹, F. Dragoni¹, I. Vicenti¹, R.W. Shafer², M. Zazzi¹
¹Department of Medical Biotechnologies, University of Siena, Siena, Italy, ²Stanford University, Stanford, CA, USA
- OC 59 11.05-11.15 Pretreatment HIV drug resistance and treatment failure in non-Italian HIV-1 infected patients enrolled in ARCA**
D.F. Bavaro¹, D. Di Carlo², B. Rossetti³, B. Bruzzone⁴, I. Vicenti⁵, E. Pontali⁶, A. Zoncada⁷, F. Lombardi⁸, S. Di Giambenedetto⁸, V. Borghi⁹, M. Pecorari¹⁰, P. Milini¹¹, P. Meraviglia¹², L. Monno¹, A. Saracino¹
¹Department of Biomedical Sciences and Human Oncology, Clinic of Infectious Diseases, University of Bari Medical School, Bari, Italy, ²Pediatric Clinical Research Center "Romeo and Erica Invernizzi", University of Milan, Milan, Italy, ³Infectious Diseases Unit, Azienda Ospedaliera Universitaria Senese, Siena, Italy, ⁴Hygiene Unit, IRCCS AOU San Martino-IST, Genoa, Italy, ⁵Dipartimento di Biotecnologie Mediche, Università di Siena, Siena, Italy, ⁶Infectious Diseases Unit, Galliera Hospital, Genoa, ⁷Infectious Diseases, Istituti Ospedalieri, Cremona, Italy, ⁸Institute of Clinical Infectious Diseases, Catholic University of Sacred Heart, Policlinico Gemelli, Rome, Italy, ⁹Clinica Malattie infettive, Azienda Ospedaliero Universitaria di Modena, ¹⁰Polyclinic of Modena, Modena, Italy, ¹¹Infectious Diseases Unit, Macerata Hospital, Macerata, ¹²1st Division of Infectious Diseases, ASST Fatebenefratelli-Sacco, Milan, Italy
- OC 60 11.17-11.27 Evaluation of multidrug resistance over the last two decades in ART-experienced HIV-1 infected patients in the ARCA database**
F. Lombardi¹, A. Giacomelli², D. Armenia^{3,4}, A. Lai⁵, A. Dusina¹, A. Bezenchek⁶, L. Timelli⁶, F. Saladini⁷, F. Vichi⁸, P. Corsi⁹, G. Colao¹⁰, B. Bruzzone¹¹, A. Callegaro¹², A. Castagna^{13,14}, M.M. Santoro⁴
¹Clinic of Infectious Diseases, Catholic University of Sacred Heart, Rome, ²Infectious Diseases Unit, DIBIC Luigi Sacco, University of Milan, Milan, ³UniCamillus, Saint Camillus International University of Health Sciences, Rome, ⁴Department of Experimental Medicine, University of Rome "Tor Vergata", Rome, ⁵Department of Biomedical and Clinical Sciences L. Sacco, University of Milan, Milan, ⁶IPro - InformaPRO S.r.l., Rome, ⁷Department of Medical Biotechnologies, University of Siena, Siena, ⁸Unit of Infectious Diseases, Santa Maria Annunziata Hospital, Firenze, ⁹Infectious and Tropical Diseases Unit, Careggi University Hospital, Florence, ¹⁰Laboratory of Virology, Careggi Hospital, Florence, ¹¹Hygiene Unit, Azienda Ospedaliero-Universitaria San Martino, Genoa, ¹²Department of Laboratory Medicine, ASST Papa Giovanni XXIII, Bergamo, ¹³Clinic of Infectious Diseases, Istituto Scientifico San Raffaele, Milano, ¹⁴Clinic of Infectious Diseases, Vita-Salute San Raffaele University, Milano



EXPERT MEETING 10.30-11.30

Con il supporto incondizionato di ViiV Healthcare

Innovation vs novelty

Chair: M. Galli (Milano)

Although the significant advances in HIV therapy in recent years, many treatment-related needs persist. New medicines are needed for a broad range of patients to ensure continued improvements in efficacy as well as other important areas for people living with HIV and physicians, such as tolerability, safety, long-term toxicity, resistance, drug drug interactions and convenience. In addition, recent results with pre-exposure prophylaxis (PrEP) for the prevention of HIV infection warrant further exploration of new delivery technologies to give people at greatest risk of HIV infection a number of prevention methods from which to choose.

- 10.30-10.50 **The relevance of innovation in medicine**
- 10.50-11.10 **Innovation in mechanism of action**
- 11.10-11.30 **Innovation in therapeutic strategy**

AULA MALLIANI

- Giovanni Apolone, Milano
- Antonella Castagna, Milano
- Diego Ripamonti, Bergamo

SPONSORED SYMPOSIUM 11.40-12.25

Con la sponsorizzazione di Gilead Sciences

The beauty of what is possible

Chair: A. d'Arminio Monforte (Milano)

Evolution of antiretroviral therapy transformed the HIV from a fatal disease to a manageable chronic condition, moving forward the unmet medical needs. The meaning in the real world practice is that efficacy, tolerability and simplicity should be evaluated in a longer timeframe, as life lasting treatment. Since the therapy will be for a longer life, also QoL plays a relevant role so the Italian guidelines states that HRQoL should be measured at baseline and at each clinical evaluation becoming one of the primary goal of ART. How can this evaluation can be done in clinical practice? It's time to rethink the point of view by adding pts' lifestyle consideration on top of the clinical aspects.

- 11.40-11.55 **Evolving triple therapy - filling the unmet need**
- 11.55-12.10 **Patient Reported Outcomes (PROs) in the clinical practice - changing the point of view**
- 12.10-12.25 **Discussion on Symposium issues**

- Sergio Lo Caputo, Bari
- Antonella Cingolani, Roma

ORAL COMMUNICATIONS 11.40-13.10

From naive to highly treated subjects. Efficacy of cART

Chairs: L. Butini (Ancona), M. Clerici (Milano), L. Sarmati (Roma)

OC 61 11.40-11.50 Lower response to antiretroviral therapy (ART) and persistently poor survival for AIDS presentation in people seen for care in Italy from 2009 to 2018

A. Mondì¹, P. Lorenzini¹, A. Cozzi-Leprì², A. Cingolani³, M. Farenga⁴, S. Rusconi⁵, G. Di Girolamo⁶, A. Gori⁷, M. Camici¹, C. Mussini⁸, A. d'Arminio Monforte⁹, A. Antinori¹ on behalf of the Icona Foundation Study Cohort

¹HIV/AIDS Department, National Institute for Infectious Diseases "Lazzaro Spallanzani" IRCCS, Rome, Italy, ²Centre for Clinical Research, Epidemiology, Modelling and Evaluation (CREME), Institute for Global Health, UCL, London, UK, ³Infectious Diseases Unit, Catholic University of Sacred Heart, Rome, Italy, ⁴Infectious Diseases Unit A, Amedeo di Savoia Hospital, Torino, Italy, ⁵Infectious Diseases Unit, ASST FBF-Sacco, DIBIC "L. Sacco", University of Milan, Milan, Italy, ⁶Department of Public Health and Infectious Diseases, Sapienza University of Rome, Roma, Italy, ⁷Department of Pathophysiology and Transplantation, School of Medicine and Surgery, University of Milan, Milan, Italy; ⁸Infectious Diseases Unit, Department of Internal Medicine, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy, ⁹Infectious Diseases Clinic, AOU Policlinico of ModenaUniversity of Modena and Reggio Emilia, Modena, Italy, ⁹Clinic of Infectious and Tropical Diseases, Department of Health Sciences, ASST Santi Paolo e Carlo, University of Milan, Milan, Italy

AULA 211



- OC 62 11.52-12.02** **Virological outcomes of first line regimens in women living with HIV from Icoha cohort: comparison with clinical trials data**
C. Mussini¹, P. Lorenzini², A. Cingolani³, M. Lichtner⁴, S. Di Giambenedetto³, A.M. Cattelan⁵, E. Balletto⁶, L. Sighinolfi⁷, C. Abeli⁸, M. Malena⁹, G. d'Eitorre⁴, A. d'Arminio Monforte¹⁰
¹University of Modena and Reggio Emilia, ²INMI L. Spallanzani, Rome, ³S. Cuore Catholic University, Rome, ⁴La Sapienza University, Rome, ⁵Padova Hospital, ⁶Clinic of Infectious diseases, University of Genoa, ⁷Sant'Anna Hospital, Ferrara, ⁸Busto Arsizio Hospital, ⁹US Malattie Infettive, Azienda Scaligera, Verona, ¹⁰University of Milan
- OC 63 12.04-12.14** **Determinants of switching to TAF-based cART or dual combinations (DT) from TDF-based regimens in a cohort of HIV-infected individuals with controlled viral load ≤50 copies/mL**
A. Vergori¹, R. Gagliardini¹, N. Gianotti², A. Gori³, M. Lichtner⁴, A. Saracino⁵, A. De Vito⁶, A. Cascio⁷, A. Di Biagio⁸, A. d'Arminio Monforte⁹, A. Antinori¹, A. Cozzi-Lepri¹⁰
¹HIV/AIDS Unit, National Institute for Infectious Diseases, L. Spallanzani, IRCCS, Rome, Italy, ²Infectious Diseases Department, San Raffaele Scientific Institute, IRCCS, Milan, Italy, ³Department of Internal Medicine, Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico, Milan, Italy; University of Milan, Milan, Italy, ⁴Department of Public Health and Infectious Diseases, Sapienza University of Rome, Polo Pontino, Latina, Italy, ⁵Clinic of Infectious Diseases, University of Bari, Bari, Italy, ⁶Unit of Infectious Diseases, Department of Clinical and Experimental Medicine, University of Sassari, Sassari, Italy, ⁷Department of Infectious Diseases, AOU Policlinico "P.Giaccone", University of Palermo, Palermo, Italy, ⁸Infectious Diseases Clinic, Policlinico Hospital San Martino, Genova, Italy, ⁹Clinic of Infectious and Tropical Diseases, ASST Santi Paolo e Carlo, University of Milan, Milan, Italy, ¹⁰Centre for Clinical Research, Epidemiology, Modelling and Evaluation (CREME), Institute for Global Health, UCL, London, UK
- OC 64 12.16-12.26** **Residual viremia in HIV-infected patients who continue a 2-drug regimen with dolutegravir plus one reverse transcriptase inhibitor or switch to elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide: a randomized study (Be-One Study)**
N. Gianotti¹, L. Galli¹, A. Poli¹, L. Della Torre¹, C. Vinci¹, E. Carini¹, A. Galli¹, S. Nozza¹, V. Spagnuolo^{1,2}, C. Muccini^{1,2}, A. Lazzarin¹, A. Castagna^{1,2}
¹IRCCS Ospedale San Raffaele, Milano, ²Università Vita-Salute San Raffaele, Milano
- OC 65 12.28-12.38** **Viral potency and durability of emtricitabine/tenofovir alafenamide (F/TAF) based regimens in the real life setting**
A. Antinori¹, A. Cozzi-Lepri², D. Moschese³, S. Nozza⁴, L. Comi⁵, M. Santoro⁶, L. Sarmati⁷, C. Pinnetti¹, F. Ceccherini-Silberstein⁶, G. Marchetti⁸, F. Maggiolo⁵, A. d'Arminio Monforte⁸ for the Icoha Foundation Study Group
¹Clinical Division of HIV/AIDS, INMI "L. Spallanzani" IRCCS, Rome, Italy, ²Institute for Global Health, University College of London, London, UK, ³Institute of Clinical Infectious Diseases, Catholic University of Sacred Heart, Policlinico Gemelli, Rome, Italy, ⁴Division of Infectious Diseases, IRCCS San Raffaele Scientific Institute, Milan, Italy, ⁵Division of Infectious Diseases, ASST Papa Giovanni XXIII, Bergamo, Italy, ⁶Department of Experimental Medicine, University of Rome Tor Vergata, Rome, Italy, ⁷Clinical Infectious Diseases, Fondazione Policlinico Tor Vergata, University of Rome Tor Vergata, Rome, Italy, ⁸ASST Santi Paolo e Carlo, University of Milan, Clinic of Infectious and Tropical Diseases, Dept of Health Sciences, Milan, Italy
- OC 66 12.40-12.50** **Burden of disease in PLWH harbouring a 4-class drug resistant virus: data from PRESTIGIO Registry**
M.R. Parisi¹, A. Poli¹, M. Menozzi³, M. Ficon⁴, E. Garlassi⁵, D. Francisci⁶, A. Di Biagio⁷, G. Sterrantino⁸, C. Fornabai⁹, A. Degli Antoni¹⁰, G. Angarano¹¹, F.M. Fusco¹², A. d'Arminio Monforte¹³, G.M. Corbelli¹⁴, M.M. Santoro¹⁵, M. Zazzi¹⁶, A. Castagna^{1,2} on behalf of the PRESTIGIO Study Group
¹Clinic of Infectious Diseases, Istituto Scientifico San Raffaele, Milano, ²Clinic of Infectious Diseases, Vita-Salute San Raffaele University, Milano, ³Malattie Infettive, Policlinico di Modena, Modena, ⁴UOS Malattie Infettive dell'Azienda Scaligera di Verona, Verona, ⁵Malattie Infettive Arcispedale S.Maria Nuova-IRCCS, Reggio Emilia, ⁶Clinica Malattie Infettive, Santa Maria della Misericordia, Perugia, ⁷Clinica Malattie Infettive, Ospedale Policlinico San Martino, Genova, ⁸Dipartimento di Medicina clinica e Sperimentale, Università degli studi di Firenze, Firenze, ⁹ASST Cremona, Cremona, ¹⁰Malattie Infettive ed Epatologia, Azienda Ospedaliero-Universitaria di Parma, Parma, ¹¹Università degli Studi di Bari "Aldo Moro", Malattie Infettive, Policlinico, Bari, ¹²Ospedale Santa Maria Annunziata, Bagno a Ripoli, Firenze, ¹³Clinic of Infectious Diseases, Dept of Health Sciences, ASST Santi Paolo e Carlo, Milano, ¹⁴Plus Onlus, Bologna, ¹⁵Department of Experimental Medicine, University of Rome "Tor Vergata", Rome, ¹⁶University of Siena, Siena, Italy
- OC 67 12.52-13.02** **Variables related to becoming Heavily Treated Experienced (HTE) patients in a large Italian cohort**
S. Lo Caputo¹, A. Antinori², A. Tavelli³, F. Ceccherini-Silberstein⁴, C.F. Perno⁵, A. Castagna⁶, N. Bobbio⁷, G. Parruti⁸, R. Gagliardini⁹, S. Bonora⁹, A. d'Arminio Monforte¹⁰, A. Cozzi-Lepri¹¹ for the ICONA Foundation Study Group
¹Clinic of Infectious Diseases, A.O.U. Policlinico, University of Bari, Bari, Italy, ²National Institute for Infectious Diseases "L. Spallanzani" IRCCS, Rome, Italy, ³Icoha Foundation Milan, Italy, ⁴Department of Experimental Medicine and Surgery, University of Rome Tor Vergata, Rome, Italy, ⁵Dept of Oncology and Oncohematology, University of Milan, Milan, Italy, ⁶Department of Infectious Diseases, San Raffaele Scientific Institute, University Vita-Salute San Raffaele, Milan, Italy, ⁷Department of Infectious Diseases, Galliera Hospital, Genoa, Italy, ⁸Infectious Disease Unit "Santo Spirito Civil Hospital", Pescara, Italy, ⁹Unit of Infectious Diseases, Department of Medical Sciences, University of Torino, Torino, Italy, ¹⁰Clinic of Infectious and Tropical Diseases, Department of Health Sciences, University of Milan, ASST Santi Paolo e Carlo, Milan, Italy, ¹¹Institute for Global Health, University College London, London, UK

ORAL COMMUNICATIONS 11.40-12.30

AULA 201

Changing HIV epidemiology

Chairs: G. d'Ettore (Roma), G. Nunnari (Messina)

OC 68 11.40-11.50 Change of prevalence and factors associated with the risk of AIDS presentation in Italy over last decade (2009-2018)

A. Antinori¹, A. Mondì¹, P. Lorenzini¹, A. Cozzi-Lepri², A. Cingolani³, A. Latini⁴, A. Saracino⁵, A. Bandera⁶, G. Marchetti⁷, C. Mussini⁸, E. Girardi⁹, A. d'Arminio Monforte⁷

¹HIV/AIDS Department, National Institute for Infectious Diseases "Lazzaro Spallanzani" IRCCS, Rome, Italy, ²Centre for Clinical Research, Epidemiology, Modelling and Evaluation (CREME), Institute for Global Health, UCL, London, UK, ³Infectious Diseases Unit, Catholic University of Sacred Heart, Rome, Italy, ⁴STI/HIV Unit, San Gallicano Dermatologic Institute IRCCS, Rome, Italy, ⁵Division of Infectious Diseases, University of Bari, Policlinic Hospital, Bari, Italy, ⁶Department of Pathophysiology and Transplantation, School of Medicine and Surgery, University of Milan, Milan, Italy; Infectious Diseases Unit, Department of Internal Medicine, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy, ⁷Clinic of Infectious and Tropical Diseases, Department of Health Sciences, ASST Santi Paolo e Carlo, University of Milan, Milan, Italy, ⁸Infectious Diseases Clinics, Azienda Ospedaliero-Universitaria Policlinico di Modena, University of Modena and Reggio Emilia, Modena, Italy, ⁹Clinical Epidemiology Unit, National Institute for Infectious Diseases "Lazzaro Spallanzani", IRCCS, Rome, Italy

OC 69 11.52-12.02 Non B subtypes are the major driver of HIV-1 transmission dynamics in North Italy over the years 2012-2018

L. Colagrossi¹, M.C. Moiola², A. Nava³, S. Carta³, S. Chiappetta², V. Costabile⁴, D. Motta², L.G. Chianura², R. Rossotti², D. Fanti³, C.F. Perno^{3,5}, M. Puoti², C. Alteri^{3,5}

¹Residency in Microbiology and Virology, University of Milan, Milan, Italy, ²Infectious Diseases, ASST Grande Ospedale Metropolitano Niguarda, Milan, Italy, ³Chemical-clinical and Microbiological Analysis, ASST Grande Ospedale Metropolitano Niguarda, Milan, Italy, ⁴Department of Pathophysiology and Transplantation, University of Milan, Milan, Italy, ⁵Department of Oncology and Hemato-oncology, University of Milan, Milan, Italy

OC 70 12.04-12.14 Multicenter phylogenetic analysis of acutely infected individuals shows that non-B subtypes are associated to transmission clusters in Italy

L. Fabeni¹, G. Bozzi², I. Abbate³, G. Bero³, A. Muscatello², L. Taramasso², M. Fabbiani⁴, S. Nozza⁵, G. Tambussi⁵, S. Rusconi⁶, E. Focà⁷, C. Pinnetti³, G. D'Ettore⁸, C. Mussini⁹, V. Borghi⁹, B.M. Celesia¹⁰, G. Madeddu¹¹, A. Antinori³, A. Gori², M.R. Capobianchi³, A. Bandera² for the INACTION study group

¹University of Rome "Tor Vergata", Rome, Italy, ²IRCCS Ca Granda Ospedale Maggiore Policlinico - University of Milan, Milan, Italy, ³National Institute for Infectious Diseases L. Spallanzani-IRCCS, Rome, Italy, ⁴Infectious Diseases Unit, IRCCS San Matteo Hospital Foundation, University of Pavia, ⁵Clinic of Infectious Diseases, San Raffaele Hospital, University Vita Salute, Milan, Italy, ⁶Infectious Diseases Unit, Department of Biomedical and Clinical Sciences "Luigi Sacco" Hospital, University of Milan, Italy, ⁷Division of Infectious and Tropical Diseases, University of Brescia, ASST Spedali Civili Hospital, Brescia, ⁸Infectious Diseases Unit, Umberto I Hospital, La Sapienza University, Rome, Italy, ⁹Clinic of Infectious Diseases, University of Modena and Reggio Emilia, Modena Hospital, Italy, ¹⁰Unit of Infectious Diseases, Garibaldi Hospital, Catania, Italy, ¹¹Department of Clinical and Experimental Medicine, Unit of Infectious Diseases, University of Sassari

OC 71 12.16-12.26 Higher rate of virologic failure in African migrants compared with newly HIV- diagnosed natives and foreigners from other regions

F. Lagi¹, S. Tekle Kiro¹, S. Di Giambenedetto², F. Lombardi², M. Pecorari³, V. Borghi⁴, L. Lepore⁵, L. Monno⁵, M. Setti⁶, V. Micheli⁷, P. Bagnarel- li⁸, E. Paolini⁹, P. Cicconi¹⁰, A. Bartoloni¹¹, G. Sterrantino¹

¹Department of Experimental and Clinical Medicine, University of Florence, Florence Italy, ²Institute of Clinical Infectious Diseases, Catholic University of Sacred Heart, Policlinico Gemelli, Rome, Italy, ³Microbiology and Virology Unit, Azienda Ospedaliero Universitaria di Modena, Modena, Italy, ⁴Department of Infectious Diseases, Università di Modena, Modena, Italy, ⁵Department of Biomedical Sciences and Human Oncology, Clinic of Infectious Diseases, University of Bari, Italy, ⁶Clinic of Immunology and Internal Medicine, Ospedale Policlinico San Martino, Genoa, Italy, ⁷Microbiology and Virology Laboratory, L. Sacco Hospital, Milano, Italy, ⁸Virology Unit, Azienda Ospedaliero Universitaria Ospedali Riuniti di Ancona, Ancona, Italy, ⁹Immuno-Ematology and Transfusion Medicine Service, Cremona Hospital, Cremona, Italy, ¹⁰Infectious Diseases, San Paolo H. Milan, Italy, ¹¹Infectious and Tropical Diseases Unit, Careggi University Hospital, Florence, Italy





EXPERT MEETING 11.40-12.40

AULA MALLIANI

Effects of vitamin D deficiency and respiratory infections' prevention in HIV population

Hypovitaminosis D is a very common disorder, regarding both Western and developing countries. A growing amount of data over the last years have shown vitamin D deficiency to be high prevalent among HIV-positive subjects. In addition to "classic" risk factors, such as female sex, low dietary intake, dark skin pigmentation and low sun exposure, HIV-related factors, including immune activation and antiretroviral adverse effects, may affect vitamin D status. We report an interventional, non-randomized experience of OM-85 BV immunization in a group of 104 HIV-infected subjects presenting recurrent seasonal respiratory bacterial infections. We compared the number of respiratory events, the use of antibiotics and the cost related to antibiotics before (2005-2006) and after (2008-2011) the introduction of such intervention. Respiratory infections dropped in all groups but in subjects with recurrent otitis, leading to a reduction in the use of antibiotics. This is the first report of the effect of OM-85 BV in vivo in HIV-infected subjects.

11.40-12.00	Vitamin D deficiency in HIV infection: an underestimated and undertreated epidemic	Marco Borderi, Bologna
12.00-12.20	Four years of immunization with OM-85 BV to prevent respiratory infections	Amedeo Capetti, Milano
12.20-12.40	Discussion on Expert Meeting issues	

FERNANDO AIUTI SYMPOSIUM 12.30-14.00

AULA MAGNA

New immune tools and targets towards an HIV cure

Chairs: M. Clementi (Milano), C.M. Mastroianni (Roma), G. Silvestri (Atlanta USA)

As we are conveying our scientific efforts towards the achievement of a cure for HIV infection, different strategies are nowadays being investigated. During this symposium, the major pathways exploitable within strategies of functional cure will be reviewed, that include the role of different immune cells involved in both viral persistence and protective immunity in both peripheral blood and tissues, the detailed insight of protective immune responses may that be delivered via vaccination or monoclonal therapeutics, as well as the fine characterization of the immunologic consequences of HIV infection within the gut. the symposium will also review the latest findings in terms of vaccination strategies.

12.30-12.45	Gut damage and dysfunction: any insight towards an HIV cure?	Giulia Marchetti, Milano
12.45-13.00	Broadly neutralizing antibodies in the prevention and treatment of HIV infection	Florian Klein, Cologne D
13.00-13.15	HIV vaccines: how far are we from a cure?	Beatriz Mothe, Badalona E
13.15-13.30	New cells in HIV persistence and immune control	Chiara Agrati, Roma
13.30-14.00	Discussion on Symposium issues	

POSTER DISCUSSION 12.30-14.00

AULA 201

HIV co-morbidities

Chairs: M. Borderi (Bologna), P. Maggi (Napoli)

PD 20 12.30-12.35 Sexually transmitted infections knowledge in high risk populations

S. Giaché¹, L. Cotte², C. Chidiac²

¹Department of Experimental and Clinical Medicine, University of Florence, Florence, Italy, ²Infectious Diseases Department, Hospices Civils de Lyon, Hôpital de la Croix-Roussse, Lyon, France

PD 21 12.38-12.43 Bioimpedance vectorial analysis (BIVA) usefulness in evaluating body composition changes in HIV-1 infected patients in course of ART

D.F. Bavaro, P. Laghetti, R. Lattanzio, S. Lo Caputo, L. Monno, G. Angarano, A. Saracino

Department of Biomedical Sciences and Human Oncology, Clinic of Infectious Diseases, University of Bari Medical School, Bari, Italy

PD 22 12.46-12.51 Changes in bone mineral density switching from tenofovir disoproxil fumarate: a comparison between lamivudine plus dolutegravir versus FTC/TAF plus an integrase inhibitor

A. Ciccullo¹, A.P. Lassandro¹, G. Baldin¹, A. Emiliozzi¹, D. Moschese¹, C. Picarelli¹, A. Dusina¹, D. Farinacci¹, S. Belmonti¹, F. Lombardi¹, A. Borghetti², A. Pontecorvi^{3,4}, S. Di Giambenedetto^{1,2}

¹Institute of Infectious Diseases, Catholic University of the Sacred Heart, Rome, Italy, ²Fondazione Policlinico Universitario Agostino Gemelli IRCCS, UOC Malattie Infettive, Rome, Italy, ³Department of Endocrinology, Università Cattolica del Sacro Cuore, Rome, Italy, ⁴Endocrinology Unit, Fondazione Policlinico Universitario "A. Gemelli" - IRCCS, Rome, Italy

PD 23 12.54-12.59 Annexin A1 plasma levels and cardiovascular risk score in HIV positive patients

C. Ucciferri¹, F. Vignale¹, E. Costantini², M. Pontolillo¹, C. D'Angelo², M. Reale², J. Vecchiet¹, K. Falasca¹

¹Clinic of Infectious Diseases, Department of Medicine and Science of Aging, University "G. d'Annunzio" Chieti-Pescara, Chieti, ²Unit of Immunodiagnostic and Molecular Pathology, Department of Medical, Oral and Biotechnological Sciences, University "G. d'Annunzio", Chieti-Pescara, Italy

PD 24 13.02-13.07 Plasma fibrinogen is associated with higher inflammation and subclinical atherosclerosis in HIV-1-infected patients on combination antiretroviral therapy

L. Calza¹, V. Colangeli¹, M. Borderi¹, A. Borioni¹, F. Volpato¹, I. Bon², M.C. Re², P. Viale¹

Department of Medical and Surgical Sciences, ¹Clinics of Infectious Diseases, ²Unit of Microbiology, S.Orsola Hospital, University of Bologna

PD 25 13.10-13.15 Impact of chemotherapy relative dose intensity (RDI) in treatment of HIV-associated lymphoma (HIV-L)

V. Mazzotta, P. Lorenzini, C. Pinnetti, M. Bibas, A. Giannetti, A. Plazzi, A. Mondì, R. Gagliardini, A. Vergori, E. Grilli, S. Cicalini, F. Baldini, A. Grisetti, L. Alba, A. Antinori

National Institute of infectious Disease Lazzaro Spallanzani, Rome

PD 26 13.18-13.23 Effect of alphafetoprotein on survival in HIV-infected patients with hepatocellular carcinoma

E. Messina^{1,2}, L. Galli¹, G. Morsica¹, H. Hasson¹, S. Bagaglio¹, S. Salpietro¹, A. Lazzarin¹, A. Castagna^{1,2}, C. Uberti Foppa^{1,2}

¹IRCCS San Raffaele Scientific Institute, Milano, Italy, ²Vita Salute San Raffaele University, Milano, Italy

PD 27 13.26-13.31 The UCSD Performance-Based Skills Assessment is associated to cognitive performance in HIV positive population with very good immunological condition

V. Delle Donne¹, N. Ciccarelli², A. Borghetti⁴, F. Lombardi⁴, A. Dusina⁴, D. Farinacci⁴, A. Emiliozzi⁴, E. Visconti⁴, E. Tamburrini^{1,4}, M. Fabbiani³, S. Di Giambenedetto^{1,4}

¹Università Cattolica del Sacro Cuore, Roma Italia, Istituto di Clinica Malattie Infettive, ²Dipartimento di Psicologia, Università Cattolica di Milano, ³U.O. Malattie Infettive e Tropicali, Fondazione IRCCS Policlinico San Matteo, Pavia, ⁴Fondazione Policlinico Universitario A. Gemelli IRCCS, Roma Italia, UOC malattie infettive

PD 28 13.34-13.39 Resting EEG-LORETA and CSF Biomarkers in Patients with HAND

V. Pirriatore¹, G. Noce², A. Barco¹, G. Stroffolini¹, S. Orlando³, D. Vai³, A. Bianco³, M. Trunfio¹, D. Imperiale³, S. Bonora¹, G. Di Perri¹, C. Babiloni^{4,5}, A. Calcagno¹

¹Unit of Infectious Diseases, Amedeo di Savoia hospital, Department of Medical Sciences, University of Torino, Torino, ²IRCCS SDN, Naples, Italy, ³Unit of Neurology, Ospedale Maria Vittoria, ASL "Città di Torino", ⁴Department of Physiology and Pharmacology, University of Rome "La Sapienza", Rome, ⁵IRCCS S. Raffaele Pisana and Cassino, Rome and Cassino, Italy

PD 29 13.42-13.47 Aging with HIV or getting infected at older age define two distinct groups of aged HIV patients

E. Maggiolo, L. Comi, R. Teocchi, E. Di Filippo, A.P. Callegaro, M. Rizzi

ASST Papa Giovanni XXIII, Bergamo



POSTER DISCUSSION 12.45-14.00

AULA MALLIANI

Viral Hepatitis

Chairs: A. Cascio (Palermo), V. Esposito (Napoli)

PD 30 12.45-12.50 No changes in longitudinal evaluation of neurocognitive performance (NPA) in antiretroviral-treated HIV/HCV co-infected patients receiving Directly-Acting Antivirals (DAAs)

S. Cicalini, A.C. Brita, P. Lorenzini, A. Vergori, E. Grilli, S. Menichetti, R. Gagliardini, A. Giannetti, A. Antinori, C. Pinnetti
National Institute for Infectious Diseases Lazzaro Spallanzani, IRCCS, Rome

PD 31 12.53-12.58 Immune inflammation markers in HCV infected subjects with low liver fibrosis undergoing DAA treatment

B. Kertusha, C. Mascia, P. Nijhawan, I. Pozzetto, L. Fondaco, A. Carraro, R. Marocco, S. Vita, C. Mastroianni, M. Lichtner
Sapienza Università di Roma, Dipartimento di Malattie Infettive e Sanità Pubblica, Latina

PD 32 13.01-13.06 Virological patterns of HCV-patients with failure to the last generation pan-genotypic direct-acting antivirals

M. Starace¹, M. Pisaturo¹, C. Minichini¹, S. De Pascalis¹, M. Macera¹, L. Occhiello¹, A. Di Fraia¹, L. Alessio², V. Messina², E. Claar³, T. Ascione⁴, A. Marrone⁵, G. Brancaccio⁶, I. Gentile⁷, G. D'Adamo⁸, G.B. Gaeta¹, N. Coppola¹ HCV infection Campania group (CampC)
¹Infectious Diseases Unit, Department of Mental and Physical Health and Preventive Medicine, University L. Vanvitelli, Naples, Italy, ²Infectious Diseases Unit, AO Caserta, Caserta, Italy, ³Internal Medicine Unit, Evangelical Hospital Villa Betania Naples, Italy, ⁴IX Interventional Ultrasound Unit for Infectious Diseases, AORN dei Colli, P.O. Cotugno, Naples, Italy, ⁵Internal Medicine, University of Campania L. Vanvitelli, ⁶Department of Molecular Medicine University of Padua, ⁷Infectious Diseases Unit, University Federico II, Naples, Italy, ⁸Internal Medicine Unit, P.O. Umberto I Nocera Inferiore

PD 33 13.09-13.14 The presence of specific mutations in HBsAg C-terminus correlates with lower HBsAg levels in vivo, interfere with HBsAg release in vitro and alter HBsAg structure in HBeAg-negative chronic HBV genotype D infection

L. Piermatteo¹, A. Battisti², L. Carioti¹, D. Di Carlo³, O.E. Anastasiou⁴, U.S. Gill², L. Colagrossi⁵, A. Bertoli¹, M. Aragri¹, L. Fabeni¹, A. Iuvara⁶, V. Malagnino⁷, C. Cerva⁷, M. Lichtner⁸, C.M. Mastroianni⁸, G.M. De Sanctis⁹, M. Paoloni¹⁰, M. Marignani¹¹, C. Pasquazzi¹¹, N. Iapadre¹², T. Mari¹³, G. Parruti¹⁴, J. Vecchiet¹⁵, L. Sarmati⁷, M. Andreoni⁷, M. Angelico¹⁶, S. Grelli^{1,6}, P. Kennedy², J. Verheyen³, F. Ceccherini-Silberstein¹, C.F. Perno¹⁷, V. Svircher¹, R. Salpini¹
¹"Tor Vergata" University of Rome, Experimental Medicine, Rome, Italy, ²Barts Liver Centre, Blizard Institute, Barts and The London SMD, QMUL, London, United Kingdom, ³University of Milan, Paediatric Clinical Research Center "Romeo and Enrica Invernizzi", Milan, Italy, ⁴Institute of Virology, University-Hospital, University Duisburg-Essen, Essen, Germany, ⁵University of Milan, Microbiology and virology, Milan, Italy, ⁶Tor Vergata University Hospital, Microbiology and Virology Unit, Rome, Italy, ⁷Tor Vergata University Hospital, Infectious Disease Unit, Rome, Italy, ⁸"Sapienza" University, Public Health and Infectious Disease, Rome, Italy, ⁹"Umberto I" University Hospital, Rome, Italy, ¹⁰"S.S. Filippo e Nicola" Hospital, Infectious Disease Unit, Avezzano, Italy, ¹¹"S.Andrea Hospital", Department of Gastroenterology, Rome, Italy, ¹²"San Salvatore Hospital", L'Aquila, Italy, ¹³"Nuovo Regina Margherita" Hospital, Rome, Italy, ¹⁴Pescara General Hospital, Infectious Disease Unit, Pescara, Italy, ¹⁵University "G. d'Annunzio" Chieti-Pescara, Clinic of Infectious Diseases, Department of Medicine and Science of Aging, Chieti, Italy, ¹⁶Tor Vergata University Hospital, Hepatology Unit, Rome, Italy, ¹⁷University of Milan, Oncology and Haemato-oncology, Milan, Italy

PD 34 13.17-13.22 Tackling the undiagnosed fraction: evidence-based public health guidance for integrated HBV, HCV and HIV testing in the EU/EEA

A.K. Sullivan^{1,2}, L. Combs³, L. Tavoschi^{4,5}, S. Croxford², S. Desai², L. Mason⁶, M. Hoekstra⁷, V. Delpech², S. Finne Jakobsen³, A.J. Amato-Gauci⁴, D. Raben³
¹Chelsea and Westminster Hospital NHS Foundation Trust, United Kingdom, ²Public Health England, United Kingdom, ³University of Copenhagen, Denmark, ⁴European Centre for Disease Prevention and Control, Sweden, ⁵University of Pisa, Italy, ⁶Pallas health research and consultancy, The Netherlands, ⁷Freelance consultant

PD 35 13.25-13.30 Efficacy and safety of velpatasvir plus sofosbuvir regimen in HCV chronic patients without advanced liver disease naive to previous DAA therapy: a meta-analysis

M. Pisaturo, A. Russo, L. Onorato, N. Coppola
Department of Mental Health and Public Medicine – Infectious Diseases Unit. University of Campania Luigi Vanvitelli

PD 36 13.33-13.38 Acceptability and effectiveness of a pragmatic comprehensive project of linkage to care from Addiction Services to Infectious Diseases Unit in HCV people who inject drugs

A. Soria¹, E. Colella¹, E. Chiesa², A. Cardia³, M. Bramani Araldi⁴, D. Leto³, G. Scaffidi⁴, S. Mancastroppa², C. De Ferrari³, A. Caruso⁴, S. Marangon², M. Pecoraro⁵, P. Columpsi¹, B. Tinghino⁵, G. Galimberti², G. Migliorino¹, G. Lapadula¹
¹Unit of Infectious Diseases, San Gerardo Hospital, ASST Monza, ²Addiction service (SERD) of Monza, ASST Monza, ³Addiction service (SERD) of Limbiate, ASST Monza, ⁴Addiction service (SERD) of Carate Brianza, ASST Vercate, ⁵Service of Alcohol disorders and new addictions (NOA) of Seregno, ASST Vercate

PD 37 13.41-13.46 DAAs based treatment for HIV/HCV coinfecting patients: virological and metabolic outcomes in a real-life study

L. Onorato^{1,6}, L. Alessio¹, V. Sangiovanni², F. Borrelli³, E. Manzillo⁴, V. Esposito⁵, F. Simeone¹, S. Martini⁶, N. Capoluongo², S. Leone⁷, G. Di Filippo³, M. D'Abbraccio⁵, L. Aprea⁴, A. Salomone Megna⁸, E. Milano⁹, A. Saracino⁹, N. Coppola^{1,6}

¹Infectious Diseases Unit, AORN Sant'Anna e San Sebastiano, Caserta, ²Third Infectious Diseases Unit, AORN dei Colli, P.O. Cotugno, Naples, ³Infectious Diseases Unit, University Federico II, Naples, ⁴IX Infectious Diseases Unit, AORN dei Colli, P.O. Cotugno, Naples, ⁵Department of Infectious Disease and Infectious Emergencies, General Infectious Diseases Unit, AORN dei Colli, P.O. Cotugno, Naples, ⁶Department of Mental Health and Preventive Medicine, Section of Infectious Diseases, University of Campania "L. Vanvitelli", Naples, ⁷Infectious Diseases Unit, A.O.S.G. Moscati, Avellino, ⁸Infectious Diseases Unit, A.O.G. Rummo, Benevento, ⁹Department of Biomedical Sciences and Human Oncology, Clinic of Infectious Diseases, University of Bari

PD 38 13.49-13.54 Serious liver events and liver-related deaths in HIV/HCV co-infected patients with diabetes: data from the ICONA Foundation Cohort Study

S. Leone¹, P. Lorenzini², A. Cozzi-Leperi³, G. Orofino⁴, D. Bernacchia⁵, A. Castagna⁶, M. Menozzi⁷, G. Guaraldi⁷, G. Madeddu⁸, A. Di Biagio⁹, A. Gori¹⁰, A. d'Arminio Monforte¹¹, for the ICONA Foundation Cohort Study

¹Division of Infectious Diseases, Department of Internal Medicine, San Giuseppe Moscati Hospital, Avellino, Italy, ²National Institute for Infectious Diseases L. Spallanzani, Rome, Italy, ³Institute for Global Health, University College London, London, UK, ⁴Infectious Diseases Unit A, Amedeo di Savoia Hospital, Turin, Italy, ⁵Infectious Diseases Unit, ASST Fatebenefratelli-Sacco, DIBIC 'L. Sacco', University of Milan, Milan, Italy, ⁶Infectious Diseases Department, IRCCS San Raffaele Scientific Institute & Vita-Salute University, Milan, Italy, ⁷Clinic of Infectious Diseases, University of Modena and Reggio Emilia, Modena, Italy, ⁸Infectious Diseases Unit, Department of Clinical and Experimental Medicine, University of Sassari, Sassari, Italy, ⁹Infectious Diseases Unit, Policlinico San Martino Hospital, Genoa, Italy, ¹⁰Infectious Diseases Unit, Department of Internal Medicine, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy and Department of Pathophysiology and Transplantation, School of Medicine and Surgery, University of Milan, Milan, Italy, ¹¹Clinic of Infectious and Tropical Diseases, Department of Health Sciences, ASST Santi Paolo e Carlo, University of Milan, Milan, Italy

SATELLITE SYMPOSIUM 13.15-14.00

AULA 211

Con il supporto incondizionato di ViiV Healthcare

HIV: same day treatment in real life

Chair: A. Lazzarin (Milano)

Discussant: M.L. Cosmaro (Milano)

The de-stigmatization of PHLWA and the process of normalization of HIV disease should not lead to the minimization of its relevance for both individuals and society. Behind the slogan "test and treat" lies this dualism: the virtuous promptness of care, the absolute protagonist of the virtuous mentioned path, should not be confused with the hasty beginning of a therapy that must be taken longlife. It is important that all the stakeholders discuss and find together the way to enhance the drive of T & T in the context of the high standards of care obtained in our country.

- 13.15-13.30 **Same day treatment: the evidence**
- 13.30-13.45 **Same day treatment: the road map**
- 13.45-14.00 **Discussion on Symposium issues**

Giovanni Di Perri, Torino
 Massimo Andreoni, Roma

ORAL COMMUNICATIONS 14.05-15.35

AULA MAGNA

New challenges of viral hepatitis

Chairs: V. Cento (Milano), M. Di Pietro (Pistoia), V. Svicher (Roma)

OC 72 14.05-14.15 The use of accurate virological and immunological hepatitis B markers can allow an early diagnosis of HBV reactivation in HBsAg-negative/anti-HBc-positive patients with oncohematological diseases

R. Salpini¹, C. Cerva², M. Alkhatib¹, A. Battisti¹, L. Piermatteo¹, A. Sacco¹, V. Malagnino², W. Arcese³, M. Cantonetti³, F. Ceccherini-Silberstein¹, C.F. Perno⁴, M. Andreoni², L. Sarmati², V. Svicher¹

¹Department of Experimental Medicine, Tor Vergata University, Rome, Italy, ²Clinical Infectious Disease, Department of System Medicine, Tor Vergata University, Rome, Italy, ³Department of Hematology, Stem Cell Transplant Unit, Tor Vergata University, Rome, Italy, ⁴Department of Oncology and Haematology, University of Milan



OC 73 14.17-14.27 The integration of Hepatitis B virus in relevant regions of human genome occurs frequently in HBsAg negative chronic infection despite limited liver disease and low-viraemia: implications for an altered cell metabolism

R. Salpini¹, L. Carioti¹, A. Battisti^{1,2}, L. Colagrossi^{1,3}, L. Piermatteo¹, M. Surdo⁴, V. Cacciafesta⁴, A. Nuccitelli⁴, N. Hansi², F. Ceccherini-Silberstein¹, C.F. Perno⁵, U.S. Gill⁶, P.T.F. Kennedy², V. Svicher¹

¹Tor Vergata University of Rome, Department of Experimental Medicine and Surgery, Rome, Italy, ²Barts Liver Centre, Blizard Institute, Barts and The London SMD, QMUL, London, United Kingdom, ³Department of Microbiology and Virology, University of Milan, Milan, Italy, ⁴GENOMA, Molecular Genetics Laboratory, Rome, Italy, ⁵Department of Oncology and Haematology, University of Milan, Milan, Italy

OC 74 14.29-14.39 Decline of Prevalence of Resistance Associated Substitutions to NS3 and NS5A inhibitors at DAA-failure in Hepatitis C Virus in Italy over the years 2015 to 2018

D. Redi^{1,2}, B. Rossetti¹, V.C. Di Maio³, M. Aragri³, S. Paolucci⁴, C. Masetti⁵, L. Paglicci^{1,2}, B. Bruzzone⁶, C. Minichini⁷, F. Montagnani^{1,2}, V. Michel⁸, S. Landonio⁹, E. Degasperi¹⁰, G. Zanelli^{1,2}, R. Maserati¹¹, I. Maida¹², A.P. Callegaro¹³, S. Barbaliscia³, A. Bertoli³, C. Paternoster¹⁴, S. Marengo¹⁵, F. Morisco¹⁶, V. Calvaruso¹⁷, G. Taliani¹⁸, M. Puoti¹⁹, G. Cenderello²⁰, A. De Santis²¹, M. Lichtner²², N. Coppola⁷, R. Gulminetti¹¹, V. Cento²³, M. Rendina²⁴, E. Teti²⁵, G. Parruti²⁶, T. Ruggiero²⁷, V. Ghisetti²⁷, C. Pasquazzi²⁸, L.A. Nicolini²⁹, V. Vullo³⁰, A. Pellicelli³¹, T. Prestileo³², R. Cozzolongo³³, V. Sangiovanni³⁴, M. Biolato³⁵, I. Lenci⁵, A. Licata³⁶, A. Ciaccio³⁷, V. Pace Palitti³⁸, A. Giorgini³⁹, G. Cariti⁴⁰, A. Ciancio⁴¹, A. Aghema⁴², V. Borghi⁴³, P. Andreone⁴⁴, M. Brunetto⁴⁵, T. Pollicino⁴⁶, T. Santantonio⁴⁷, N. Cuomo⁴⁸, C. Cauda⁴⁹, S. Babudieri¹², P. Lampertico¹⁰, G.B. Gaeta⁷, G. Raimondo⁴⁶, M. Andreoni²⁵, G. Rizzardi¹⁹, M. Angelico⁵, C.F. Perno⁵⁰, A. Craxi¹⁷, M. Zazzi², F. Ceccherini-Silberstein³ on behalf of HCV Virology Italian Resistance Network (Vironet C)

¹Infectious Diseases Unit, AOU Senese, Siena, Italy, ²Department of Medical Biotechnology, University of Siena, Siena, Italy, ³Department of Experimental Medicine, University of Rome Tor Vergata, Rome, Italy, ⁴Molecular Virology Unit, Microbiology and Virology department, IRCCS Policlinic San Matteo, Pavia, Italy, ⁵Hepatology Unit, University Hospital of Rome Tor Vergata, Rome, Italy, ⁶Hygiene Unit, IRCCS AOU San Martino-IST, Genoa, Italy, ⁷Infectious Diseases Unit, University of Campania L. Vanvitelli, Naples, Italy, ⁸Clinical Microbiology, Virology and Bioemergencies Diagnosis, L. Sacco University Hospital, Milan, Italy, ⁹Division of Infectious Diseases, ASST Fatebenefratelli Sacco, Milan, Italy, ¹⁰CRC "A.M. e A. Migliavacca" Center for Liver Diseases, Division of Gastroenterology and Hepatology, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, University of Milan, Milan, Italy, ¹¹Institute of Infectious Diseases, University of Pavia, Pavia, Italy, ¹²Medical, Surgical and Experimental Sciences, University of Sassari, Sassari, Italy, ¹³Department of Laboratory Medicine, ASST Papa Giovanni XXIII, Bergamo, Italy, ¹⁴Infectious Disease Unit, Ospedale di Trento, Trento, Italy, ¹⁵Division of Hepatology, University of Genoa-AOU IRCCS San Martino-IST, Genoa, Italy, ¹⁶Department of Clinical Medicine and Surgery, University "Federico II" of Naples, Naples, Italy, ¹⁷Gastroenterology, "P. Giaccone" University Hospital, Palermo, Italy, ¹⁸Department of Clinical Medicine, Clinic of Tropical Medicine, Sapienza University of Rome, Rome, Italy, ¹⁹Division of Infectious Diseases, ASST Grande Ospedale Metropolitano Niguarda, Milan, Italy, ²⁰Infectious Diseases Unit, Ente Ospedaliero Galliera Hospital, Genoa, Italy, ²¹Gastroenterology Unit, "La Sapienza" University of Rome, Rome, Italy, ²²Infectious Diseases Unit, Sapienza University, Polo Pontino, Latina, Italy, ²³Residency program in Microbiology and Virology, Università degli Studi di Milano, Milan, Italy, ²⁴Department of Emergency and Organ Transplantation, Section of Gastroenterology, University Hospital, Bari, Italy, ²⁵Infectious Diseases, University Hospital of Rome Tor Vergata, Rome, Italy, ²⁶Infectious Disease Unit, Pescara General Hospital, Pescara, Italy, ²⁷Laboratory of Microbiology and Virology, Amedeo di Savoia Hospital, ASL Città di Torino, Turin, Italy, ²⁸Infectious Diseases, Sant'Andrea Hospital – "La Sapienza", Rome, Italy, ²⁹Department of Health Sciences (DISSAL), University of Genoa, ³⁰Department of Public Health and Infectious Diseases, Sapienza University, Rome, ³¹Hepatology Unit, San Camillo Forlanini Hospital, Rome, Italy, ³²Infectious Diseases Unit, ARNAS Civico-Di Cristina-Beneffratelli, Palermo, Italy, ³³Division of Gastroenterology, National Institute of Gastroenterology S De Bellis, Castellana Grotte (Bari), Italy, ³⁴Hospital Cotugno, Naples, Italy, ³⁵Liver Transplant Medicine, Fondazione Policlinico Universitario A. Gemelli IRCCS, Università Cattolica del Sacro Cuore, Roma, Italy, ³⁶Internal Medicine and Hepatology, Di.Bi.M.I.S. University of Palermo, Palermo, Italy, ³⁷Unit of Gastroenterology, Department of Medicine, Hospital San Gerardo, Monza, Italy, ³⁸Hepatology Unit, Pescara General Hospital, Pescara, Italy, ³⁹ASST Santi Paolo e Carlo, Milan, Italy, ⁴⁰Department of Medical Sciences, University of Turin, Amedeo di Savoia Hospital, Turin, Italy, ⁴¹Unit of Gastroenterology, University of Turin, Department of Medical Sciences, City of Health and Science of Molinette Turin Hospital, Turin, Italy, ⁴²Department of Biomedical Sciences, Humanitas University, Pieve Emanuele (MI), Italy, ⁴³Department of Biomedical Sciences, University of Modena School of Medicine, Modena, Italy, ⁴⁴Department of Medical and Surgical Sciences, Maternal-fantile and Adult Sciences, University of Modena and Reggio Emilia, Modena, Italy, ⁴⁵Hepatology Unit, University Hospital of Pisa, Pisa, Italy, ⁴⁶Department of Internal Medicine, University Hospital of Messina, Messina, Italy, ⁴⁷Infectious Diseases Unit, University of Foggia, Foggia, Italy, ⁴⁸Microbiology and Virology, Azienda Ospedaliera Specialistica dei Colli Monaldi - Cotugno - C.T.O., Naples, Italy, ⁴⁹Microbiology and Virology Unit, Siena University Hospital, ⁵⁰Department of Oncology and Oncohematology, University of Milan, Milan, Italy

OC 75 14.41-14.51 Evaluation of selective pressure on target regions of anti-HCV direct antivirals in liver and plasma compartments: application of Mixed Effects Model of Evolution (MEME) algorithm

S. Bagaglio¹, E. Messina¹, H. Hasson¹, C. Uberti-Foppa², G. Morsica¹

¹Division of Infectious Diseases, Ospedale San , Italy, ²Vita-Salute University, Milan, Italy

OC 76 14.53-15.03 Specific NS5A polymorphisms correlate with hepatocellular carcinoma in cirrhotic patients infected with HCV genotype 1b

M. Alkhatib¹, V.C. Di Maio¹, V. De Murtas², M. Aragri¹, R. Scutari¹, A. Sacco¹, E. Polilli³, C. Masetti⁴, E. Teti⁵, S. Barbaliscia¹, A. Bertoli¹, V. Cento⁶, V. Calvaruso⁷, F. Morisco⁸, V. Pace Palitti⁹, C. Pasquazzi¹⁰, P. Cacciatore³, S. Francioso⁴, F. Sozio³, A. Pieri³, S. Babudieri², C. Mussini¹¹, G. Parruti³, V. Borghi¹¹, I. Lenci⁴, A. Craxi⁶, M. Andreoni⁵, M. Angelico⁴, I. Maida², A. Orro¹², L. Milanese¹², M.M. Santoro¹, C.F. Perno⁶, V. Svicher¹, F. Ceccherini-Silberstein¹, R. Salpini¹

¹Department of Experimental Medicine and Surgery, University of Rome "Tor Vergata", Rome, Italy, ²Department of Clinical and Experimental Medicine, University of Sassari, Sassari, Italy, ³Infectious Diseases Unit, Pescara General Hospital, Pescara, Italy, ⁴Hepatology Unit, University Hospital of Rome "Tor Vergata", Rome, Italy, ⁵Infectious Diseases Unit, University Hospital of Rome "Tor Vergata", Rome, Italy, ⁶University of Milan, Milan, Italy, ⁷Gastroenterology, "P. Giaccone" University Hospital, Palermo, Italy, ⁸Gastroenterology, «Federico II» University, Naples, Italy, ⁹Hepatology Unit, Pescara General Hospital, Pescara, Italy, ¹⁰Infectious Diseases Unit, Sant'Andrea Hospital – "Sapienza" University, Rome, Italy, ¹¹Polyclinic of Modena, Modena, Italy, ¹²Institute of Biomedical Technologies, National Research Council, Segrate, Milan, Italy

OC 77 15.05-15.15 Occurrence of HIV virological failure in HIV-1 positive patients during direct acting antivirals (DAAs) treatment for hepatitis C virus

G. Morsica¹, E. Messina¹, A. Castagna^{1,2}, S. Bagaglio¹, S. Salpietro¹, L. Della Torre¹, C. Uberti-Foppa^{1,2}, H. Hasson¹

¹Division of Infectious Diseases, IRCCS San Raffaele Scientific Institute, Milan, Italy, ²Vita-Salute University, Milan, Italy

OC 78 15.17-15.27 High efficacy of resistance-guided retreatment in HCV infected patients who previously failed a NS5A inhibitor-containing regimen: the Italian Vironet C real life experience

V.C. Di Maio¹, M. Aragri¹, C. Masetti², S. Paolucci³, B. Bruzzone⁴, E. Degasperis⁵, S. Barbaliscia¹, T. Pollicino⁶, C. Minichini⁷, V. Calvaruso⁸, M. Rendina⁹, V. Cento¹⁰, E. Teti¹¹, V. Micheli¹², V. Ghisetti¹³, E. Polilli¹⁴, V. Pace Palitti¹⁵, S. Landonio¹⁶, I. Lenci², S. Francioso², L. Donnarumma¹⁷, L.A. Nicolini¹⁸, A. Bertoli¹, M. Starace⁷, C. Pasquazzi¹⁹, A.P. Callegaro²⁰, F. Morisco¹⁷, G. Cenderello²¹, S. Marengo²², R. Gulminetti²³, S. Novati²³, A. Scuteri²⁴, P. Andreone²⁵, S. Galli²⁶, A. Ciancio²⁷, V. Sangiovanni²⁸, N. Cuomo²⁹, A. Raddi²⁹, G. Morsica³⁰, H. Hamid³⁰, V. Borghi³¹, I. Maida³², M. Brunetto³³, P. Colombatto³³, R. Cozzolongo³⁴, A. De Santis³⁵, M. Lichtner³⁶, S. Babudier³², E. Biliotti³⁷, G. Taliani³⁷, T. Santantonio³⁸, M. Di Stefano³⁸, C. Paternoster³⁹, R. Ganga⁴⁰, M. Puoti⁴¹, G. Rizzardini¹⁶, A. Pellicelli⁴², E. Milano⁴³, C. Mastroianni⁴⁴, A. Licata⁴⁵, F. Di Lorenzo⁴⁶, A. Giorgini⁴⁷, L. Sighinolfi⁴⁸, C. Dentone⁴⁹, A. Leo⁵⁰, B. Rossetti⁵¹, I. Beretta⁵², P. Lampertico⁵, G. Parruti¹⁴, N. Coppola⁷, M. Zazzi⁵³, G. Raimondo⁶, M. Andreoni¹¹, A. Craxi⁸, M. Angelico², C.F. Perno³⁴, F. Ceccherini-Silberstein¹ on behalf of HCV Virology Italian Resistance Network (Vironet C)

¹Department of Experimental Medicine, University of Rome Tor Vergata, Rome, Italy, ²Hepatology Unit, University Hospital of Rome Tor Vergata, Rome, Italy, ³Molecular Virology Unit, Microbiology and Virology department, IRCCS Policlinic Foundation San Matteo, Pavia, Italy, ⁴Hygiene Unit, IRCCS AOU San Martino-IST, Genoa, Italy, ⁵CRC "A.M. e A. Migliavacca" Center for Liver Diseases, Division of Gastroenterology and Hepatology, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, University of Milan, Milan, Italy, ⁶Department of Internal Medicine, University Hospital of Messina, Messina, Italy, ⁷Infectious Diseases Unit, University of Campania L. Vanvitelli, Naples, Italy, ⁸Gastroenterology, "P. Giaccone" University Hospital, Palermo, Italy, ⁹Department of Emergency and Organ Transplantation, Section of Gastroenterology, University Hospital, Bari, Italy, ¹⁰Residency program in Microbiology and Virology, Università degli Studi di Milano, Milan, Italy, ¹¹Infectious Diseases, University Hospital of Rome Tor Vergata, Rome, Italy, ¹²Clinical Microbiology, Virology and Bioemergencies Diagnosis, L. Sacco University Hospital, Milan, Italy, ¹³Laboratory of Microbiology and Virology, Amedeo di Savoia Hospital, ASL Città di Torino, Turin, Italy, ¹⁴Infectious Disease Unit, Pescara General Hospital, Pescara, Italy, ¹⁵Hepatology Unit, Pescara General Hospital, Pescara, Italy, ¹⁶Division of Infectious Diseases, ASST Fatebenefratelli Sacco, Milan, Italy, ¹⁷Department of Clinical Medicine and Surgery, University "Federico II" of Naples, Naples, Italy, ¹⁸Department of Health Sciences (DISSAL), University of Genoa, ¹⁹Infectious Diseases, Sant'Andrea Hospital - "La Sapienza", Rome, Italy, ²⁰Department of Laboratory Medicine, ASST Papa Giovanni XXIII, Bergamo, Italy, ²¹Infectious Diseases Unit, Ente Ospedaliero Galliera Hospital, Genoa, Italy, ²²Division of Hepatology, University of Genoa-AOU IRCCS San Martino-IST, Genoa, Italy, ²³Institute of Infectious Diseases, University of Pavia, Pavia, Italy, ²⁴Department of Medical and Surgical Sciences, DIMEC, Alma Mater Studiorum - University of Bologna, Bologna, Italy, ²⁵Department of Medical and Surgical Sciences, Maternal-Infantile and Adult Sciences, University of Modena and Reggio Emilia, Modena, Italy, ²⁶Microbiology Unit, Ospedale S.Orsola-Malpighi, Bologna, Italy, ²⁷Unit of Gastroenterology, University of Turin, Department of Medical Sciences, City of Health and Science of Molinette Turin Hospital, Turin, Italy, ²⁸Hospital Cotugno, Naples, Italy, ²⁹Microbiology and Virology, Azienda Ospedaliera Specialistica dei Colli Monaldi - Cotugno - C.T.O., Naples, Italy, ³⁰Division of Infectious Diseases, IRCCS, Ospedale San Raffaele, Milan, Italy, ³¹Department of Biomedical Sciences, University of Modena School of Medicine, Modena, Italy, ³²Medical, Surgical and Experimental Sciences, University of Sassari, Sassari, Italy, ³³Hepatology Unit, University Hospital of Pisa, Pisa, Italy, ³⁴Division of Gastroenterology, National Institute of Gastroenterology S De Bellis, Castellana Grotte (Bari), Italy, ³⁵Gastroenterology Unit, "La Sapienza" University of Rome, Rome, Italy, ³⁶Infectious Diseases Unit, Sapienza University, Polo Pontino, Latina, Italy, ³⁷Department of Clinical Medicine, Clinic of Tropical Medicine, Sapienza University of Rome, Rome, Italy, ³⁸Infectious Diseases Unit, University of Foggia, Foggia, Italy, ³⁹Infectious Disease Unit, Ospedale di Trento, Trento, Italy, ⁴⁰Azienda Ospedaliera G. Brotzu-Cagliari, Cagliari, Italy, ⁴¹Division of Infectious Diseases, ASST Grande Ospedale Metropolitano Niguarda, Milan, Italy, ⁴²Hepatology Unit, San Camillo Forlanini Hospital, Rome, Italy, ⁴³Clinic of Infectious Diseases, University of Bari, Bari, Italy, ⁴⁴Department of Public Health and Infectious Diseases, Policlinico Umberto I, Sapienza University of Rome, Rome, Italy, ⁴⁵Internal Medicine and Hepatology, Di.Bi. M.I.S. University of Palermo, Palermo, Italy, ⁴⁶Infectious Diseases Unit, ARNAS Civico-Di Cristina-Benefratelli, Palermo, Italy, ⁴⁷ASST Santi Paolo e Carlo, Milan, Italy, ⁴⁸Unit of Infectious Diseases, University Hospital of Ferrara, Ferrara, Italy, ⁴⁹Infectious Diseases Department, Sanremo Hospital, Sanremo, Italy, ⁵⁰Department of Biomedical Sciences, Humanitas University, Pieve Emanuele (MI), Italy, ⁵¹Infectious Diseases Unit, AOU Senese, Siena, Italy, ⁵²Infectious Disease Unit, ASST Monza- San Gerardo Hospital, Monza, Italy, ⁵³Department of Medical Biotechnology, University of Siena, Siena, Italy, ⁵⁴Department of Oncology and Oncohematology, University of Milan, Milan, Italy

ORAL COMMUNICATIONS 14.05-15.35

AULA 211

Social and PLWHIV related issues

Chairs: A. Cingolani (Roma), S. Mattioli (Bologna), L. Rancilio (Milano)

OC 79 14.05-14.15 Promoting migrant access to sexual and reproductive health services for sexual gender based violence (SGBV) prevention and response (Pro-access)

K. Ceessay, D. Di Dio, S.B. Dhiab, G. Florida, M.C. Longo, M. Manuli, D. Matheson, G. Petrelli, S. Reale, S. Scalzo, A.A. Sleemankhel, M.G. Di Benedetto, F. Bellissimo, L. Nigro for the ProAccess/LILA Volunteer Group
 Lega Italiana per la Lotta contro l'AIDS (LILA) - Catania

OC 80 14.17-14.27 Immigrated HIV Transgenders in Italy: clinical and neurocognitive outcome and needs

C. Atzori, P. Meraviglia, L. Valsecchi, G. Rizzardini, D. Minisci, N. Marazzi
 Infectious Diseases Department, Luigi Sacco University Hospital, Milan, Italy

OC 81 14.29-14.39 Does material deprivation affect late HIV presentation? Analysis from data of Italian HIV-surveillance System, 2010-2016

M. Dorrucchi¹, V. Regine², P. Pezzotti¹, L. Pugliese², B. Suligo² and the Regional representatives of the Italian HIV Surveillance System³

¹Dipartimento Malattie Infettive, Istituto Superiore di Sanità, Roma, ²Centro Operativo AIDS, Istituto Superiore di Sanità, Roma, ³Regional representatives of the Italian HIV Surveillance System. Abruzzo: M. Di Giacomo, L. Scancelli; Basilicata: F. Locuratolo, G. Cauzillo; Calabria: A.D. Mignoli, D.G. Chirico; Campania: G. Borgio; Emilia Romagna: E. Massimiliano; Friuli Venezia Giulia: T. Gallo, C. Braidà; Lazio: V. Puro, P. Scognamiglio, A. Mammone; Liguria: G. Icardi, P.L. Lai; Lombardia: M. Gramegna, D. Cereda; Marche: F. Filippetti; Molise: A. Prozzo; Piemonte: C. Pasqualini; Provincia Autonoma di Bolzano: L. Paganì, R. Binazzi; Provincia Autonoma di Trento: P. Lanzafame, L. Collini, D. Bossetti; Puglia: M. Chironna, D. Loconsole; Sardegna: M.A. Palmas; Sicilia: G. Dardanoni; Toscana: F. Voller, M. Puglia, L. Pecori; Umbria: A. Tosti, R. Papi; Valle d'Aosta: M. Ruffier, M.G. Verardo, A. Catania; Veneto: F. Russo, F. Da Re



- OC 82 14.41-14.51 Exercising with the support of the SmartApp: results on physical fitness, metabolic profile and psychological parameters**
M. Bonato^{1,2}, F. Turrini³, V. De Zan³, A. Meloni¹, R. Caccia³, M. Plebani¹, E. Brambilla¹, A. Giordani³, C. Vitobello³, M. F. Piacentini⁴, A. La Torre^{1,2}, G. Merati^{1,5}, L. Galli³, P. Cinque³
¹Università degli Studi di Milano, Milan, Italy, ²IRCCS, Istituto Ortopedico Galeazzi, Milano, Italy, ³IRCCS, San Raffaele Scientific Institute, Milan, Italy, ⁴Foro Italico University of Rome, Rome, Italy, ⁵IRCSS, Fondazione Don Carlo Gnocchi, Milan, Italy
- OC 83 14.53-15.03 Analysis of efficacy, adherence and quality of life (QoL) of early proactive switch to Elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide (E/C/T/TAF) in patients with a primary HIV-1 infection (ESTER study)**
M. Camici, A. Mondì, P. Lorenzini, S. Ottou, A. Vergori, M.M. Plazzi, R. Bellagamba, S. Cicalini, A. Antinori, C. Pinnetti
HIV/AIDS Clinical Unit, INMI Spallanzani, Rome
- OC 84 15.05-15.15 Organization and activity of a vaccination service for HIV + people: ASST-FBF-Sacco experience**
P. Meraviglia¹, C. Gulisano¹, A. Ridolfo¹, M.V. Cossu¹, C. Negri¹, D. Minisci¹, L. Valsecchi¹, A. Capetti¹, L. Confalonieri¹, C. Boriello², M. Galli¹, G. Rizzardini¹
¹Department infection disease ASST-FBF-Sacco, Milan, ²UOC vaccination ASST-FBF-Sacco, Milan
- OC 85 15.17-15.27 "Amare con Sapienza": an innovative digital prevention campaign to increase HIV new knowledge and test access in a large university community**
S. Vita¹, M. Lichtner², G. Morlino³, L. Celani², M.A. Zingaropoli², V. Perri², S. Valeri², F. Cogliati Dezza², L. Santinelli², G. Masci², M. Falciano², A. Salotti², O. Turriziani⁴, G. Antonelli⁴, C.M. Mastroianni², V. Vullo²
¹Infectious Disease Unit, SM Goretti Hospital Latina, ²Department of Public Health and Infectious disease, Sapienza, University of Rome, ³Snapback, Rome, ⁴Department of Molecular Medicine, Sapienza, University of Rome

POSTER DISCUSSION 14.05-15.35

AULA 201

Virology, Immunology and Basic science

Chairs: M.R. Capobianchi (Roma), F. Ceccherini-Silberstein (Roma)

- PD 39 14.05-14.10 Pre-existing Psychiatric Comorbidities Predict Dolutegravir Discontinuation in people living with HIV**
M. Milesi¹, A. Borghetti², J. Cusato¹, C. Alcantarini¹, S. Bonora¹, A. Ciccullo³, A. D'Avolio¹, G. Di Perri¹, S. Di Giambenedetto^{2,3}, A. Calcagno¹
¹Unit of Infectious Diseases, Amedeo di Savoia hospital, Department of Medical Sciences, University of Torino, Torino, ²IRCCS, Fondazione Policlinico Gemelli, Rome, ³Institute of Clinical Infectious Diseases, Catholic University of Sacred Heart, Rome, Italy
- PD 40 14.13-14.18 Glecaprevir/pibrentasvir pharmacokinetics when co-administered with antiretroviral drugs in a cohort of HCV/HIV patients**
V. Pirriatore¹, L. Marinaro¹, R. Angilletta¹, A. Palazzo¹, A. Barco¹, C. Alcantarini¹, N. Forni¹, C. Montrucchio², M. Ferrara¹, A. Lazzaro¹, M. Tettoni¹, A. De Nicolò³, A. D'Avolio³, A. Calcagno¹, G. Di Perri¹, S. Bonora¹
¹Unit of Infectious Diseases, Department of Medical Sciences, University of Torino, Torino, Italy, ²Unit of Infectious Diseases, Cardinal Massaia Hospital, Asti, Italy, ³Interdepartmental Center for Clinical and Experimental Pharmacology (CIFACS), University of Torino, Torino, Italy
- PD 41 14.21-14.26 Analysis of miRNAs in treated HIV-1 patients with different levels of viral suppression**
E. Falasca¹, D. Di Carlo¹, L. Mazzuti¹, M. Calabretto¹, L. Celani², G. D'Ettore², I. Mezzaroma³, G. Antonelli¹, O. Turriziani¹
¹Department of Molecular Medicine, ²Department of Public Health and Infectious Diseases, ³Department of Translational and Precision Medicine; Sapienza University of Rome
- PD 42 14.29-14.34 Prevalence of resistance mutations in a large cohort of perinatally HIV-1 infected patients**
R. Ungaro¹, L. Taramasso^{1,2}, B. Bruzzone³, I. Vicenti⁴, L. Galli⁵, V. Borghi⁶, D. Francisci⁷, M. Pecorari⁸, A. Zoncada⁹, A.P. Callegaro¹⁰, E. Paolini¹¹, L. Monno¹², S. Bonora¹³, A. Di Biagio¹⁴
¹University of Genoa, Department of Health Sciences (DISSAL), Genoa, ²Infectious Diseases Unit, Department of Internal Medicine, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milano, ³Igiene Unit, Policlinico San Martino Hospital, Genova, ⁴Department of Medical Biotechnology, University of Siena, Siena, ⁵Department of Health Sciences, University of Florence, Pediatric Infectious Diseases Division, Anna Meyer Children's University Hospital, Firenze, ⁶Department of Infectious Diseases, University of Modena, Modena, ⁷Infectious Diseases Clinic, Department of Medicine, University of Perugia, Perugia, ⁸Microbiology and Virology Unit, Azienda Ospedaliera Universitaria di Modena, Modena, ⁹Clinic of Infectious Diseases, Cremona Hospital, Cremona, ¹⁰Microbiology and Virology Unit, ASST Papa Giovanni XXIII, Bergamo, ¹¹Unit of Immunohematology and Transfusional Medicine, Cremona Hospital, Cremona, ¹²Infectious Diseases Unit, Bari Hospital, Bari, ¹³Infectious Diseases Unit, Amedeo di Savoia Hospital, University of Turin, Torino, ¹⁴Infectious Diseases Unit, Policlinico San Martino Hospital, Genova

- PD 43 14.37-14.42 Some HIV-1 gp120 polymorphisms could be involved in resistance to Fostemsavir**
L. Fabeni¹, B. Yagai¹, G. Berno², L. Carioti¹, R. Salpini¹, V. Svicher¹, C.F. Perno³, M.M. Santoro¹, F. Ceccherini-Silberstein¹
¹Department of Experimental Medicine and Surgery, University of Rome "Tor Vergata", Rome, Italy, ²Virology Unit, INMI L. Spallanzani, IRCCS, Rome Italy, ³Department of Oncology and Hemato-Oncology, University of Milan, University of Milan, Milan, Italy
- PD 44 14.45-14.50 Mycobacterium tuberculosis complex genetic variation and macrophage polarization status influence phagolysosomal acidification during infection**
M. Chiacchiareta¹, N. Bresciani¹, A. Agresti², S. Zambrano^{2,4}, D. Mazza³, F. Cugnata⁴, C. Tassan Din⁵, D.M. Cirillo¹, P. Miotto¹
¹Emerging Bacterial Pathogens Unit, Division of Immunology, Transplantation and Infectious Diseases, IRCCS Ospedale San Raffaele, Milano, Italy, ²Chromatin Dynamics Unit, San Raffaele University and Scientific Institute, Milano, Italy, ³Cancer Imaging Unit, Experimental Imaging Center, IRCCS Ospedale San Raffaele, Milano, Italy, ⁴Vita-Salute San Raffaele University, Milano, Italy, ⁵Infectious Diseases Clinical Department, Division of Immunology, Transplantation and Infectious Diseases, IRCCS Ospedale San Raffaele, Milano, Italy
- PD 45 14.53-14.58 Plasma and intracellular pharmacokinetics of cobicistat in the clinical setting**
M. Ferrara, A. Trentalange, C. Alcantarini, A. Lazzaro, N. Forni, A. Ianniello, V. Avataneo, A. D'Avolio, A. Calcagno, G. Di Perri, S. Bonora
Unit of Infectious Diseases, Department of Medical Sciences, University of Torino, Torino
- PD 46 15.01-15.06 Chronic infections balance inflammaging: immunity of centenarians with HIV or HCV**
G. Guaraldi¹, G. Dolci¹, S. De Biasi¹, D. Lo Tartaro¹, M. Nasi¹, J. Milic¹, C. Vaccari¹, H. Santos², I. Pintasilgo², C. Martins², C. Mussini¹, A. Cossarizza¹
¹University of Modena and Reggio Emilia, Modena, Italy, ²Hospital Garcia de Orta, Lisbon, Portugal
- PD 47 15.09-15.14 Maraviroc as a Latency Reversing Agent in cell line models**
L. Vicenti¹, F. Dragoni¹, M. Monti^{2,4}, A. Giannini¹, A. Ciabattini¹, B. Rossetti³, A. De Luca^{1,3}, D. Medagliani¹, E. Montomoli^{2,4}, M. Zazzi¹
¹Department of Medical Biotechnologies, University of Siena, Siena, Italy, ²Department of Molecular and Developmental Medicine, University of Siena, Siena, Italy, ³Infectious Diseases Unit, Azienda Ospedaliera Universitaria Senese, Siena, Italy, ⁴VisMederi srl, Siena, Italy
- PD 48 15.17-15.22 Role of boosted vs unboosted protease inhibitors on dolutegravir plasma and intracellular pharmacokinetic in dual therapy clinical setting**
M. Ferrara, L. Marinaro, C. Alcantarini, A. Barco, M. Milesi, M.C. Tettoni, A. Ianniello, A. De Nicolò, A. D'Avolio, A. Calcagno, G. Di Perri, S. Bonora
Unit of Infectious Diseases, Department of Medical Sciences, University of Torino, Torino

POSTER DISCUSSION 14.05-15.35

AULA MALLIANI

HIV therapy and management

Chairs: P. Cinque (Milano), A. Di Biagio (Genova)

- PD 49 14.05-14.10 Durability and efficacy of dolutegravir-based 2 drug regimens in virologically suppressed patients: a real life clinical setting**
V. Micheli¹, D. Rizzelli¹, D. Mileto¹, A. Mancon¹, F. Romeri¹, A. Giacomelli², M.V. Cossu³, L. Oreni², A.F. Capetti³, S. Rusconi², M.R. Gismondo¹
¹Laboratory of Clinical Microbiology, Virology and Bioemergencies, ASST Fatebenefratelli-Sacco, L. Sacco University Hospital, Milano, Italy, ²Infectious Diseases Clinic, DIBIC Luigi Sacco, University of Milano, Milano, Italy, ³1st Division of Infectious Diseases, ASST Fatebenefratelli-Sacco, L. Sacco University Hospital, Milano, Italy
- PD 50 14.13-14.18 Improvement of CD4/CD8 ratio in experienced patients switching to dolutegravir based dual therapies**
L. Taramasso^{1,2}, A. Di Biagio³, E. Ricci², N. Squillace⁴, R. Gulminetti⁵, G.V. De Socio⁶, B. Menzaghi⁷, G.C. Orofino⁸, G. Madeddu⁹, G. Pellicanò¹⁰, B.M. Celesia¹¹, A. Bandera^{1,2}, A. Gori^{1,2}, P. Bonfanti^{1,3} on behalf of CISA study group
¹Department of Health Sciences (DISSAL), University of Genova, Genova, Italy, ²Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milano, Italy, ³Infectious Diseases Unit, Policlinico Hospital San Martino, Genova, Italy, ⁴Infectious Diseases Unit ASST-MONZA, San Gerardo Hospital-University of Milano-Bicocca, Monza, ⁵Department of Medical Sciences and Infectious Diseases, Fondazione IRCCS Policlinico San Matteo -University of Pavia, ⁶Department of Internal Medicine 2, Infectious Diseases Unit, Perugia "Santa Maria della Misericordia" General Hospital, ⁷Unit of Infectious Diseases, ASST della Valle Olona - Busto Arsizio (VA), ⁸Division I of Infectious and Tropical Diseases, ASL Città di Torino, ⁹Unit of Infectious Diseases, Department of Medical, Surgical and Experimental Sciences, University of Sassari, Sassari, ¹⁰Department of Human Pathology of the Adult and the Developmental Age "G. Barresi", Unit of Infectious Diseases, University of Messina, Messina, Italy, ¹¹Unit of Infectious Diseases University of Catania ARNAS Garibaldi Catania, ¹²University of Milan, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milano, Italy, ¹³Unit of Infectious Diseases, A. Manzoni Hospital, Lecco



- PD 51 14.21-14.26 Simplification to high-genetic-barrier 2DR in PLWH harbouring 4-class drug-resistant HIV-1 enrolled in the PRESTIGIO Registry**
D. Canetti^{1,2}, L. Galli¹, N. Gianotti¹, A. Celotti³, L. Calza⁴, R. Gagliardini⁵, S. Rusconi⁶, S. Modica^{7,8}, G. Cenderello⁹, M. Ferrara¹⁰, M. Santoro¹¹, M. Zazzi⁸, A. Castagna^{1,2} on behalf of the PRESTIGIO Study Group
¹Clinic of Infectious Diseases, IRCCS San Raffaele, Milano, Italy, ²Clinic of Infectious Diseases, Vita-Salute San Raffaele University, Milano, Italy, ³Università degli Studi di Brescia, Spedali Civili di Brescia, Brescia, Italy, ⁴Unit of Infectious Diseases, Policlinico Sant'Orsola-Malpighi, Bologna, Italy, ⁵National Institute for Infectious Diseases L. Spallanzani, IRCCS, Roma, Italy, ⁶Sacco Hospital, Infectious Diseases, University of Milan, Milano, Italy, ⁷Infectious Diseases Unit, AOU Senese, Siena, Italy, ⁸Department of Medical Biotechnologies, University of Siena, Siena, Italy, ⁹Infectious Diseases Department, Galliera Hospital, Genova, Italy, ¹⁰Unit of Infectious Diseases, Department of Medical Sciences, University of Torino, Torino, Italy, ¹¹Department of Experimental Medicine and Surgery, University of Rome Tor Vergata, Rome, Italy
- PD 52 14.29-14.34 A ductile dual therapy with enhanced genetic barrier for multi-experienced patients**
F. Maggiolo, L. Comi, E. Di Filippo, D. Valenti, A.P. Callegaro, M. Rizzi
ASST Papa Giovanni XXIII, Bergamo
- PD 53 14.37-14.42 Predictors of incomplete virologic response and virological failure in patients with acute HIV infection. Results of Italian Network of ACUTE HIV INFECTION (INACTION) cohort**
L. Taramasso¹, M. Fabbiani², G. Bozzi¹, A. Muscatello¹, S. Nozza³, I. De Benedetto⁴, M. Ripa³, R. Dell'Acqua³, A. Antinori⁵, C. Pinnetti⁵, A. Calcagno⁴, M. Ferrara⁴, E. Focà⁶, E. Quiros-Roldan⁶, D. Ripamonti⁷, M. Campus⁸, B.M. Celesia⁹, C. Torti¹⁰, L. Cosco¹¹, A. Di Biagio¹², S. Rusconi¹³, G. Marchetti¹⁴, C. Mussini¹⁵, R. Gulminetti², A. Cingolani¹⁶, G. d'Ettore¹⁷, N. Geremia¹⁸, G. Madeddu¹⁸, A. Franco¹⁹, G. Orofino²⁰, N. Squillace²¹, A. Gori^{1,22}, G. Tambussi³, A. Bandera²² on behalf of INACTION study group
¹Infectious Diseases Unit, Department of Internal Medicine, Fondazione IRCCS Ca' Granda, Policlinico Maggiore Hospital, Milan, Italy, ²Infectious Diseases Unit, IRCCS San Matteo Hospital Foundation, University of Pavia, ³Clinic of Infectious Diseases, San Raffaele Hospital, University Vita Salute, Milan, Italy, ⁴Department of Medical Sciences, University of Turin, Amedeo di Savoia Hospital, Turin, Italy, ⁵National Institute for Infectious Diseases Lazzaro Spallanzani IRCCS, Rome, Italy, ⁶Division of Infectious and Tropical Diseases, University of Brescia, ASST Spedali Civili Hospital, Brescia, Italy, ⁷Infectious Disease Unit, ASST Papa Giovanni XXIII, Bergamo, Italy, ⁸Infectious Diseases Unit, SS Trinità Hospital, ASSL Cagliari, Italy, ⁹Unit of Infectious Diseases, Garibaldi Hospital, Catania, Italy, ¹⁰Unit of Infectious Diseases, Department of Medical and Surgical Sciences, University "Magna Graecia", Catanzaro, Italy, ¹¹Infectious Diseases Unit, "Pugliese-Ciaccio" Hospital, Catanzaro, Italy, ¹²Department of Infectious Diseases, IRCCS AOU San Martino IST, (DISSAL), University of Genoa, Genoa, Italy, ¹³Infectious Diseases Unit, Department of Biomedical and Clinical Sciences "Luigi Sacco" Hospital, University of Milan, Italy, ¹⁴Clinic of Infectious Diseases, Department of Health Sciences, University of Milan, ASST Santi Paolo e Carlo, Milan, Italy, ¹⁵Clinic of Infectious Diseases, University of Modena and Reggio Emilia, Modena Hospital, Italy, ¹⁶Institute of Clinical Infectious Diseases, Agostino Gemelli Hospital, Catholic University of Sacred Heart, Rome, Italy, ¹⁷Infectious Diseases Unit, Umberto I Hospital, La Sapienza University, Rome, Italy, ¹⁸Department of Clinical and Experimental Medicine, Unit of Infectious Diseases, University of Sassari, Italy, ¹⁹Infectious Diseases Unit, ASP Siracusa, Italy, ²⁰Unit of Infectious Diseases, Divisione A, Amedeo di Savoia Hospital, Turin, Italy, ²¹Infectious Diseases Unit, Department of Internal Medicine, ASST San Gerardo, Monza, Italy, ²²Infectious Diseases Unit, Department of Internal Medicine, Fondazione IRCCS Ca' Granda, Policlinico Maggiore Hospital, School of Medicine and Surgery, University of Milan, Italy
- PD 54 14.45-14.50 Trends of Transmitted Resistance Mutations to Four Drug Classes and HIV-Subtypes Among Subjects Recently Diagnosed as HIV Infected Over 2004-2019**
M. Basso¹, B. Parisatto¹, C. Stagni¹, R. Scaggiante², M. Cruciani³, R. Ferretto⁴, V. Manfrin⁵, E. Francavilla⁶, S. Panese⁷, F. Dal Bello¹, M. Andreon⁸, G. Palù¹, S.G. Parisi¹
¹Department of Molecular Medicine, University of Padova, Italy, ²Infectious Diseases, Padova Hospital, Italy, ³Center of Diffusive Diseases, Verona, Italy, ⁴Clinical Infectious Diseases, Hospital of Santorso, Italy, ⁵Infectious Diseases, Vicenza Hospital, Italy, ⁶Infectious Diseases, Belluno Hospital, Italy, ⁷Infectious Diseases Unit, dell'Angelo Hospital, Venezia, Italy, ⁸Clinical Infectious Diseases, Tor Vergata University, Rome, Italy
- PD 55 14.53-14.58 Presence of V72I, G123S and R127K Integrase Inhibitors polymorphisms could reduce cART effectiveness**
A. Celotti¹, F. Gargiulo², M. Properzi¹, M.A. De Francesco², E. Quiros-Roldan¹, I. Izzo¹, M.C. Pezzoli¹, A. Caruso², F. Castelli¹, E. Focà¹
¹Department of Infectious and Tropical Diseases, University of Brescia and ASST Spedali Civili Hospital, Brescia, ²Institute of Microbiology, Department of Molecular and Translational Medicine, University of Brescia and ASST Spedali Civili Hospital, Brescia
- PD 56 15.01-15.06 Trend of estimated glomerular filtration rate in a large cohort of HIV mother-to-child infected patients, an observational multicenter study from 2010 to 2018**
G. Sarteschi^{1,2}, A. Celotti³, M. Mirabella^{1,2}, A. Della Vecchia^{1,2}, S. Mora⁴, M. Giacomini⁴, E. Focà³, A. Di Biagio¹
¹Infectious Diseases Unit, IRCCS Policlinico San Martino Hospital, Genoa, ²Department of Health Sciences (DISSAL), University of Genoa, Genoa, ³Infectious and Tropical Diseases Department, University of Brescia and ASST Spedali Civili Hospital, Brescia, ⁴Department of Informatics Bioengineering, Robotics and Systems Engineering (DIBRIS), University of Genoa, Genoa
- PD 57 15.09-15.14 Vitamin D insufficiency is associated with subclinical atherosclerosis in HIV-1-infected patients on combination antiretroviral therapy**
L. Calza¹, V. Colangeli¹, M. Borderi¹, B. Granozzi¹, P. Malosso¹, I. Bon², M.C. Re², P. Viale¹
Department of Medical and Surgical Sciences, ¹Clinics of Infectious Diseases, ²Unit of Microbiology, S.Orsola Hospital, University of Bologna

PD 58 15.17-15.22 Predicting 2-drug antiretroviral regimen efficacy by genotypic susceptibility score: results from a cohort study

*B. Rossetti*¹, *S. Modica*², *R. Gagliardini*³, *D. Redi*^{1,2}, *F. Montagnani*^{1,2}, *G. Zanelli*^{1,2}, *S. Di Giambenedetto*⁴, *F. Lombardi*⁴, *M. Pecorari*⁵, *V. Borghi*⁶, *P. Meraviglia*⁷, *F. Maggiolo*⁸, *V. Micheli*⁹, *M. Zazzi*², *A. De Luca*^{1,2} on behalf of ARCA study group

¹Infectious Diseases Unit, AOU Senese, Siena, Italy, ²Department of Medical Biotechnologies, University of Siena, Siena, Italy, ³Lazzaro Spallanzani National Institute for Infectious Diseases IRCCS, Rome, Italy, ⁴Clinic of Infectious Diseases, Catholic University of Sacred Heart, Rome, Italy, ⁵Unit of Microbiology and Virology, Modena University Hospital, Modena, Italy, ⁶Infectious Diseases Unit, Modena Hospital, Modena, Italy, ⁷First Division of Infectious Diseases, ASST Fatebenefratelli-Sacco, Milan, Italy, ⁸Infectious Diseases Unit, Bergamo Hospital, Bergamo, Italy, ⁹Unit of Clinical Microbiology and Virology, ASST Fatebenefratelli-Sacco, Milan, Italy

ROUND TABLE 15.40-16.45

U=U

Chair: M. Tavio (Ancona)

Moderator: G. D'Amico (Roma)

The message U=U is a dramatic change in the history of HIV/AIDS epidemics. This message is the final demonstration that treatment as prevention (TASP) works. It is not a case that recently CDC, HHI and several other National Agencies have launched a program to stop HIV epidemics in 10 years in USA just concentrating on these two variables. If the message has an intrinsic objective value in terms of public health, its subjective meaning for PLWHIV is even greater. It means that stigma (or a large part of it) has no more reason to exist and it means that PLWHIV have the right and possibility to regain a normal life of relationships overcoming self-induced stigma. All these aspects will be discussed in the round-table that will approach the message in a holistic way.

Participants: A. Antinori (Roma), G.M. Corbelli (Bologna), F. Dal Molin (Milano), F. Maggiolo (Bergamo), P. Mazzoli (Milano), C. Mussini (Modena), A. Nava (Milano), M. Oldrini (Como), B. Richman (New York USA), M. Stagnitta (Firenze)

AULA MAGNA

ICAR AND SIMIT SPECIAL AWARDS 16:45-17:00

Chairs: A. Castagna (Milano), A. d'Arminio Monforte (Milano), M. Puoti (Milano), G. Rizzardini (Milano)

ICAR 2019 Scientific Committee Awards

Antonella d'Arminio Monforte, Milano

SIMIT Awards to Best Oral Communications for Young Researchers

Massimo Galli, Milano

AULA MAGNA

CLOSING REMARKS 17.00-17.15

A. Castagna (Milano), A. d'Arminio Monforte (Milano), M. Puoti (Milano), G. Rizzardini (Milano)



11° CONGRESSO NAZIONALE



**Italian Conference on
AIDS and Antiviral Research**

Promosso da



5-7 GIUGNO 2019
UNIVERSITÀ DEGLI STUDI DI MILANO

Presidenza del Congresso
Antonella Castagna
Antonella d'Arminio Monforte
Massimo Puoti
Giuliano Rizzardini

POSTER
EXHIBITION





POSTER EXHIBITION

BACTERIAL AND FUNGAL INFECTIONS IN IMMUNOCOMPROMISED HOST

- P 1 A rare case of disseminated *Fusarium* spp infection in a patient with recurrence of acute myeloid leukemia**
S. Mazzanti, L. Brescini, V. Barocci, A. Polenta, M. Di Pietrantonio, P. Mantini, V. Iencinella, S. Castelletti, A. Giacometti
Clinica malattie infettive, Ospedali Riuniti di Ancona, Università Politecnica delle Marche
- P 2 Prevalence of Syphilis in HIV infected individuals: a retrospective study in tertiary University Hospital**
Z. Di Rosa¹, C. Rovelli¹, D. Lombardi², M.L. Balsamo², A. Rossi², D. Dalla Gasperina¹, P.A. Grossi¹
¹University of Insubria, ²ASST-Sette Laghi Varese
- P 3 Epidemiology and Outcomes of Antibiotic Resistant patterns of Bloodstream Infections in HIV-Patients; a 14 year Single Center Study**
E. Franceschini, A. Santoro, S. Zona, G. Orlando, M. Menozzi, A. Bedini, I. Franconi, M. Meschiari, M. Di Gaetano, G. Guaraldi, C. Mussini
Azienda Ospedaliero-Universitaria di Modena
- P 4 Changes in the proportion of AIDS-defining events from 2000 to 2018 in antiretroviral-naive HIV-positive patients**
A. Dusina¹, A. Emiliozzi¹, A. Ciccullo¹, G. Baldin¹, D. Farinacci¹, D. Moschese¹, C. Picarelli¹, S. Belmonte¹, F. Lombardi¹, S. Lamonica¹, A. Borghetti², S. Di Giambenedetto^{1,2}
¹Institute of Clinical Infectious Diseases, Catholic University of the Sacred Heart, Rome, Italy, ²Fondazione Policlinico Universitario Agostino Gemelli IRCCS, UOS Malattie Infettive, Rome, Italy
- P 5 Non-Tuberculous Mycobacteria (NTM) among HIV+: preliminary findings from a systematic review, 2008-2018**
F.M. Fusco¹, A. Calcagno², A. Bandera³, F. Bartalesi⁴, A. Di Biagio⁵, C. Fabbri⁶, G. Gualano⁷, D. Goletti⁸, C. Palotto⁹, M. Trezzi⁸, A. Gori¹⁰ on behalf of the IRENE Network
¹Infectious Diseases Unit 1, S. Maria Annunziata Hospital, USL Toscana Centro, Florence, ²Department of Medical Sciences, University of Turin, Amedeo di Savoia Hospital, Turin, ³Infectious Diseases Unit, Department of Internal Medicine, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, ⁴Infectious and Tropical Diseases Unit, Careggi University Hospital, University of Florence, Florence, ⁵Clinic of Infectious Diseases, San Martino Hospital, Genoa, ⁶Infectious Diseases Unit 2, S. Jacopo Hospital, USL Toscana Centro, Pistoia, ⁷Respiratory Infectious Diseases Unit, National Institute for Infectious Diseases "L. Spallanzani" IRCCS, Rome, ⁸Translational Research Unit, National Institute for Infectious Diseases "L. Spallanzani" IRCCS, Rome, ⁹Infectious Diseases Unit, S. Donato Hospital, Azienda USL Toscana Sud Est, Arezzo, ¹⁰School of Medicine and Surgery, University of Milan; Infectious Diseases Unit, IRCCS Ca' Granda, Ospedale Maggiore Policlinico Foundation, Milan
- P 6 Clinical presentation and outcome of pneumococcal diseases according to HIV infection: data from San Paolo Hospital, Milan from 2015 to 2018**
F. Bai¹, F. Parolo¹, C. Tincati¹, E. Suardi¹, M. Allegrini¹, C. Biassoni², G. Ortisi², O. Viganò¹, C. Aldieri¹, A. Cona¹, T. Bini¹, G. Marchetti¹, A. d'Arminio Monforte¹
¹Clinic of Infectious Diseases, S. Paolo Hospital, ASST Santi Paolo e Carlo, University of Milan, Milan, ²Department of Diagnostic Sciences, ASST Santi Paolo e Carlo, University of Milan, Milan

BASICS IN VIRAL HEPATITIS

- P 7 Amino acid substitutions in the NS5A of different hepatitis C genotypes and different fibrosis levels or hepatocellular carcinoma**
S. Paolucci¹, A. Piralla¹, F. Novazzi¹, A. Fratini¹, R. Maserati², R. Gulminetti², S. Novati², G. Barbarini³, P. Sacchi³, M. Mondelli⁴, S. Mantovani⁴, F. Baldanti^{1,5}
¹Molecular Virology Unit, Microbiology and Virology Department, Fondazione IRCCS Policlinico San Matteo, Pavia, ²Institute of Infectious Diseases, University of Pavia, Pavia, ³Division of Infectious and Tropical Diseases, Fondazione IRCCS Policlinico San Matteo, Pavia, ⁴Division of Infectious Diseases and Immunology, Department of Medical Sciences and Infectious Diseases Fondazione IRCCS Policlinico San Matteo, Pavia, ⁵Department of Clinical, Surgical, Diagnostic and Pediatric Sciences, University of Pavia, Pavia
- P 8 HCV genetic variability in patients with HCV-genotype 1-related hepatocellular carcinoma**
A. Di Fraia¹, M. Pisatura¹, C. Minichini¹, M. Starace¹, L. Occhiello¹, N. Farella², G. De Stefano², V. Iodice², N. Coppola^{1,3}
¹Department of Mental Health and Public Medicine, Division of Infectious Diseases, University of Campania, Luigi Vanvitelli, Naples, Italy ²AORN dei Colli, Cotugno Hospital, Naples, Italy ³AORN S. Anna S. Sebastiano, Caserta, Italy



CANCERS IN HIV

P 9 A rare case of metastatic GIST on HIV patient

I. Uccella, G. Scevola, P.L. Alo, M. Mella, K. Casinelli, V. Dell'Uomo, P. Fabrizi, C. Falco, G. Farinelli, M. Limodio, L. Sarracino, M. Sebastiani, E. Anzalone

Ospedale Fabrizio Spaziani, Frosinone

P 10 Kaposi's Sarcoma onset in a stably suppressed HIV-1 infected MSM on PI-containing dual therapy

D. Moschese¹, G. Baldin¹, A. Ciccullo¹, A. Emiliozzi¹, C. Picarelli¹, A. Dusina¹, D. Farinacci¹, F. Lombardi¹, S. Belmonti¹, A. Borghetti², S. Di Giambenedetto^{1,2}

¹Università Cattolica del Sacro Cuore, Roma, ²Fondazione Policlinico Universitario "Agostino Gemelli" IRCCS, Roma

P 11 Thyroid neoplasia in a cohort of HIV-infected people of Northern Italy

A. Chiesa, T. Della Giustina, M. Properzi, N. Gregori, F. Castelli, E. Quiros Roldan

Department of Infectious and Tropical Diseases, University of Brescia and Spedali Civili General Hospital, Brescia, Italy

P 12 Analysing the need for anal pap testing in HIV-positive women for screening of anal squamous cell carcinoma

M. Digaetano¹, E. Bacca¹, A. Bonazza¹, C. Rogati¹, M. Menozzi¹, G. Cuomo¹, E. Franceschini¹, V. Borghi¹, C. Mussini^{1,2}

¹Infectious Diseases Clinic, Azienda Ospedaliero-Universitaria Policlinico di Modena, Modena, Italy, ²Department of Surgery, Medicine, Dentistry and Morphological Sciences, University of Modena and Reggio Emilia, Modena, Italy

P 13 Impact of antiretroviral therapy on the risk of recurrence in HIV-1 infected patients with Kaposi Sarcoma: a Multicenter Cohort Experience

M. Colafigli¹, A. Ciccullo², A. Borghetti², I. Fanti², F. Melis³, S. Modica^{4,5}, I. Uccella⁶, A. Bonadies⁷, V. Ferraresi⁸, E. Anzalone⁹, A. Pennica¹⁰, B. Rossetti⁵, G. Madeddu³, R. Cauda², A. Cristaudo¹, S. Di Giambenedetto², A. Latini¹

¹Infectious Dermatology and Allergology, IFO San Gallicano, Rome, Italy, ²Clinical Infectious Diseases, Catholic University of S. Heart, Rome, Italy, ³Unit of Infectious Diseases, Department of Medical, Surgical and Experimental Sciences, University of Sassari, Italy, ⁴Department of Medical Biotechnologies, Azienda Ospedaliera Universitaria Senese, Siena, Italy, ⁵Infectious Diseases Unit, Azienda Ospedaliera Universitaria Senese, Siena, Italy, ⁶UOC Malattie Infettive, Frosinone, Italy, ⁷Plastic Surgery, IFO Regina Elena, Rome, Italy, ⁸Clinical Oncology, IFO Regina Elena, Rome, Italy, ⁹UOSD AIDS, Frosinone, Italy, ¹⁰AOU S Andrea, Rome, Italy

P 14 Factors associated with HCC occurrence/recurrence in a cohort of HIV/HCV patients treated with DAAs. Preliminary data from the REC-HIV study

A. Toschi¹, L. Badia¹, S. Coladonato¹, B. Tazza¹, M.A. Ursitti², E. Salsi³, D. Laccabue³, R. Corsini², M. Massari², A.M. Degli Antoni³, L. Sighinolfi⁴, G. Verucchi¹, V. Guardigni¹

¹San'Orsola-Malpighi, Bologna, ²Arcispedale S. Maria Nuova, Reggio Emilia, ³Ospedale di Parma, Parma, ⁴Arcispedale Sant'Anna, Ferrara

P 15 Burkitt lymphoma in HIV-infected patients: treatment and survival in the modern ART era

G. Bozzi¹, L. Verga², M. Rossi², C. Gambacorti Passerini², D. Dalu³, C. Fasola³, I. De Benedetto^{2,9}, F. Crippa^{4,8}, E. Suardi⁴, C. Zeroli⁵, P. Vitellio^{2,5}, M. Mena⁶, O. Giglio⁷, A. Gori¹, A. Bandera¹ on behalf of the Musthal Study Group

¹IRCCS Ca Granda Ospedale Maggiore Policlinico - University of Milan, Milan, Italy, ²ASST Monza, San Gerardo Hospital, Monza, Italy, ³ASST FBF-Sacco, Luigi Sacco Hospital, Milan, Italy, ⁴San Paolo Hospital - University of Milan, Milan, Italy, ⁵Ospedale di Circolo di Busto Arsizio, Italy, ⁶Ospedale civile di Legnano, Legnano, Italy, ⁷ASST Lariana, Sant'Anna Hospital, Como, Italy, ⁸Niguarda Hospital, Milan, Italy, ⁹Università degli Studi di Torino, Turin, Italy

P 16 HPV genotyping is as important as cytology in anal squamous cell carcinoma early diagnosis

M. Digaetano¹, C. Rogati¹, F. Spatafora², R.P. Iachetta³, R.D. Villani³, A. Farinetti², M. Menozzi¹, S. Tagliazucchi⁴, M. Pecorari⁴, R. Gelmini², C. Mussini^{1,2}

¹Infectious Diseases Clinic, Azienda Ospedaliero-Universitaria Policlinico di Modena, Modena, Italy, ²Department of Surgery, Medicine, Dentistry and Morphological Sciences, University of Modena and Reggio Emilia, Modena, Italy, ³Nuovo Ospedale Civile di Sassuolo (Modena), Pelvic Floor Center, Department of Proctology, ⁴Unit of Microbiology and Virology, Polyclinic University Hospital, Modena, Italy

GENDER ISSUES

P 17 Physician gender differences in HIV infection chronic management

N. Gregori, A. Piazzoli, M. Properzi, A.C. Chiesa, C. Pezzoli, C. Carriero, D. Coletto, F. Castelli, M.E. Quiros Roldan

Department of Infectious Diseases and Tropical Diseases, University of Brescia and ASST Spedali Civili Hospital, Brescia, Italy

P 18 Is Sexual Health an issue to be addressed in HIV-1 infected and uninfected women?

R. Marocco, S. Vita, A. Carraro, B. Kertusha, I. Pozzetto, L. Fondaco, L. Ansaldo, M. D'Achille, G. Masci, C.M. Mastroianni, M. Lichtner

Infectious Disease Unit, Sapienza University, Latina, Italy



- P 19 Vaginal immunity and HPV infection in HIV infected women undergoing successful ART**
A. Carraro, S. Vita, R. Marocco, B. Kertusha, I. Pozzetto, L. Fondaco, L. Ansaldo, M. D'Achille, G. Masci, C.M. Mastroianni, M. Lichtner
Infectious Disease Unit, Sapienza University, Latina, Italy

HCV ELIMINATION

- P 20 The barriers for HCV treatment in Italian Drug Dependence Services (SerDs): data from the SCUDO Project**
F.A. Nava, P. Fasciani, L. Cammarata, A. Lucchini, A. Manfredi, M. Riglietta, G. Taglianti, P. Trotta
Italian Society of Addiction Medicine (FeDerSerD), Milan, Italy
- P 21 Elimination of Hepatitis C Virus in key population: experience from two prisons in Rome**
S. Lardo, S. Rosati, G. Iannicelli, P. Magrini, M. Zaccarelli
INMI L. Spallanzani-IRCCS, Rome
- P 22 HCV and prison: high rates of tolerability, compliance and efficacy of Direct Acting Antivirals (DAA) treatments in a real-life population of HCV incarcerated patients from two complex prison settings in Florence, Italy**
E. Salomoni¹, A. Gabbuti¹, P. Pierotti¹, F.M. Fusco¹, M.A. Di Pietro², P. Blanc¹
¹SOC Malattie Infettive 1, Ospedale S. Maria Annunziata, Bagno a Ripoli (FI), ²SOC Malattie Infettive 2, Ospedale S. Jacopo, Pistoia
- P 23 Subgroup analysis of HCV infected patients treated with directly acting antivirals in real clinical practice: do age and cirrhosis have an impact?**
V. Scaglione, C. Costa, V. Pisani, E.M. Trecarichi, M. Mazzitelli, G. Greco, F. Serapide, R. Lionello, V. La Gamba, S.D. Similia, C. Torti
Unità Operativa di Malattie Infettive e Tropicali, Azienda Ospedaliera Universitaria "Mater Domini", Università degli Studi "Magna Graecia" di Catanzaro
- P 24 Hepatitis C micro-elimination project**
P. Casella¹, A. Cruciata², A.M. Lupi¹, D. Contucci¹, M.S. Garofalo¹, T. Girolami¹, M. Rivano², A. Rugova², M. Santori², F. Tamburrini², E. Biliotti², B. Di Vico³, G. Taliani³
¹Azienda Sanitaria Locale Roma 1 (ASL Roma 1), Rome, Italy, ²Sapienza University of Rome, Department of Translational and Precision Medicine, Rome, Italy, ³Azienda Ospedaliero-Universitaria Policlinico Umberto I, Rome, Italy
- P 25 HCV post-eradication: a real-life experience**
R. Curetti¹, D. Bossi¹, F. Bai¹, M. Chiamenti², G. Marchetti¹, A. De Bona¹, A. d'Arminio Monforte¹
¹Clinic of Infectious Diseases, Department of Health Sciences, ASST Santi Paolo e Carlo, University of Milan, Italy, ²Department of Diagnostics and Public Health, University of Verona, Gianbattista Rossi Hospital, Verona VR, Italy
- P 26 Is the elimination of HCV infection feasible in people who inject drugs in a roman suburb?**
C. Taibi¹, I. Luzzitelli¹, U. Visco Comandini¹, R. Lionetti¹, M.G. De Palo¹, P. Carabini², L. Rapisarda², A.R. Garbuglia¹, G. D'Offizi¹ and HEPP group
¹INMI Lazzaro Spallanzani IRCCS, Rome, ²Ser.D. ASL RM D, Rome
- P 27 Strategies to improving the cascade of care for Hepatitis C virus-infected people who inject drugs: the experience of a single center**
E. Ciraci¹, S. Semeraro¹, S. De Fazio², F. Dambra³, M. D'Ancona⁴, A. Gaspari⁵, P. Gatti¹
¹UO Medicina Interna, Ospedale di Ostuni, ASL BR, ²SERD Mesagne, ASL BR, ³SERD Fasano, ASL BR, ⁴SERD Francavilla, ASL BR, ⁵SERD Ostuni, ASL BR
- P 28 First Italian experience of the Xpert HCV Viral Load Finger-Stick: a useful street-tool for vulnerable population**
E. Teti^{1,2}, V. Malagnino¹, C. Cerva¹, L. Foroghi¹, L. Coppola¹, M. Compagno¹, L. Campogiani¹, G. De Simone¹, I. Spalliera¹, L. Ferrari¹, C. Stingone¹, D. Masci², B. Coladarce², P. Sammarco², G. Rodoquino², E. Rossi², L. Sarmati¹, M. Barra², M. Andreoni¹
¹Infectious Diseases Clinic, Tor Vergata University, Rome, Italy, ²Villa Maraini Foundation, Rome, Italy
- P 29 Hepatitis C management and treatment among People Who Inject Drugs in Italy: an exploratory pilot survey**
E. Teti¹, S. Babudieri², M. Barra³, A. Di Biagio⁴, G. Parruti⁵, R. Ranieri⁶, T. Santantonio⁸, G. Taliani⁹, L. Sarmati¹, M. Galli², M. Andreoni¹, SIMIT (Società Italiana Malattie Infettive e Tropicali)
¹Infectious Diseases Clinic, Tor Vergata University, Rome, Italy, ²Unit of Infectious Diseases, Department of Clinical and Experimental Medicine, University of Sassari, Sassari, Italy, ³Villa Maraini Foundation, Rome, Italy, ⁴Infectious Diseases, Policlinico San Martino Hospital, Genoa, Italy, ⁵Infectious Diseases Unit, Pescara General Hospital, Pescara, Italy, ⁶Penitentiary Infectious Diseases Unit, A.O. Santi Paolo e Carlo, University of Milan, Milan, Italy, ⁷Infectious Diseases, University of Foggia, Foggia, Italy, ⁸Hepatology Unit, Department of Clinical Medicine, Sapienza University of Rome, Rome, Italy, ⁹Institute of Tropical and Infectious Diseases, L. Sacco Hospital, University of Milan, Milan, Italy



POSTER EXHIBITION

- P 30 Late relapser and reinfection in HCV patients treated with direct-acting antiviral (DAA) drugs: real-life data**
C. Minosse¹, C. Taibi¹, I. Luzzitelli¹, R. Lionetti¹, E. Grilli¹, M. Zaccarelli¹, A.R. Garbuglia², M.R. Capobianchi², A. Antinori¹, G. D'Offizi¹
¹Infectious Disease – Clinical Department National Institute for Infectious Diseases, INMI Lazzaro Spallanzani IRCCS, Rome, ²Virology Unit, National Institute for Infectious Diseases, INMI Lazzaro Spallanzani IRCCS, Rome
- P 31 Efficacy of Direct Acting Antivirals for treatment of chronic hepatitis in HIV-HCV co-infected patients. The real life experience in a cohort of Sardinian patients**
F. Pes¹, I. Maida², S. Onali¹, E. Dore², C. Balestrieri³, M. Casale¹, F. Ortu⁴, P. Piano⁴, L. Peddis¹, A. Cola³, L. Barca³, L. Chessa^{1,3}
¹Department of Medical Sciences and Public Health, University of Cagliari, Cagliari, Italy, ²Department of Clinical and Experimental Medicine, University of Sassari, Sassari, Italy, ³Liver Unit, Department of Internal Medicine, University Hospital of Cagliari, Cagliari, Italy, ⁴Immunology Unit, Department of Internal Medicine, University Hospital of Cagliari, Cagliari, Italy
- P 32 Extra-hospital HCV counselling, testing and treatment among people who inject drugs and homeless: results from the Stop HCV project in Bologna**
G.M. Corbelli¹, B. Granozzi², L. Badia², P. Malosso², D. Testi², A. Toschi², V. Guardigni², G. Verucchi², P. Viale², S. Pieralli³
¹Plus onlus, Bologna, ²Policlinico S. Orsola-Malpighi – Dipartimento di Malattie infettive, Bologna, ³Open Group, Bologna
- P 33 Factors limiting access to HCV treatment in a conventional hospital setting: focus on vulnerable populations**
B. Tazza, L. Badia, L. Bussini, G. Fornaro, B. Granozzi, V. Guardigni, G. Verucchi, P. Viale
Infectious Disease Unit, Department of Medical and Surgical Sciences, S. Orsola-Malpighi Hospital, University of Bologna
- P 34 1-Year Experience Treating Hepatitis C Virus in Turin**
T. Lupia, L. Boglione, D. Piccioni, G. Cinnirella, G. Cariti, G. Di Perri
Unit of Infectious Diseases, Department of Medical Sciences, University of Torino, Torino, Italy

HEPATITIS EPIDEMIOLOGY

- P 35 Characterization of transmission clusters in chronic HCV infected individuals in Italy**
L. Fabeni¹, M. Aragri¹, E. Teti², C. Masetti³, V. C. Di Maio¹, L. Foroghi², S. Barbaliscia¹, A. Bertoli¹, R. Salpini¹, Spalliera², K. Yu La Rosa¹, V. Cento⁴, L. Ferrarini⁵, S. Francioso³, G. Fiorentino⁵, P. Beghini⁶, V. Pace Palitti⁷, A. Pieri⁸, F. Sozio⁸, P. Paba⁹, R. Marocco¹⁰, B. Bruzzone¹¹, S. Paolucci¹², E. Degasperis¹³, V. Calvaruso¹⁴, I. Maida¹⁵, C. Furlan¹⁶, M. Marignani¹⁶, G. Taliani¹⁶, V. Borghi¹⁷, W. Gennari¹⁸, S. Landonio¹⁹, S. Babudieri¹⁵, C.F. Magni¹⁹, M. Lichtner¹⁰, C. Pasquazzi⁵, G. Parruti⁸, L. Sarmati², A. Craxi¹⁴, M. Angelico³, C.F. Perno²⁰, M. Andreoni², F. Ceccherini-Silberstein^{1*}
¹Experimental Medicine and Surgery, University of Rome "Tor Vergata", Rome, Italy, ²Infectious Diseases Unit, University Hospital of Rome "Tor Vergata", Rome, Italy, ³Hepatology Unit, University Hospital of Rome "Tor Vergata", Rome, Italy, ⁴Residency program in Microbiology and Virology, Università degli Studi di Milano, Milan, Italy, ⁵Infectious Diseases Unit, Sant'Andrea Hospital – "Sapienza" University, Rome, Italy, ⁶Digestive and Liver Diseases Department, Sant'Andrea Hospital, Sapienza University, Rome, Italy, ⁷Hepatology Unit, Pescara General Hospital, Pescara, Italy, ⁸Infectious Diseases Unit, Pescara General Hospital, Pescara, Italy, ⁹Virology Unit, Policlinico Fondazione Tor Vergata, Rome, Italy, ¹⁰Infectious Diseases Unit, Sapienza University, Polo Pontino, Latina, Italy, ¹¹Hygiene Unit, IRCCS AOU San Martino-IST, Genoa, Italy, ¹²Molecular Virology Unit, Microbiology and Virology Department, IRCCS Policlinico Foundation San Matteo, Pavia, Italy, ¹³A.M. e A. Migliavacca", Center for Liver Diseases, Division of Gastroenterology and Hepatology, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, University of Milan, Milan, Italy, ¹⁴Gastroenterology, "P. Giaccone" University Hospital, Palermo, Italy, ¹⁵Medical, Surgical and Experimental Sciences, University of Sassari, Sassari, Italy, ¹⁶Department of Tropical and Infectious Diseases, Policlinico Umberto I, Rome, Italy, ¹⁷Department of Infectious Diseases, University of Modena, Modena, Italy, ¹⁸Microbiology and Virology Unit, University Hospital Policlinico di Modena, Modena, Italy, ¹⁹Division of Infectious Diseases, ASST Fatebenefratelli Sacco, Milan, Italy, ²⁰Department of Oncology and Hemato-Oncology, University of Milan, Milan, Italy, *On behalf of HCV Virology Italian Resistance Network (Foundation Vironet C)
- P 36 Hepatitis E surveillance in Liguria: molecular characterization of strains detected from 2017 to 2019**
G. Barisione¹, P. Canepa¹, G. Guarona¹, C. Arcuri¹, A. Orsi^{1,2}, G. Icardi^{1,2}, B. Bruzzone²
¹Department of Health Sciences (DiSSal), University of Genoa, Italy, ²Hygiene Unit, Polyclinic Hospital San Martino, Genoa, Italy
- P 37 Epidemiology of HCV in main prison institution in Florence, Tuscany**
A. Gabbuti, F.M. Fusco, P. Pierotti, E. Salomoni, P. Blanc
SOC Malattie Infettive 1, Osp. S. Maria Annunziata, USL Toscana Centro, Florence
- P 38 Hepatitis C virus genotype distribution pattern according to age in Italian and in non-Italian patients in the 2016-2018 period**
M. Basso¹, D. Zago¹, I. Pozzetto², M. Pacenti³, G. Brancaccio¹, S. Ragolia¹, G. Palù¹, S.G. Parisi¹
¹Department of Molecular Medicine, University of Padova, Italy, ²Department of Public Health and Infectious Diseases, Sapienza University of Rome, Italy, ³Microbiology and Virology Unit, Padova University Hospital, Italy



- P 39 HBV and HDV infection in immigrants living in South Italy: epidemiological and virological characteristics**
M. Pisaturo^{2,6}, L. Onorato², C. Sagnelli^{2,4}, L. Alessio^{1,4}, C. Monari¹, L. Gualdieri⁵, C. Minichini², G. Di Caprio¹, M. Starace², M. Caroprese¹, L. Occhiello¹, G. Scotta⁶, M. Macera², E. Sagnelli², N. Coppola^{1,2}

¹UOC di Malattie Infettive, AORN Sant'Anna e San Sebastiano, Caserta, ²Sezione di Malattie Infettive, Dipartimento di Salute Mentale e Medicina Pubblica, Università della Campania Luigi Vanvitelli, Napoli, ³Centro di Accoglienza "La tenda di Abramo", Caserta, ⁴Centro Suore Missionarie della Carità, Napoli, ⁵Centro per la Tutela della Salute degli Immigrati, Napoli, ⁶Centro sociale ex canapificio Caserta, ⁷UOC di Malattie Infettive, Foggia

- P 40 An estimation of the prevalence of occult HBV infection in Western countries: a meta-analysis**

A. Russo, M. Pisaturo, L. Onorato, P. Chiodini, N. Coppola

Department of Mental Health and Public Medicine – Infectious Diseases Unit. University of Campania Luigi Vanvitelli

- P 41 Low number of HEV cases in HIV-1 infected patients in a Roman Hospital: the seroprevalence was associated with other viral hepatitis coinfection history**

B. Yagai¹, C. Cerva², V. Malagnino², M. Ciotti³, L. Piermatteo¹, D. Armenia^{1,4}, A. Giovinazzo¹, C. Stingone², T. Guenci³, L. Foroghi², P.P. Paba³, A. Bertoli¹, E. Teti², V. Svicher¹, L. Sarmati², M.M. Santoro¹, S. Grelli^{1,3}, M. Andreoni², F. Ceccherini-Silberstein¹

¹Department of Experimental Medicine, University of Rome Tor Vergata, Rome, Italy, ²Infectious Diseases, University Hospital of Rome Tor Vergata, Rome, Italy, ³Virology Unit, University Hospital of Rome Tor Vergata, Rome, Italy, ⁴UniCamillus, Saint Camillus International University of Health Sciences, Rome, Italy

HIV AND NERVOUS SYSTEM

- P 42 Prevalence of alexithymia among HIV-infected patients on combination antiretroviral therapy**

A. Spinelli¹, L. Calza¹, G. Piazza², S. Vitale², L. Appolloni², G. Pensalfine², M. Morotti², C. Puggioli², V. Colangeli¹, M. Borderi¹, P. Viale¹

Department of Medical and Surgical Sciences, ¹Unit of Infectious Diseases, ²Hospital Pharmacy, S.Orsola-Malpighi Hospital, University of Bologna

- P 43 Example of comprehensive neurocognitive assessment in a HIV population in Northern Italy**

A. Parisini¹, C. Bolla¹, M. Gay¹, E. Mantia¹, E. Sarchi¹, F. Lanzieri Pignataro¹, E. Blasi Vacca¹, F. De Luca², A. Pepoli², G. Chichino¹

¹Division of Infectious Diseases, SS.Antonio e Biagio e Cesare Arrigo, Alessandria, Italy, ²Unit of Psychology, SS.Antonio e Biagio e Cesare Arrigo, Alessandria, Italy

- P 44 Guillain-Barré Syndrome as Immune Reconstitution Inflammatory Syndrome in a primary HIV infection: a case report**

M. Cantone^{1,2}, S. Chiappetta¹, M. Merli¹, M.C. Moiola¹, D. Motta¹, C. Orcese¹, A. Pazzi¹, R. Rossotti¹, G. Travi¹, B.P. Vigo¹, M. Puoti¹

¹Infectious Disease Department ASST Grande Ospedale Metropolitano Niguarda, Milan, Italy, ²University Federico II, Naples, Italy

- P 45 Preliminary data on the link between alexithymia and neurocognitive deficit in HIV**

A. Cappabianca, M. Vitale, S. Madonia, A.M. Spera, V. Fortunato, A. Masullo, R. Santoro

Unit of Infectious Diseases – University Hospital S. Giovanni di Dio e Ruggi D'Aragona, Salerno, Italy

- P 46 Self-report tests as screening tool for HIV-Associated Neurocognitive Disorders**

M. Allegrini¹, F. Bai¹, L. Borghi², I. Strada², E. Merlini, S. Cannizzo, G. Marchetti¹, A. d'Arminio Monforte¹

¹Clinic of Infectious Diseases, San Paolo Hospital, ASST Santi Paolo e Carlo, University of Milan, Milan, Italy, ²Clinical Psychology Unit, San Paolo Hospital, ASST Santi Paolo e Carlo, University of Milan, Milan, Italy

- P 47 Clinical inferences for the association between mode of HIV acquisition and different patterns of neurocognitive impairment**

M. Trunfio¹, D. Vai², G. De Zan¹, V. Pirriatore¹, F. Bai³, G. Palazzo¹, C. Alcantarini¹, M.C. Tettoni¹, D. Imperiale², S. Bonora¹, G. Di Perri¹, A. Calcagno¹

¹Unit of Infectious Diseases, Amedeo di Savoia hospital, Department of Medical Sciences, University of Turin, Turin, Italy, ²Unit of Neurology, Maria Vittoria hospital, ASL Città di Torino, Turin, Italy, ³Unit of Infectious Diseases, Santi Paolo e Carlo hospital, University of Milano, Milano, Italy

HIV CURE AND VACCINES

- P 48 Association between undetectable HIV-1 DNA and HIV-1 Pol in chronic HIV-1 infection**

C. Muccini¹, L. Galli², V. Spagnuolo^{1,2}, A. Poli², S. Rolla³, F. Rinaldi⁴, R. dell'Acqua⁵, A. Mastrangelo¹, D. Canetti², A. Lazzarin², A. Castagna^{1,2}

¹Vita-Salute San Raffaele University, Milan, Italy, ²Infectious Diseases, IRCCS San Raffaele Scientific Institute, Milan, Italy, ³Laboratory of Microbiology and Virology, IRCCS San Raffaele Scientific Institute, Milan, Italy, ⁴University of Florence Department of Experimental and Clinical Medicine, Florence, Italy, ⁵University Hospital Policlinico, Bari, Italy



P 49 Efficacy and safety of two agents antiretroviral regimens: our experience in "real life"

L. Massoli¹, C. Contini², M. Libanore¹, A. Trentini³, E. Biagi¹, M. Di Nuzzo¹, D. Segala¹, L. Sighinolfi¹

¹O.U. of Infectious and Tropical Diseases and of the Migrants, University of Ferrara, Italy, ²Full Professor of Infectious and Tropical Diseases, Department of Medical Sciences, University of Ferrara, Italy, ³Section of Medical Biochemistry, Molecular Biology and Genetics, Department of Biomedical and Specialist Surgical Sciences, University of Ferrara, Ferrara, Italy

P 50 How are organized HIV clinical centers for vaccinations in their patients? Results from a survey in the CISA network

G. Orofino¹, A. Cascio², G. De Socio³, P. Bonfanti⁴, R. Gulminetti⁵, M.C. Moiol⁶, N. Forni⁷, N. Squillace⁸, K. Falasca⁹, S. Martini¹⁰, B. Menzaghini¹¹, G. Pellicanò¹², E. Sarchi¹³, M. Guastavigna¹, E. Ricci¹⁴

¹Mal. Inf. e Trop. A, Torino, ²Mal. Inf. Policlinico Palermo, ³Mal. Inf. Perugia, ⁴Mal. Inf. Lecco, ⁵Mal. Inf. Policlinico Pavia, ⁶Mal. Inf. Osp. Niguarda, Milano, ⁷C.U. Mal. Inf. Torino, ⁸Mal. Inf. Monza, ⁹C.U. Mal. Inf. Chieti, ¹⁰Univ. Napoli L. Vanvitelli, ¹¹Mal. Inf. Busto Arsizio, ¹²Mal. Inf. Policlinico Messina, ¹³Mal. Inf. Alessandria, ¹⁴CISA Group

P 51 Efficacy and safety of MVC-containing regimen in treatment-experienced patients

L. Pagnucco^{1,2}, D. Devita², R. Gulminetti¹

¹Fondazione IRCCS Policlinico San Matteo, Dipartimento di Malattie Infettive, ²Università degli Studi di Pavia

HIV EPIDEMIOLOGY AND RETENTION IN CARE

P 52 Different dynamics of the HIV epidemics in PLWHIV of Italian or non-Italian origin in a Province of Northern Italy

F. Maggiolo, L. Comi, R. Teocchi, E. Di Filippo, A.P. Callegaro, D. Valenti, M. Rizzi

ASST Papa Giovanni XXIII, Bergamo

P 53 Molecular epidemiology of HIV-1 infection in immigrant population in norther Italy

C. Sagnelli¹, C. Uberti-Foppa², E. Cella³, S. Bagaglio², V. Scolamacchia³, H. Hasson², S. Salpietro², E. Messina², G. Morsica², S. Angeletti⁴, M. Ciccozzi³, A. Lazzarin², E. Sagnelli¹

¹Department of Mental Health and Public Medicine, Campania University Luigi Vanvitelli, Naples, Italy, ²Department of Infectious Diseases, Vita-Salute University, San Raffaele Scientific Institute, Milan, Italy, ³Medical Statistics and molecular Epidemiology Unit, Campus Bio-Medico University, Rome, Italy, ⁴Laboratory clinical Science; Campus Bio-Medico University, Rome, Italy

P 54 HIV-1 recombinant forms in migrant population living in Milan, Norther Italy

C. Sagnelli¹, C. Uberti-Foppa², E. Cella³, H. Hasson², S. Salpietro², E. Messina², S. Bagaglio², S. Angeletti⁴, M. Ciccozzi³, A. Lazzarin², E. Sagnelli¹

¹Dept. of Mental Health and Public Medicine, Campania University Luigi Vanvitelli, Naples, Italy, ²Dept. of Infectious Diseases, Vita-Salute University, San Raffaele Scientific Institute, Milan, Italy, ³Medical Statistics and Epidemiology, Campus Bio-Medico University, Rome, Italy, ⁴Laboratory clinical Science; Campus Bio-Medico University, Rome, Italy

P 55 New HIV diagnoses among non-Italians, from 2010 to 2017

V. Regine¹, L. Pugliese¹, B. Suligoi¹ and the Regional representatives of the National HIV Surveillance System²

¹Centro Operativo AIDS, Istituto Superiore di Sanità, Roma, ²Regional representatives of the National HIV Surveillance System
Abruzzo: M. Di Giacomo, L. Scancella; Basilicata: F. Locuratolo, G. Cauzillo; Calabria: A.D. Mignuoli, D.G. Chirico; Campania: G. Borgia; Emilia Romagna: E. Massimiliani; Friuli Venezia Giulia: T. Gallo, C. Braidà; Lazio: V. Puro, P. Scognamiglio, A. Mammine; Liguria: G. Icardi, P.L. Lai; Lombardia: M. Gramagna, D. Cereda; Marche: F. Filippetti; Molise: A. Prozzo; Piemonte: C. Pasqualini; Provincia Autonoma di Bolzano: L. Paganì, R. Binazzi; Provincia Autonoma di Trento: P. Lanzafame, L. Collini, D. Bassetti; Puglia: M. Chironna, D. Loconsole; Sardegna: M.A. Palmas; Sicilia: G. Dardanoni; Toscana: F. Voller, M. Puglia, L. Pecori; Umbria: A. Tosti, R. Papili; Valle d'Aosta: M. Ruffier, M.G. Verardo, A. Catania; Veneto: F. Russo, F. Da Re

P 56 Capacity Assessment for Provision of Quality Sexual Reproductive Health and HIV-Integrated Services in Karoja, Uganda

F. Di Gennaro¹, P. Lochoro², D. Pizzol³, G. Putoto³, W. Mazzucco⁴, C. Marotta⁴, J. Itho², L. Monno¹, A. Saracino¹

¹Clinic of Infectious Diseases, University of Bari, Italy, ²Doctors with Africa CUAMM, Kampala, Uganda, ³Doctors With Africa Cuamm, Research Section Padua, Italy, ⁴University of Palermo, Department of Science for Health Promotion and Mother to Child Care "G. D'Alessandro", Palermo, Italy

P 57 A retention in care program in HIV patients: who is lost and found in 2018?

A. Raimondi¹, M. Digaetano¹, N. Riva¹, A. Bianchi¹, A. Bonazza¹, I. Franconi¹, C. Lucentini¹, E. Roncaglia¹, V. Borghi¹, G. Guaraldi¹, E. Girardi², A. d'Arminio Monforte³, C. Mussini¹

¹Clinica di Malattie Infettive, Azienda Ospedaliera-Universitaria di Modena - Modena, ²Unità di Epidemiologia Clinica, Istituto Nazionale per le Malattie Infettive Lazzaro Spallanzani - Roma, ³Clinica di Malattie Infettive e Tropicali, Università degli Studi di Milano, ASST Santi Paolo e Carlo - Milano



POSTER EXHIBITION

- P 58 First exploratory analysis of quality of life among people living with HIV in Calabria region**
M. Mazzitelli¹, D. D'Elia¹, G. Greco¹, F. Serapide¹, C. Sorace¹, A. Vallone², G. Berardelli³, G. Foti⁴, C. Mangano⁴, L. Cosco⁵, P. Scerbo⁵, A. Priamo⁵, F. Bulla⁵, N. Serrao⁶, G. Guadagnino⁷, A. Mastroianni⁷, C. Torti¹
¹Unità Operativa di Malattie Infettive e Tropicali, Azienda Ospedaliera Universitaria "Mater Domini", Università degli Studi "Magna Graecia" di Catanzaro, ²Unità Operativa di Malattie Infettive e Tropicali, Presidio Ospedaliero "G. Jazolino" di Vibo Valentia, ³Unità Operativa di Malattie Infettive, Polo Ospedaliero "Giovanni Paolo II", Lamezia Terme, ⁴Unità Operativa di Malattie Infettive e Tropicali, Azienda Ospedaliera "Bianchi Melacchino Morelli" di Reggio Calabria, ⁵Unità Operativa di Malattie Infettive e Tropicali, Azienda Ospedaliera "Pugliese-Ciaccio" di Catanzaro, ⁶Unità Operativa di Malattie Infettive e Tropicali, Ospedale Civile "San Giovanni di Dio" di Crotona, ⁷Unità Operativa di Malattie Infettive e Tropicali, Azienda Ospedaliera "Annunziata" di Cosenza
- P 59 Epidemiological Trends of HIV infections in Province of Viterbo: considerations for the future**
G. Maffongelli¹, S. Aviani Barbacci¹, B. Koeler¹, S. Farinelli¹, R. Preziosi¹, F. Ferri¹, G. Sebastiani¹, D. Migliorini¹, L. Guastini¹, S. Dell'isola², E. Rastrelli², E. Liguori², A. Ialungo², R. Monarca², G. Starnini², L. Caterini¹
¹U.O.C. Infectious Diseases, Belcolle Hospital, Viterbo, Italy, ²U.O.C. Medicina Protetta-Unit of Infectious Diseases, Belcolle Hospital, Viterbo, Italy
- P 60 HIV infection indicator disease-based active case finding in a University Hospital: results from the SHOT project**
M.S. Mameli¹, P. Bagella¹, A. De Vito¹, C. Fozza², A. Murtas², M.A. Montes³, G. Deligia³, A.G. Fois⁴, S. Negri⁴, F. Filigheddu⁵, N. Manzoni⁶, C. Putzu⁷, S. Babudieri¹, G. Madeddu¹
¹Unit of Infectious Diseases, Department of Medical, Surgical and Experimental Medicine, University of Sassari, ²Unit of Hematology, Department of Medical, Surgical and Experimental Medicine, University of Sassari, ³Unit of Dermatology, Department of Medical, Surgical and Experimental Medicine, University of Sassari, ⁴Unit of Respiratory Diseases, Department of Medical, Surgical and Experimental Medicine, University of Sassari, ⁵Unit of Internal Medicine, Department of Medical, Surgical and Experimental Medicine, University of Sassari, ⁶Unit of Internal Medicine, University Hospital of Sassari, ⁷Unit of Oncology, University Hospital of Sassari
- P 61 Care is all you need: factors associated with loss to follow-up in a cohort of newly diagnosed HIV-positive patients**
G. Ferraro, L. Badia, D. Testi, P. Malosso, B. Granozzi, G. Verucchi, P. Viale, L. Calza
Policlinico Sant'Orsola-Malpighi, Bologna

HIV IMMUNOLOGY AND IMMUNE-BASED THERAPIES

- P 62 Seroreversion from positive to negative western blot HIV-1 Pol**
F. Rinaldi¹, S. Rolla², L. Galli³, A. Poli³, C. Muccini⁴, A. Mastrangelo⁴, C. Tavano², A. Lazzarin³, A. Castagna^{3,4}, A. Bartoloni^{1,5}
¹University of Florence, Department of Experimental and Clinical Medicine, Florence, Italy, ²IRCCS San Raffaele Scientific Institute, Laboratory of Microbiology and Virology, Milan, Italy, ³IRCCS San Raffaele Scientific Institute, Infectious Diseases, Milan, Italy, ⁴Vita-Salute San Raffaele University, Infectious Diseases, Milan, Italy, ⁵Infectious and Tropical Diseases Unit, Careggi University Hospital, Florence, Italy
- P 63 Differential NKp44 expression on pDC of HIC patients associates with conserved IFN α production and is correlated to CD4-protective NKp44 expression on NK cells**
F. Bozzano¹, F. Marras², I. Bonaccorsi³, E. Pontali⁴, L. Nicolini⁵, A. Di Biagio⁵, C. Dentone⁶, G.C. Orofino⁷, L. Moretta¹, G. Ferlazzo⁸, A. De Maria^{5,9,10}
¹IRCCS Bambino Gesù Children's Hospital, Rome, Italy, ²Istituto Giannina Gaslini, Genoa, Italy, ³Laboratory of Immunology and Biotherapy, Department of Human Pathology, University of Messina, Messina, Italy, ⁴S.C. Malattie Infettive, Ospedale Galliera, Genoa, Italy, ⁵Clinica Malattie Infettive, Ospedale Policlinico San Martino Genova, Istituto Nazionale per la Ricerca sul Cancro, Genoa, Italy, ⁶U.O.C. Malattie Infettive, Ospedale Sanremo, V.priv.Barabino 15, Sanremo (IM), Italy, ⁷U.O.C. Malattie Infettive, Ospedale Amedeo di Savoia, Torino, Italy, ⁸Dipartimento di Patologia Umana, University of Messina, Messina, Italy, ⁹Center of Excellence for Biomedical Research (CEBR), University of Genova, Genova, Italy, ¹⁰Department of Health Sciences, DISSAL, University of Genova, Genova, Italy
- P 64 Luciferase Immunoprecipitation System (LIPS) anti-HIV antibody assay during treatment interruption**
A. Mastrangelo^{1,3}, P. Burbelo², L. Galli⁴, A. Poli⁴, C. Muccini¹, V. Spagnuolo^{1,4}, R. Caccia³, F. Turrini³, A. Bigoloni⁴, A. Galli⁴, A. Castagna^{1,4}, P. Cinque^{3,4}
¹Vita-Salute San Raffaele University, Milan, Italy, ²Dental Clinical Research Core, National Institute of Dental and Craniofacial Research, National Institutes of Health, Bethesda, Maryland, ³Neurovirology Unit, IRCCS San Raffaele Scientific Institute, Milan, Italy, ⁴Infectious Diseases, IRCCS San Raffaele Scientific Institute, Milan, Italy
- P 65 Analysis of the role of c-cytokines in HIV latency establishment in different T cell subsets**
G.M. Butta¹, M.C. Crosti¹, M.M. Hernandez^{2,5}, V. Simon^{2,3,4}, R. De Francesco^{1,6}, L. Manganaro¹
¹INGM-Istituto Nazionale di Genetica Molecolare, Milan, Italy, ²Department of Microbiology, Icahn School of Medicine at Mount Sinai, New York, New York, USA, ³Global Health and Emerging Pathogens Institute, Icahn School of Medicine at Mount Sinai, New York, USA, ⁴Division of Infectious Diseases, Department of Medicine, Icahn School of Medicine at Mount Sinai, New York, USA, ⁵The Graduate School of Biomedical Sciences, Icahn School of Medicine at Mount Sinai, New York, USA, ⁶Department of Pharmacological and Biomolecular Sciences, Università degli Studi di Milano, Italy
- P 66 Characterization of HIV-1 Specific T-Cell Responses in an Italian Cohort of HIV-1 Natural Controllers**
D. De Battista¹, S. Heltai¹, F. Sironi¹, A. Riva², M. Tinelli³, S. Nozza¹, G. Tambussi¹, S. Ghezzi¹, G. Poli⁴, P. Lusso⁵, M.S. Malnati¹
¹OSR Scientific Institute, Milan Italy, ²L. Sacco Hospital, University of Milan, Italy, ³Hospital of Lodi, Lodi Italy, ⁴Vita-Salute San Raffaele University, School of Medicine, Milan, Italy, ⁵NIAD-NIH, Bethesda MD USA



HIV PATHOGENESIS

P 67 The effect of seminal plasma on colonic mucosa and its possible role in HIV-1 transmission

V. Iannone¹, S. Dispinseri¹, M. Cavarelli², C. Moog³, C. Foglieni⁴, U. Elmore⁵, S. Nozza⁶, M. Alfano⁷, P. Viganò⁸, G. Scarlatti¹

¹San Raffaele Scientific Institute, Division of Immunology, Transplantation, and Infectious Diseases, Viral evolution and transmission, ²CEA, Center for immunology of Viral infections and Autoimmune diseases (ImVA) CEA/DRF/Universite Paris Saclay/JACOB/IDMIT INSERM U1184, Fontenay-aux-Roses, ³U1109 INSERM/UDS Faculte de Medecine, Strasbourg FRANCE, ⁴San Raffaele Scientific Institute, Cardiovascular Research area, Strategic research on heart failure, ⁵San Raffaele Scientific Institute, Division of Experimental oncology, Gastrointestinal surgical oncology, ⁶San Raffaele Scientific Institute, Infectious diseases Area, ⁷San Raffaele Scientific Institute, Division of Experimental oncology - URI - Urological Research Institute, Bladder cancer, ⁸San Raffaele Scientific Institute, Division of Genetics and Cell biology, Reproductive sciences Lab

P 68 Natural HIV control in a HIV/HCV co-infected patient with a severe leukopenia: a case report

C. Agrati¹, V. Mazzotta², V. Bordoni¹, I. Abbate³, A. Amendola³, F. Forbici³, E. Cimini¹, R. Casetti¹, M.R. Capobianchi³, M. Bibas², A. Antinori²

¹Laboratory of Cellular Immunology and Pharmacology, INMI "L. Spallanzani" - IRCCS, Rome, ²Clinical Department, INMI "L. Spallanzani" - IRCCS, Rome, ³Laboratory of Virology, INMI "L. Spallanzani" - IRCCS, Rome

P 69 Serum microvesicles as new inflammation markers in HIV infection

A. Auricchio, K. Falasca, C. Ucciferri, M. Pontolillo, F. Vignale, J. Vecchiet

Clinics of Infectious Diseases, PO SS. Annunziata, "G. d'Annunzio" University, Chieti

P 70 CMV vaginal shedding in a cohort of HIV women under suppressive ART

S. Vita¹, P. Hawan², C. Mascia², A. Carraro², R. Marocco¹, B. Kertusha², L. Fondaco², I. Pozzetto², L. Ansaldo², G. Masci², M. D'Achille¹, V.S. Mercurio¹, M. Lichtner^{1,2}

¹S.M.Goretti Hospital, Latina, ²Sapienza University of Rome, Rome

HIV PREVENTION (PREP AND PEP)

P 71 Anlaidi Lazio and the experience in the field of Bachelor Degree in Nursening

R. Galipò¹, S. Bartolucci², E. Farinola¹, P. Ferri¹, S. Ondedei¹, C. Salvatori¹, M.A. Pulimeno², M. Ghenzer¹

¹Anlaidi Lazio, Roma, ²Opi di Roma

P 72 Efficacy, safety and risk compensation in subjects using PrEP in Milan: a case-control study

R. Rossotti, M. Merli, L.G. Chianura, M.C. Moiali, M. Cantone, S. Chiappetta, F. Crippa, D. Motta, C. Orcese, A. Pazzi, G. Travi, B.P. Vigo, M. Puoti

Department of Infectious Diseases, ASST Grande Ospedale Metropolitano Niguarda, Milan

P 73 No increase in prevalence of Chlamydia trachomatis and Neisseria gonorrhoeae infections after 6 months of follow up in a cohort of MSM with high prevalence of risk factors for HIV acquisition evaluated in a PrEP community-based service in Italy: preliminary data from the SEX-CHECK Study

P. Malosso¹, L. Badia¹, B. Granozzi¹, R. Pascale¹, V. Guardigni¹, A. Maccaro¹, G. Fornaro¹, B. Tazza¹, P. Viale¹, G. Verucchi¹, G. Corbelli², S. Mattioli²

¹Department of Medical and Surgical Science - Alma Mater Studiorum - University of Bologna, ²PLUS Onlus, Bologna

HIV VIROLOGY

P 74 Evaluation of usefulness of integrase genotypic resistance test in PBMCs in HIV-1 infected patients with low/ undetectable plasma viral load

D. Armenia^{1,2}, B. Yagai², V. Borghi³, C. Gori⁴, W. Gennari³, G. Berno⁴, R. Gagliardini⁴, A. Vergori⁴, A. Latini⁵, C. Mussini³, A. Antinori⁴, F. Ceccherini-Silberstein², C.F. Perno^{4,6}, M.M. Santoro²

¹UniCamillus, Saint Camillus International University of Health Sciences, Rome, Italy, ²University of Rome "Tor Vergata", Rome, Italy, ³University of Modena and Reggio Emilia, Modena, Italy, ⁴National Institute for Infectious Diseases L. Spallanzani, IRCCS, Rome, Italy, ⁵San Gallicano Dermatological Institute, IRCCS, Rome, Italy, ⁶University of Milan, Milan, Italy

P 75 Sanger and NGS method in comparison

P. Caligiuri², L. Boatti⁵, P. Canepa², N. Nigro¹, C. Arcuri², G. Guarona², S. Razeri⁴, A. Di Biagio³, M. Setti³, B. Bruzzone¹

¹Igiene Unit, Polyclinic Hospital San Martino, Genoa, Italy, ²Igiene Unit, Department of Health Sciences, University of Genoa, IRCCS San Martino - IST, Genoa, Italy, ³Internal Medicine and Clinical Immunology Unit, IRCCS AOU San Martino-IST, Genoa, Italy, ⁴Arrow Diagnostics Srl, Genoa, Italy, ⁵SmartSeq Srl Spin-Off dell'Università del Piemonte Orientale, Alessandria, Italy



- P 76 Test repetition in low-level HIV viremia**
B. Bruzzone¹, G. Barisione², S. Varesano², M. Setti³, A. Di Biagio⁴, N. Nigro¹, F. Torretta⁵, P. Strada⁵, G. Ubezio⁵
¹Hygiene Unit, Polyclinic Hospital San Martino, Genoa, Italy, ²Hygiene Unit, Department of Health Sciences, Polyclinic Hospital San Martino, Genoa, Italy, ³Internal Medicine and Clinical Immunology Unit, Polyclinic Hospital San Martino, Genoa, Italy, ⁴Infectious Diseases, Department of Internal Medicine, University of Genoa, Polyclinic Hospital San Martino, Genoa, Italy, ⁵Transfusional Service, Polyclinic Hospital San Martino, Genoa, Italy
- P 77 Quantitative detection of HIV-1-Proviral DNA with a freeze-dried ready-to-use PCR-based Real Time PCR assay: preliminary clinical outcomes**
L. Spinelli¹, V. Micheli², A. Mancon², M. Ballarini¹, L. Bavagnoli¹, G. Ferri¹, M.L. Incandela¹, D. Rigamonti¹, M. Gramegna¹
¹Sentinel CH. SpA, Milano, Italy, ²ASST Fatebenefratelli Sacco – Microbiologia clinica, Virologia e Diagnostica Bioemergenze
- P 78 Therapeutic management of HIV positive patient by a new Real time PCR device for viral DNA quantification**
A. Renesto¹, A. Gani¹, N. Paccagnella¹, A. Dalla Pozza², N. Montesano Gesualdi¹, S. Mason¹
¹AB ANALITICA srl, Padova, Italy, ²University of Padova, Padova, Italy
- P 79 The dual-target approach in the method for HIV-1 RNA testing unveils unexpected virological patterns, with possible impact on clinical management**
A. Amendola¹, F. Forbici¹, I. Abbate¹, C. Pinnetti², A. Antinori², M.R. Capobianchi¹
¹Laboratory of Virology, INMI L. Spallanzani, Rome, ²Clinical Department, INMI L. Spallanzani, Rome
- P 80 Development of a modified quantitative commercial assay for extraction and quantification of HIV-1 proviral DNA**
L. Di Sante¹, S. Belladonna², A. Corsi¹, P. Sestilli³, R. Longo⁴, S. Caucci⁴, S. Menzo⁴, A. Costantini¹, P. Bagnarelli⁴
¹Department of Molecular and Clinical Sciences, Polytechnic University of Marche, Ancona, Italy, ²Molecular Division, Abbott srl, Roma, Italy, ³Virology Unit, Azienda Ospedaliera Ospedali Riuniti, Ancona, Italy, ⁴Department of Biomedical Sciences and Public Health, Polytechnic University of Marche, Ancona, Italy
- P 81 Impact of analytical treatment interruption on reassortment of HIV-1 drug resistance mutations in peripheral reservoir**
R. Scutari¹, M.C. Bellocchi¹, V. Spagnuolo^{2,3}, S. Barbaliscia¹, L. Galli², A. Galli², A. Poli², L. Carioti¹, M.M. Santoro¹, C.F. Perno⁴, C. Alteri⁴, F. Ceccherini-Silberstein¹, A. Castagna^{2,3}
¹Department of Experimental Medicine, University of Rome Tor Vergata, Rome, Italy, ²Infectious Diseases, San Raffaele Scientific Institute, Milan, Italy, ³Università Vita-Salute San Raffaele, Milan, Italy, ⁴Department of Oncology and Hemato-oncology, University of Milan, Milan, Italy

ISSUES ON ANTIRETROVIRAL THERAPY

- P 82 Retrospective evaluation of effectiveness, persistence in treatment and safety of older (≥50 years old) HIV-infected patients who started with an antiretroviral combination therapy including darunavir/cobicistat (DRV/c)**
A. Vergori¹, A. Giannetti¹, G. Passavanti¹, S. Cicalini¹, P. Lorenzini¹, R. Bellagamba¹, A. Antinori¹, C. Bottaro², R. Termini², A. Uglietti²
¹HIV/AIDS Unit, National Institute for Infectious Diseases L. Spallanzani, IRCCS, Rome, Italy, ²Janssen-Cilag SpA, Cologno Monzese, Italy
- P 83 3TC-DTG predicts a reduced probability of hepatic steatosis in monoinfected HIV+ patients**
D. Moschese¹, A. Ciccullo¹, F. Taccari¹, A. Borghetti², E. Emiliozzi¹, D. Farinacci¹, A. Dusina¹, F. Lombardi¹, S. Belmonti¹, G. Baldin¹, S. Di Giambenedetto^{1,2}
¹Università Cattolica del Sacro Cuore, Roma, ²Fondazione Policlinico Universitario "Agostino Gemelli" IRCCS, Roma
- P 84 Switch to dolutegravir-based regimens and decrease in sCD14 levels in HIV-1 infected patients on suppressive ART**
S. Belmonti¹, F. Lombardi¹, A. Cingolani^{1,2}, E. Visconti^{1,2}, A. Borghetti², G. Baldin¹, A. Ciccullo¹, E. Tamburrini^{1,2}, R. Cauda^{1,2}, S. Di Giambenedetto^{1,2}
¹Università Cattolica del Sacro Cuore, Roma Italia, Istituto di Clinica Malattie Infettive, ²Fondazione Policlinico Universitario A. Gemelli IRCCS, Roma Italia, UOC Malattie Infettive
- P 85 Introduction of generics medicines into clinical practice: problem or resource?**
C.B. Traversi¹, S. Bertini¹, A. Ferrero¹, D. Piccioni¹, E. Geninatti², E. Marrazzo², G. Cinnirella¹
¹Amedeo di Savoia Hospital Pharmacy, ASL City of Turin, ²Pharmacovigilance Regional Centre of Piedmont, ASL City of Turin



- P 86 Evaluation of abacavir-related adverse reactions in a cohort of HIV positive patients non-carrying HLA B*5701 allele**
G. Gardini, M. Properzi, A. Marchi, A. Chiesa, N. Gregori, F. Castelli, E. Quiros-Roldan
Department of Infectious and Tropical Diseases, University of Brescia and Spedali Civili General Hospital, Brescia, Italy
- P 87 Does raltegravir 1200 mg once daily actually improve adherence over raltegravir 400 mg twice daily? Results from clinical practice**
A. Emiliozzi¹, A. Ciccullo¹, G. Baldin¹, A. Dusina¹, D. Farinacci¹, C. Picarelli¹, D. Moschese¹, S. Belmonte¹, F. Lombardi¹, S. Lamonica¹, A. Borghetti², S. Di Giambenedetto^{1,2}
¹Institute of Clinical Infectious Diseases, Catholic University of the Sacred Heart, Rome, Italy, ²Fondazione Policlinico Universitario Agostino Gemelli IRCCS, UOS Malattie Infettive, Rome, Italy
- P 88 The HIV-1 integrase genetic background influences the resistance pathways that patients treated with Raltegravir select in vivo**
S. Caucci¹, E. Di Mercurio¹, M.L. Ferreri¹, K. Marinelli¹, L. Monno², P. Bagnarelli¹, S. Menzo¹
¹Department of Biomedical Sciences and Public Health, Polytechnic University of Marche, Ancona, Italy, ²Department of Biomedical Sciences and Human Oncology, University of Bari, Bari, Italy
- P 89 Evaluation of bone health and renal function in HIV-infected youths treated with an antiviral regimen containing Dolutegravir**
S. Mora¹, M. Ratti², K. Maruca¹, E. Longoni², S. Lazzarin², A. Manzo², L. Paradiso², E. Albani², G.V. Zuccotti³, V. Giacomel²
¹Laboratory of Pediatric Endocrinology Division of Genetics and Cell Biology, IRCCS San Raffaele Scientific Institute, ²Unit of Paediatric Infectious Disease, ASST FBF Sacco, University of Milan, ³Clinic of Paediatrics, V Buzzi Hospital, ASST FBF Sacco, University of Milan
- P 90 Current use of TAF/Emtricitabine + Darunavir/COBI as initial therapy or optimization strategy in 5 centres in Tuscany: demographical and clinical profile of 141 patients and reasons for choice**
F.M. Fusca¹, B. Rossetti², D. Messeri³, F. Vichi¹, F. Lagi⁴, G. Sterrantino⁴, C. Spertilli Raffaelli⁵, R. Cinelli⁶, S. Sani⁶, M. Di Pietro³
¹SOC Malattie Infettive 1, Osp. S. Maria Annunziata, Firenze, ²UOC Malattie Infettive, AOU Senese, Siena, ³SOC Malattie Infettive 2, Osp. S. Jacopo, USL Toscana Centro, Pistoia, ⁴Dipartimento Medicina Sperimentale e Clinica - Università di Firenze - Azienda Ospedaliero-Universitaria Careggi, Firenze, ⁵Dipartimento di Biotecnologie Mediche, Università di Siena, Siena, ⁶UO Malattie Infettive, Spedali Riuniti, Livorno
- P 91 Use of integrase-inhibitors as part of dual or triple regimens in the Italian MaSTER cohort between 2009 and 2017**
F. Iannuzzi⁷, S.N. Rich¹⁰, E. Quiros Roldan¹, G. Paraninfo¹, G. Migliorino⁷, F. Vichi⁵, E. De Filippo², L. Sighinolfi⁶, S. Lorenzotti⁸, A. Saracino⁴, N. Mazzini⁹, R. Cauda³, G. Carosi⁹ for the Master cohort group
¹University Division of Infectious and Tropical Diseases, University of Brescia, Brescia, ²Infectious Diseases, Papa Giovanni XXIII Hospital, Bergamo, Italy; ³Infectious Diseases, Policlinico A. Gemelli – Catholic University, Rome, Italy, ⁴Infectious Diseases, Policlinico di Bari, Italy, ⁵Infectious Diseases, S.M. Annunziata Hospital, Firenze, Italy, ⁶Infectious Diseases, Nuovo Polo Ospedaliero di Cona, Ferrara, Italy, ⁷Infectious Diseases, San Gerardo Hospital, Monza, Italy, ⁸Infectious Diseases, Istituti Ospitalieri, Cremona, Italy, ⁹M.I.S.I. Foundation, Brescia, Italy, ¹⁰Department of Epidemiology, University of Florida, USA

MANAGEMENT AND TREATMENT OF VIRAL HEPATITIS

- P 92 CD4+ T- cell count and CD4/CD8 ratio trend after HCV eradication in HCV/HIV-coinfected subjects treated with DAAs: an observational retrospective study over a 4 year period**
M. Di Nuzzo, C. Contini, M. Libanore, D. Segala, L. Sighinolfi
Malattie Infettive, Ospedale Nuovo S. Anna, Ferrara
- P 93 Positive Impact of DAA on Patient-Reported Outcomes and neurocognitive performances in HCV mono-infected and HIV/HCV coinfecting patients**
E. Pollastri¹, S. Odolini¹, S. Volpi¹, V. Cappa^{2,3}, S. Calza^{2,3}, A. Spinetti¹, S. Zaltron¹, P. Nasta¹, S. Compostella¹, G. Zuglian¹, C. Carriero¹, C. Chirico¹, F. Castelli¹, E. Focà¹
¹University department of Infectious and Tropical diseases, ASST Spedali Civili di Brescia, ²Unit of Biostatistics, Department of Molecular and Translational Medicine, University of Brescia, Brescia, Italy, ³Big&Open Data Innovation Laboratory (BODa-Lab), University of Brescia, Brescia, Italy
- P 94 The health saving costs of HCV treatment of drug users: evidence from the real practice of Drug Dependence Services (SerDs)**
F.A. Nava, A. Chiesa, G. Strepparola, G. Pennisi, R. Vitali, L. Trevisi, A. Lucchini
FeDerSerD (Italian Society of Addiction Medicine), Milan, Italy



POSTER EXHIBITION

P 95 The Normal ALT: achievement of transaminases true normal value in a cohort of HIV/HCV co-infected subjects after SVR

R. Rossotti, M. Merli, C. Baiguera, M. Cantone, T. Angelini Zucchetti, V. Picciotto, F. Bosca, M. Vinci, M. Puoti
Niguarda Hepatitis Center - Department of Infectious Diseases, ASST Grande Ospedale Metropolitano Niguarda, Milan

P 96 The use of intrahepatic portosystemic shunt in HIV positive patients: a retrospective multicentric study

A. Lombardi^{1,3}, R. Rossotti⁴, A. Airolidi⁵, F. Schepis⁶, L. Turco⁷, V. Zuccaro⁸, M. Tran Minh⁹, M. Colaneri^{1,3}, M. Samba^{1,3}, M.G. Lupi^{1,3}, M.T. Giordani¹⁰, P. Sacchi¹, M. Fabbiani¹, P. Quaretti⁷, L. Scudeller⁵, J. Rockstroh⁶, M. Puoti⁴, R. Bruno^{1,2}

¹Infectious Diseases Unit, IRCCS "San Matteo", Pavia, Italy, ²Department of Medical, Surgical, Diagnostic and Paediatric Science, University of Pavia, Pavia, Italy, ³Department of Internal Medicine and Therapeutics, University of Pavia, Italy, ⁴ASST Grande Ospedale Metropolitano Niguarda, Infectious Diseases Department, Milano, Italy, ⁵Clinical Epidemiology and Biostatistic Unit, Fondazione IRCCS "San Matteo", Pavia, Italy, ⁶Bonn University Hospital, Bonn, Germany, ⁷Interventional Radiology, Fondazione IRCCS Policlinico San Matteo Pavia, Pavia, Italy, ⁸Department of Hepatology and Gastroenterology, ASST Grande Ospedale Metropolitano Niguarda, Milano, Italy, ⁹Department of Gastroenterology, Policlinico di Modena, Modena, Italy, ¹⁰Infectious and Tropical Diseases Unit, Vicenza Hospital, Vicenza, Italy

P 97 A liquid chromatography-tandem mass spectrometry method for simultaneous determination of simeprevir, daclatasvir, sofosbuvir, and GS-331007 applied to a retrospective clinical pharmacological study

D. Ferrari^{1,2}, S. Bagaglio³, M. Raso², L. Galli³, S. Premaschi², E. Messina³, G. Morsica³, M. Locatelli², C. Uberti-Foppa^{3,4}, H. Hasson³

¹SCVSA Department, University of Parma, Parma, Italy, ²Laboratory Medicine Service, San Raffaele Hospital, Milano, Italy, ³Clinic of Infectious Diseases, San Raffaele Hospital, Milano, Italy, ⁴Vita-Salute San Raffaele University, Milano, Italy

P 98 Successful ongoing retreatment with glecaprevir/pibrentasvir+sofosbuvir+ribavirin guided by resistance test in a patient with HCV genotype 3 who failed glecaprevir/pibrentasvir with both NS3 and NS5A resistance

M. Aragri¹, C. Masetti², V. C. Di Maio¹, I. Lenci², M. Milana², A. Bertoli¹, K. Yu La Rosa¹, M. Ciotti³, S. Grelli³, C. F. Perno⁴, M. Angelico², F. Ceccherini-Silberstein^{1*}

¹Department of Experimental Medicine, University of Rome Tor Vergata, Rome, Italy, ²Hepatology Unit, University Hospital of Rome Tor Vergata, Rome, Italy, ³Virology unit, University Hospital of Rome Tor Vergata, Rome, Italy, ⁴Department of Oncology and Oncohematology, University of Milan, Milan, Italy, *On behalf of HCV Virology Italian Resistance Network (Foundation Vironet C)

P 99 Real-world effectiveness and safety of Glecaprevir/Pibrentasvir in patients with chronic Hepatitis C: an interim analysis of the italian dataset of a multicountry postmarketing observational study

The MARS Study Group: A. Aghemo¹, A. Alberti², P. Andreone³, M. Angelico⁴, A. Antinori⁵, M.R. Brunetto⁶, L. Chessa⁷, A. Ciancio⁸, A. Craxi⁹, G.B. Gaeta¹⁰, M. Galli¹¹, A. Gasbarrini¹², A. Giorgini¹³, P. Lampertico¹⁴, M. Lichtner¹⁵, M. Milella¹⁶, F. Morisco¹⁷, M. Persico¹⁸, M. Pirisi¹⁹, M. Puoti²⁰, G. Raimondo²¹, G. Rizzardin²², A. Romano²³, M. Russello²⁴, V. Sangiovanni²⁵, G. Serviddio²⁶, E. Villa²⁷, M. Vinci²⁸, A.L. Zignego²⁹, A. De Michina³⁰, G. Guida³⁰, A.S. Roscini³⁰

¹Istituto Clinico e di Ricerca Humanitas, Rozzano (MI), ²Dipartimento di Medicina Molecolare Università di Padova, ³Dipartimento di Scienze Mediche, Materno Infantili e dell'Adulto, Università di Modena e Reggio Emilia, ⁴Dipartimento di Medicina - UOC di Epatologia, Fondazione PTV - Policlinico Tor Vergata, Roma, ⁵Dipartimento Clinico UOC Immunodeficienze Virali, INMI Lazzaro Spallanzani IRCCS, Roma, ⁶Dipartimento di Medicina clinica e sperimentale Università di Pisa - UO Epatologia, Azienda Ospedaliero - Universitaria Pisana, Pisa, ⁷Medicina Interna e Malattie del Fegato, AOU Cagliari, Monserrato (CA), ⁸Dipartimento di Scienze Mediche, SC Gastroepatologia U, A.O.U. Città della Salute e della Scienza di Torino, Università di Medicina, Torino, ⁹Dipartimento Biomedico di Medicina Interna e Specialistica - Reparto di Gastroenterologia, Azienda Ospedaliera Universitaria Policlinico P. Giaccone, Palermo, ¹⁰Dipartimento Salute Mentale e Fisica, UOC Malattie Infettive, Università degli Studi della Campania "Luigi Vanvitelli", Napoli, ¹¹Dip. Scienze Biomediche e Cliniche L.Sacco - UNIMI, III Divisione Malattie Infettive, ASST Fatebenefratelli Sacco, Milano, ¹²UOC Medicina Interna, Malattie dell'Apparato digerente e del fegato, Fondazione Policlinico Universitario A. Gemelli, Roma, ¹³Dipartimento di Malattie epatologiche, gastroenterologiche e metaboliche, Reparto U.O di Epatologia e Gastroenterologia, ASST Santi Paolo e Carlo, Milano, ¹⁴Dipartimento di fisiopatologia medico chirurgica e dei trapianti /Dipartimento di Medicina, UOC Gastroenterologia ed Epatologia, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milano, ¹⁵Dipartimento di Sanità Pubblica e Malattie Infettive, Sapienza Università di Roma, polo pontino, UOC Malattie Infettive, Ospedale SM Goretti, Latina, ¹⁶DIMO - U.O.C. di Malattie Infettive, Azienda Universitaria Ospedaliera Consorziale-Policlinico Bari, Bari, ¹⁷Dipartimento di Medicina Clinica e Chirurgica, UOC di Gastroenterologia ed Epatologia, Università Federico II, Napoli, ¹⁸Dipartimento di Medicina Clinica Medica, Epatologica e Lungodegenza, AOU OO. RR. San Giovanni di Dio Ruggi e D'Aragona, Salerno, ¹⁹Università del Piemonte Or. Medicina Traslazionale, SCU Medicina Interna 1, AOU Maggiore della Carità di Novara, Novara, ²⁰Dipartimento Medico Polispecialistico, Malattie Infettive, ASST Grande Ospedale Metropolitano Niguarda, Milano, ²¹Dipartimento di Medicina Clinica e Sperimentale, UOC di Epatologia Clinica e Biomolecolare, Università ed AOU di Messina, ²²Dipartimento Malattie Infettive, ASST Fatebenefratelli Sacco, Milano, ²³Dipartimento di Medicina (DIMED) UOC Clinica Medica 5°, A. O. Di Padova, Padova, ²⁴Dipartimento Medicina Interna, UOSD Epatologia, Azienda Ospedaliera di Rilevo Nazionale e di Alta Specializzazione Garibaldi - Presidio Ospedaliero Garibaldi-Nesima, Catania, ²⁵Dipartimento Malattie Infettive e urgenze infettivologiche, Reparto infezioni sistemiche dell'immunodepresso, A.O. Domenico Cotugno, Napoli, ²⁶Unità Universitaria di Epatologia, OORR Ospedali Riuniti - Università degli Studi di Foggia, ²⁷UC Gastroenterologia, Dipartimento di Specialità Mediche, Azienda Ospedaliera Universitaria di Modena, Modena, ²⁸Dipartimento Medico Polispecialistico, S.C. Epatologia e Gastroenterologia, ASST Grande Ospedale Metropolitano Niguarda, Milano, ²⁹Centro Interdipartimentale di Epatologia MASVE, Azienda Ospedaliero-Universitaria Careggi, Firenze, ³⁰Medical Department, AbbVie srl, Roma

P 100 Trieste experience in the treatment of Hepatitis C in people who inject drugs: the integrate management between addiction treatment service (SerD), liver clinic, and infective disease department

M. Giuffrè^{1,2}, A.C. Baez³, A. Colombo^{1,2}, I.M. Crosato⁴, F. Masutti², M. Santì³, C. Stanic³, R. Balestra³, S.L. Crocè^{1,2,5}, R. Luzzati^{1,4}

¹Dipartimento Universitario Clinico di Scienze Mediche Chirurgiche e della Salute, Università degli Studi di Trieste, ²Clinica Patologie del Fegato, Azienda Sanitaria Universitaria Integrata di Trieste, ³Dipartimento delle Dipendenze, Azienda Sanitaria Universitaria Integrata di Trieste, ⁴Malattie Infettive, Azienda Sanitaria Universitaria Integrata di Trieste, ⁵Fondazione Italiana Fegato

P 101 Weight gain, lipid profile and body composition changes in HIV/HCV-infected Patients treated with Direct Antiviral Agents

M.F. Mariani, D.F. Bavaro, P. Laghetti, S. Lo Caputo, L. Monno, G. Angarano, A. Saracino
Department of Biomedical Sciences and Human Oncology, Clinic of Infectious Diseases, University of Bari Medical School, Bari, Italy



- P 102 DAA failure in HCV genotype not 1: virological features and efficacy of re-treatment**
L. Occhiello¹, M. Pisaturo¹, M. Starace¹, C. Minichini¹, A. Di Fraia¹, S. De Pascalis², M. Macera², V. Messina³, V. Sangiovanni⁴, E. Claar⁵, D. Precone⁶, G. Stornaiuolo², M. Stanzone², I. Gentile⁸, G. Brancaccio², S. Martini⁹, A. Masiello¹⁰, A. Salomone Megna¹¹, C. Coppola¹², A. Federico¹³, E. Sagnelli¹, M. Persico¹⁴, A. Galeota Lanza¹⁵, A. Marrone¹⁶, G.B. Gaeta², N. Coppola^{1,3}
¹Laboratory for the identification of prognostic factors of response to the treatment against infectious diseases, University of Campania "L. Vanvitelli", Napoli, Italy, ²Infectious Diseases and Viral Hepatitis, Department of Mental and Physical Health and Preventive Medicine, University of Campania "L. Vanvitelli", Napoli, Italy, ³Infectious Diseases Unit, A.O. S Anna e S Sebastiano Caserta, Italy, ⁴Third Infectious Diseases Unit, AORN dei Colli, P.O. Cotugno, Naples, Italy, ⁵Internal Medicine Unit, Evangelical Hospital Villa Betania Naples, Italy, ⁶Internal Medicine Unit A.O Sarno, Sarno (SA) Campania L. Vanvitelli, & Infectious and Transplant Medicine, AORN Ospedali dei Colli-Monaldi Hospital, Naples, Italy, ⁷Gastroenterology Unit, AOU San Giovanni di Dio Ruggi d'Aragona, Salerno Italy, ⁸Infectious Diseases Unit, University Federico II, Naples, Italy, ⁹HIV Unit, University of Campania L. Vanvitelli, Naples, Italy, ¹⁰Infectious Diseases Unit, A.O S.G. Moscati, Avellino Italy, ¹¹Infectious Diseases Unit, A. O G.Rummo, Benevento, ¹²Hepatology Unit, Grogano Hospital, Grogano, ¹³Internal Medicine and Hepatology Department of Clinical and Experimental Medicine, University of Campania "L. Vanvitelli", ¹⁴Internal Medicine and Hepatology Unit, PO G. Da Procida-AOU- San Giovanni e Ruggi D'Aragona, University of Salerno, ¹⁵Hepatology Unit, Cardarelli Hospital, Naples, Italy, ¹⁶Department of Medical, Surgical, Neurological, Metabolic, and Geriatric Sciences, University of Campania "L. Vanvitelli"
- P 103 Retention in care among chronically HBV-infected patients: one more reason to treat**
L. Magnasco¹, L. Di Nino¹, M. Mirabella¹, L.A. Nicolini²
¹Department of Health's Science, University of Genoa, Genoa, Italy, ²Infectious Diseases Unit, San Martino Policlinic Hospital, Genoa, Italy
- P 104 Liver stiffness variation after SVR achievement in a cohort of HIV/HCV co-infected subjects**
R. Rossotti, C. Baiguera, M. Merli, M. Cantone, T. Angelini Zucchetti, V. Picciotto, F. Bosca, M. Vinci, M. Puoti
Niguarda Hepatitis Center, ASST Grande Ospedale Metropolitano, Niguarda, Milan
- P 105 HCV Continuum of Care in real life in main prison in Florence, Tuscany, and factors delaying HCV treatment**
A. Gabbuti, F.M. Fusco, P. Pierotti, E. Salomoni, P. Blanc
SOC Malattie Infettive 1, Osp. S. Maria Annunziata, USL Toscana Centro, Florence
- P 106 Liver-related clinical events in a cohort of cirrhotic patients after successful HCV treatment with direct acting antivirals**
E. Colella¹, G. Lapadula¹, M. Fava², N. Squillace¹, P. Vitello¹, M. Rossi¹, F. Sabbatini¹, P. Columpsi¹, G. Migliorino¹, A. Soria¹
¹Unit of Infectious Diseases, San Gerardo Hospital, ASST Monza, ²University of Milano-Bicocca
- P 107 High SVR12 rates in patients who prematurely discontinued directly acting antivirals (DAA) regimens: data from the NAVIGATORE-Lombardia Network**
M. Fabbiani¹, A. Lombardi¹, M. Colaneri¹, P. Del Poggio², G. Colloredo², R. D'Ambrosio³, E. De Gasperi³, M. Zuin⁴, A. Giorgini⁴, L. Pasulo⁵, F. Maggiolo⁶, F. Castellì⁷, A. Pan⁸, O. Spinelli⁹, T. Re¹⁰, A. Lleo¹¹, M. Rumi¹², C. Uberti Foppa¹³, A. Soria¹⁴, A. Aghemo¹¹, P. Lampertico³, M. Puoti¹⁵, G. Rizzardini¹⁶, S. Fagioli¹⁵, R. Bruno¹ for the NAVIGATORE-Lombardia Study Group
¹U.O. Malattie Infettive e Tropicali, Fondazione IRCCS Policlinico San Matteo, Pavia, ²Policlinico S. Marco, Zingonia, ³Divisione di Gastroenterologia ed Epatologia, Fondazione IRCCS Ospedale Maggiore Policlinico, Milano, ⁴Unità di Epatologia e Gastroenterologia, Ospedale San Paolo, Milano, ⁵Unità di Gastroenterologia, ASST Papa Giovanni XXIII, Bergamo, ⁶U.O. Malattie Infettive, ASST Papa Giovanni XXIII, Bergamo, ⁷Dipartimento di Malattie Infettive, Spedali Civili, Brescia, ⁸U.O. Malattie Infettive, Istituti Ospitalieri, Cremona, ⁹UO Medicina Interna Cantù, ASST LARIANA Como, ¹⁰U.O. Malattie Infettive, ASST Ovest Milanese, Le-gnana, ¹¹Medicina Interna ed Epatologia, Humanitas Research Hospital, Rozzano, ¹²UO Epatologia, Ospedale San Giuseppe, Milano, ¹³UO Malattie Infettive, Ospedale San Raffaele, Milano, ¹⁴UO Malattie Infettive, Ospedale San Gerardo, ASST Monza, Monza, ¹⁵UO Malattie Infettive, ASST Grande Ospedale Metropolitano Niguarda, Milano, ¹⁶Dipartimento di Malattie Infettive, Ospedale Luigi Sacco, Milano
- P 108 Analysis of urinary metabolites by Nuclear Magnetic Resonance based-metabolomics in HCV patients with severe liver fibrosis receiving direct-acting antiviral agents**
E. Biliotti¹, O. Giampaoli^{2,3}, L. Volpicelli¹, G. Capuani², A. Tomassini^{2,3}, D. Palazzo¹, R. Esvan¹, M. Spaziante¹, E. Gaudio⁵, A. Micheli^{3,4}, G. Taliani¹
¹Department of Translational and Precision Medicine, Sapienza University of Rome, Italy, ²Department of Chemistry, Sapienza University of Rome, Italy, ³NMR based Metabolomics Laboratory, Sapienza University of Rome, Italy, ⁴Department of Environmental Biology, Sapienza University of Rome, Italy, ⁵Department of Anatomical, Histological, Forensic Medicine and Orthopedics Sciences, Sapienza University of Rome, Italy
- P 109 An undefined case of virological failure in an HIV-positive patient treated with DAAs for HCV recurrence after liver transplant**
D. Testi¹, L. Vizioli², L. Badia¹, V. Guardigni¹, G. Ferraro¹, V. Vero², M. Ravaioli³, G. Verucchi¹, P. Viale¹, M. Cescon³, M.C. Morelli²
¹Dipartimento di Malattie Infettive, S.Orsola-Malpighi, Bologna, ²Medicina interna trattamento gravi insuff. d'organo-Morelli, S.Orsola-Malpighi, Bologna, ³Chirurgia Generale e trapianti, S.Orsola-Malpighi, Bologna
- P 110 Evaluation of a pan-genotyping full population-based sequencing method for hepatitis C NS3, NS5A and NS5B drug resistance identification**
T. Allice¹, M.G. Milia¹, E. Burdino¹, G. Gregori¹, L. Bogleione², A. Bottoni¹, M. Cazzadore¹, P. Tremante¹, E. Scuccimarra¹, S. Bonora², V. Ghisetti¹
¹Laboratory of Microbiology and Virology, ASL Città di Torino, Torino, ²Department of Infectious Disease, University of Torino, Torino



MANAGEMENT OF HIV INFECTION

- P 111 The clinical heterogeneity of PLWH switching to dual therapy is levelled in 2 year follow up in a real-life cohort**
G. Guaraldi¹, I. Franconi, A. Malagoli, J. Milic, A. Santoro, M. Menozzi, A. Mariani, F. Carli, S. Zona, C. Mussini
Modena HIV Metabolic Clinic, Infectious Diseases Unit, University of Modena and Reggio Emilia, Italy
- P 112 Lack of HIV serological diagnosis with new generation tests in an AIDS patient : which consequences on HIV epidemiology?**
I. Uccella¹, R. Pulselli¹, I. Abbate², C. Gori², K. Casinelli¹, P. Fabrizi¹, C. Falco¹, G. Farinelli¹, M. Limodio¹, L. Sarracino¹, M. Sebastiani¹, E. Anzalone¹
¹Ospedale Fabrizio Spaziani, Frosinone, ²INMI Lazzaro Spallanzani, Roma
- P 113 HIV-1 DNA Test: a reliable method for the management of HIV infection**
E. Carloni¹, E. Omiccioli¹, C. Orlandi², L. Pucci¹, V. Ceppetelli^{1,2}, I. Bon³, A. Bertoldi³, B. Canovari⁴, Z. Pasquini^{4,5}, F. Barchiesi^{4,5}, M. Menotta², A. Casabianca², M. Magnani²
¹Diatheva srl, Cartoceto, Fano (PU), ²Dipartimento di Scienze Biomolecolari, Università di Urbino "Carlo Bo", Urbino (PU), ³Dipartimento di Medicina Specialistica, Diagnostica e Sperimentale, Università di Bologna, Bologna (BO), ⁴Malattie Infettive, Azienda Ospedaliera Ospedali Riuniti Marche Nord, Pesaro (PU), ⁵Dipartimento di Scienze Biomediche e Sanità Pubblica, Università Politecnica delle Marche, Clinica Malattie Infettive Ospedali Riuniti di Ancona, Ancona (AN)
- P 114 Organizational and economic impact of a regional clinical pathway on HIV prescription patterns: 3 year-analysis in 4 centres in Lazio Region**
R. Di Bidino¹, A. Cicchetti², R. Cauda¹, M. Andreoni³, A. Antinori⁴, C. Mastroianni⁵, V. Vullo⁵, C. Mastroianni⁵, G. D'Etto⁵, A. Borghetti¹, S. Lamonica¹, C. Cerva³, V. Malagnino³, A. Giannetti⁴
¹Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Rome, ²Alta Scuola di Economia e Management dei Sistemi Sanitari (ALTEMS), Rome ³Fondazione Policlinico Tor Vergata, Rome, ⁴Istituto Nazionale per le Malattie Infettive "Lazzaro Spallanzani" IRCCS, Rome, ⁵Azienda Policlinico Umberto I, Sapienza Università di Roma, Rome
- P 115 HIV rapid test in community setting: data from an experience in 6 Italian cities (OPEN-TEST Project)**
C. Falanga¹, S. Negri¹, F. Di Gennaro², M.C. Polisenò², D.F. Bavaro², A. Saracino², S. Lo Caputo², G. Angarano²
¹ANLAIDS Sezione Lombarda, Milan, Italy, ²Clinic of Infectious Diseases University of Bari, Italy
- P 116 Miltefosine treatment of Amfotericin-B resistant Leishmaniasis in HIV**
F. Bulla, P. Scerbo, A. Priamo, L. Cosco
U.O.C. Malattie Infettive A.O. "Pugliese-Ciaccio" Catanzaro
- P 117 The efficacy and safety of dual therapy regimens in an HIV-infected cohort**
G. Piazza¹, A. Rutter¹, S. Vitale¹, L. Appolloni¹, G. Pensalfine¹, C. Bitello¹, M. Morotti¹, L. Calza², C. Puggiolì¹
¹Clinical Pharmacy, S. Orsola-Malpighi Polyclinic, Bologna, ²Infectious Disease S. Orsola-Malpighi Polyclinic, Bologna
- P 118 Knowledge and behaviours of Italian HIV clinicians toward vaccinations recommended for people living with HIV: results of a questionnaire-based investigation**
A.L. Ridolfo¹, S. Nozza², L. Oreni¹, G. Mazzola³, G.P. Carosi⁴, S. Lo Caputo⁵, A. Di Biagio⁶, A. Muscatello⁷, A. Cascio⁸, A. Ranzani¹, M. Galli¹, for the Gruppo di Studio HIV/Vaccinazioni, Società Italiana di Malattie Infettive e Tropicali (SIMIT)
¹Infectious Diseases Unit, DIBIC Luigi Sacco, University of Milan, Italy, ²Department of Infectious Diseases, IRCCS San Raffaele Scientific Institute, University Vita-Salute San Raffaele, Milan, Italy, ³Infectious Diseases Unit, Paolo Giaccone/Azienda Ospedaliera Universitaria Policlinico, Palermo, Italy, ⁴Member of the Società Italiana di Malattie Infettive e Tropicali, ⁵Clinic of Infectious Diseases, Policlinico, University of Bari, Italy, ⁶Infectious Diseases Unit, Hospital Policlinico San Martino, University of Genoa, Italy, ⁷Infectious Diseases Unit, IRCCS Ca' Granda Ospedale Maggiore Policlinico Foundation, University of Milan, Milan, Italy, ⁸Department of Sciences for Health Promotion and Mother-Child Care, University of Palermo, Italy
- P 119 Mean platelet volume correlates with CD4+ immune activation in HIV+ older patients: results from the 36 months follow-up of the RAL-AGE cohort**
L. Celani¹, C. Borrazzo¹, P. Pavone¹, L. Santinelli¹, P. Vassalini¹, G.P. Innocenti¹, C. Fimiani², C. Mastroianni³, F. Di Sora⁴, I. Mezzaroma¹, V. Vullo¹, G. d'Etto¹
¹Department of Public Health and Infectious Diseases - "Sapienza" University of Rome, ²Azienda Ospedaliero-Universitaria Policlinico Umberto I, Rome, ³Department of Sense Organs University Sapienza Rome Azienda Ospedaliera, ⁴S. Giovanni Department of Sense Organs University Sapienza Rome Addolorata, Rome
- P 120 Prevalence and persistence of HPV in anal swabs of a cohort of people living with HIV**
N. Squillace¹, G. Lapadula¹, A. Soria¹, L. Rocca¹, F. Sabbatini¹, E. Colella¹, P. Vitiello¹, M. Rossi¹, S. Malandrino², A. Cavallero², A. Di Lucia³, M. Braga³, G.M. Migliorino¹
¹Azienda Socio Sanitaria Territoriale Monza, Ospedale San Gerardo, Unità Operativa di Malattie infettive, Monza, ²Azienda Socio Sanitaria Territoriale Monza, Ospedale San Gerardo, Laboratorio di Microbiologia e Virologia, Monza, ³Azienda Socio Sanitaria Territoriale Monza, Ospedale San Gerardo, Chirurgia generale e d'urgenza I, Monza



- P 121 Risk of failure in dual therapy versus triple therapy in naïve HIV-patients: a meta-analysis**
A. Russo¹, M. Pisaturo¹, L. Onorato¹, S. Martini¹, P. Maggi¹, N. Coppola^{1,2}
¹Department of Mental Health and Public Medicine – Infectious Diseases Unit, University of Campania Luigi Vanvitelli, ²Infectious Disease Unit, AORN Caserta
- P 122 HIV DNA form quantification in blood, tissues, CD4+ T lymphocytes and macrophages**
C. Orlandi¹, B. Canovari², M. Surdo³, S. Cannizzo⁴, F. Bozzano⁵, E. Merlini⁴, M.F. Cortese³, C. Tincati⁴, F. Marras⁶, C. Luigiano⁴, Z. Pasquini^{2,7}, S. Aquaro⁸, G. Marchetti⁴, F. Ceccherini-Silberstein³, F. Barchiesi^{2,7}, A. De Maria⁶, C.F. Perno⁹, M. Magnani¹, A. Casabianca¹
¹Department of Biomolecular Sciences, University of Urbino “Carlo Bo”, ²Malattie Infettive, Azienda Ospedaliera Ospedali Riuniti Marche Nord, Pesaro, ³Department of Experimental Medicine and Surgery, University of Rome Tor Vergata, ⁴Clinic of Infectious Diseases ASST Santi Paolo e Carlo, Department of Health Sciences-University of Milan, ⁵Bambino Gesù Hospital, Rome, ⁶Center for Excellence in Biomedical Research, University of Genova, ⁷Dipartimento di Scienze Biomediche e Sanità Pubblica, Università Politecnica delle Marche, Clinica Malattie Infettive Ospedali Riuniti di Ancona, ⁸Department of Pharmacy, Health and Nutritional Sciences, University of Calabria, Arcavacata di Rende (CS), ⁹Department of Oncology and Hemato-Oncology, University of Milan
- P 123 Solid organ transplant in HIV positive patients with 10 or more years follow-up: a sustained gero-protective outcome**
G. Dolci¹, E. Franceschini¹, J. Milic¹, G. Ciusa¹, I. Franconi¹, V. Serra², G. Alfano³, P. Magistri², F. Di Benedetto², C. Mussini¹, G. Guaraldi¹
¹Unità di Malattie Infettive, Policlinico di Modena, Università di Modena e Reggio Emilia, Modena, ²Chirurgia Oncologica Epato-Bilio-Pancreatica e dei Trapianti di Fegato, Policlinico di Modena, Università di Modena e Reggio Emilia, Modena, ³Struttura Complessa di Nefrologia e Dialisi, Policlinico di Modena, Università di Modena e Reggio Emilia, Modena
- P 124 Dr Apollo chatbot: a digital contribution to the achievement of the “fourth 90” for people living with HIV**
S. Vita¹, R. Marocco¹, G. Morlino³, V. Palmacci², A. Carraro², I. Pozzetto², M. Renzelli¹, C. Del Borgo¹, V.S. Mercurio¹, C.M. Mastroianni², M. Lichtner^{1,2}
¹Infectious Disease Unit, SM Goretti Hospital Latina, ²Department of Public health and Infectious disease, Sapienza, University of Rome, ³Snapback, Rome
- P 125 Food intake and HIV infection: a pilot study of nutrition education in a group of patients**
P. Vitiello, G. Lapadula, F. Sabbatini, G.M. Migliorino, A. Soria, E. Colella, M. Rossi, N. Squillace
U.O Malattie Infettive, Ospedale S. Gerardo, ASST Monza

NON INFECTIOUS COMORBIDITIES IN HIV

- P 126 Anemia is one of the greatest complications in HIV. Use of erythropoietins in ASL Roma 5: biosimilar and originator compared**
F. Ferrara¹, M. Mensurati¹, M. Latini¹, M. Rizzica²
¹ASL Roma 5, Tivoli (RM), ²INMI “L. Spallanzani”, Roma
- P 127 Emergency cardiac transplantation in newly diagnosed HIV infection: a case report**
M.C. Moiola¹, D. Motta¹, G. Travi¹, R. Rossotti¹, M. Merli¹, S. Chiappetta¹, C. Orcese¹, C. Santolamazza², A. Garascia², G. Foti², M. Cottini³, G. Tata³, A. Costetti³, M. Mininni⁴, G. Pedrazzini⁴, A. Nava⁵, D. Fanti⁵, C.F. Perno⁵, M. Puoti¹
¹Infectious diseases Unit, ASST Grande Ospedale Metropolitano Niguarda, Milan Italy, ²Cardiology Unit Transplant Center, ASST Grande Ospedale Metropolitano Niguarda, Milan, Italy, ³Cardiac Surgery Unit, Cardio Thoraco-Vascular Department, ASST Grande Ospedale Metropolitano Niguarda, Milan, Italy, ⁴Cardiothoracic Anesthesiology Unit, ASST Grande Ospedale Metropolitano Niguarda, Milan, Italy, ⁵Chemical-clinic and Microbiological Analysis, ASST Grande Ospedale Metropolitano Niguarda, Milan Italy
- P 128 Stevens-Johnson Syndrome/Toxic Epidermal Necrolysis (TEN) and Non-Hodgkin Lymphoma HIV-related: fortuitous association or paraneoplastic syndrome?**
V. Barocci, S. Mazzanti, M. Di Pietrantonio, A. Polenta, P. Mantini, V. Iencinella, L. Brescini, A. Giacometti
Clinica malattie infettive Ancona, Università Politecnica delle Marche
- P 129 T-cell mediated polymyositis as an unusual presentation of primary human immunodeficiency virus infection**
M. Di Pietrantonio, V. Barocci, A. Polenta, S. Mazzanti, P. Mantini, V. Iencinella, L. Brescini, A. Giacometti
Clinica Malattie Infettive Ancona, Università Politecnica delle Marche
- P 130 Rapidly progressive autoimmune hepatitis in an HIV-positive patient: a case report**
A. Borioni, L. Badia, V. Guardigni, P. Viale, G. Verucchi, G. Piazza
Osp. S.Orsola Bologna; Alma Mater Studiorum, Università di Bologna



- P 131 Dolutegravir does not induce Bone Mineral Density decrease in a real life setting**
P. Bonfanti¹, E. Ricci², B. Menzaghi³, G. Orofino⁴, N. Squillace⁵, G.V. De Socio⁶, F. Vichi⁷, M. Celesia⁸, C. Dentone⁹, S. Rusconi¹⁰, S. Mameli¹¹, C. Molteni¹, M. Guastavigna⁴, M. Nofri⁵, E. Salomoni⁷, V. Colombo¹⁰, G. Madeddu¹¹ on Behalf of CISA study group
¹Unit of Infectious Diseases, A. Manzoni Hospital, ASST di Lecco, Lecco, ²Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milano, ³Unit of Infectious Diseases, ASST della Valle Olona – Busto Arsizio (VA), ⁴Division I of infectious and Tropical Diseases, ASL Città di Torino, Torino, ⁵Infectious Diseases Unit, ASSTMONZA, San Gerardo Hospital-University of Milano-Bicocca, Monza, ⁶Department of Internal Medicine 2, Infectious Diseases Unit, "Santa Maria della Misericordia" General Hospital, Perugia, ⁷Infectious Diseases Unit, Santa Maria Annunziata Hospital, Uslcentro, Florence, ⁸Infectious Diseases University of Catania ARNAS Garibaldi, Catania, ⁹Unit of Infectious Diseases, Department of Graduated Medical Care, Sanremo Hospital, Sanremo, ¹⁰Infectious Diseases Unit, DIBIC "Luigi Sacco", University of Milan, Milan, ¹¹Unit of Infectious Diseases, Department of Medical, Surgical and Experimental Sciences, University of Sassari, Sassari
- P 132 Hypertension and HIV-related risk factors in young subjects on anti-retroviral therapy in Tanzania**
S. Trifirò¹, F. Cavallin², S. Mangi³, L. Mhaluka³, S. Maffoni⁴, S. Taddei⁵, G. Putoto⁶, G.F. Torelli^{3,7}
¹Azienda Ospedaliero-Universitaria Pisana, Pisa, Italy, ²Independent statistician, Solagna, Italy, ³Tosamaganga Council Designated Hospital, Iringa, Tanzania, ⁴University of Pavia, Italy, ⁵University of Pisa, Italy, ⁶CUAMM Doctors with Africa, Padua, Italy, ⁷CUAMM Doctors with Africa, Iringa, Tanzania
- P 133 Alexithymia is linked to neurocognitive function independently of sociodemographic and clinical predictors. A multicentric HIV cohort study**
F. Vadini¹, G. Madeddu², P. Di Stefano¹, B. Zizi², P. Maggi³, E. Tracanna¹, F. Sozio¹, F. Trave¹, D. Cibelli¹, V. Lai², F. Vichi⁴, G. De Socio⁵, C. Bartolozzi⁴, A. Sciacca¹, A. Agostinone¹, P. Bonfanti⁶, G. Parruti¹, and CISA Study Group
¹Infectious Disease Unit, Pescara General Hospital, Pescara, Italy, ²Department of Clinical and Experimental Medicine, Unit of Infectious Diseases, University of Sassari, Sassari, Italy, ³Infectious diseases Clinic, Policlinico Hospital, Bari, Italy, ⁴Infectious Diseases Unit, Santa Maria Annunziata Hospital, Bagno a Ripoli, Florence, Italy, ⁵Infectious Diseases Unit, Santa Maria Hospital, Perugia, Italy, ⁶Infectious Diseases Unit, A. Manzoni Hospital, Lecco, Italy
- P 134 Evaluation of lipid profile in HIV naive patients, treated by TAF-based regimens**
S. Martini¹, P. Maggi¹, L. Onorato¹, S. Ferrara², L. Alessio³, C. Bellacosa⁴, V. Esposito⁵, G. Di Filippo⁶, A. Masiello⁷, A. Maddaloni⁸, R. Santoro⁹, G. D'Alessio¹⁰, S.R. Bruno², V. Rizzo⁵, S. Parente⁶, A. Iodice³, N. Coppola^{1,3}
¹Infectious Disease, University of Campania, Luigi Vanvitelli, ²University of studies of Foggia, ³AORN Sant'Anna e San Sebastiano of Caserta, ⁴University of studies of Bari, ⁵IV Division AORN dei Colli, ⁶University Federico II of Naples, ⁷AO San Giuseppe Moscati of Avellino, ⁸VII Divisione AORN dei Colli, ⁹AO San Giovanni di Dio e Ruggi d'Aragona of Salerno, ¹⁰AORN San Pio di Benevento
- P 135 Archi-Prevaleat project. A National Register of color-Doppler ultrasonography of the epi-aortic vessels in Patients Living with HIV**
S. Martini¹, S. Ferrara², C. Bellacosa³, B.M. Celesia⁴, A. Tartaglia², P. Maggi¹
¹Università degli studi della Campania, Luigi Vanvitelli, ²Università degli studi di Foggia, ³Università degli Studi di Bari, ⁴Università di Catania ARNAS Garibaldi
- P 136 Abacavir hypersensitivity reaction (HSR), associated to baseline false negative HLAB5701 screening, in antiretroviral treatment naive HIV-1 patient**
S. Martini, P. Maggi, A. Russo, A. Cascone, N. Coppola
University of studies of Campania, Luigi Vanvitelli
- P 137 Cardiovascular risk score and Inflammatory markers in HIV population**
A. Auricchio¹, C. Ucciferri^{1,2}, F. Vignale¹, J. Vecchiet¹, K. Falasca¹
¹Clinic of Infectious Diseases Department of Medicine and Science of Aging, University "G. d'Annunzio" Chieti-Pescara, Chieti, ²University of Molise Department of Medicine and Health Sciences Campobasso Italy

PEDIATRIC, ADOLESCENT, MATERNAL, FETAL ASPECTS

- P 138 Noninvasive liver assessment in a population of vertically HIV-infected children adolescents and young adults**
E. Longoni¹, F.W. Basile¹, F. Forlanini¹, P. Nannini¹, G.V. Zuccotti², V. Giacomet¹
¹Unit of Paediatric Infectious Diseases, ASST FBF Sacco, University of Milan, Milan, ²Department of Paediatrics, V. Buzzi Hospital, ASST FBF Sacco, University of Milan, Milan
- P 139 An integrated model of preventive management of HIV-positive women during pregnancy and follow-up of the first year child's life**
V. Boscolo¹, G. Marini², S. Cavinato², S. Oletto¹, O. Rampon¹, S. Marinello², A. Zambon³, M. Granci³, C. Giaquinto¹, A. Cattelan²
¹Women's and Children's Health Department, University of Padua, ²Infectious Diseases Unit, University of Padua, ³Obstetrics and Gynecology Clinic, University of Padua
- P 140 A picture of clinical, immunological, and social situation in a population of HIV- infected youth followed at a reference Paediatric Center**
V. Giacomet¹, P. Erba², F.W. Basile², L. Folgori², A.R. Benincaso², G.V. Zuccotti³
¹Unit of Paediatric Infectious Disease- ASST FBF SACCO- Department of Biomedical and Clinical Sciences, University of Milan, ²Unit of Paediatric Infectious Disease- ASST FBF SACCO, University of Milan, ³Clinic of Paediatrics, V Buzzi Hospital, ASST-FBF-SACCO, University of Milan



PHARMACOLOGY, PHARMACOGENOMICS AND DRUG INTERACTIONS

- P 141 Cobicistat (COBI)-boosted Protease Inhibitors (PIs) plasma and intracellular (IC) pharmacokinetics (PK) in Nicotine Users**
M. Ferrara, A. Trentalange, C. Alcantarini, L. Marinaro, V. Pirriatore, A. Ianniello, A. De Nicolò, A. D'Avolio, A. Calcagno, G. Di Perri, S. Bonora
Unit of Infectious Diseases, Department of Medical Sciences, University of Torino, Torino
- P 142 TDF tubulopathy in a switchback patient. A case report**
N. Forni, C. Alcantarini, A. Lazzaro, V. Pirriatore, R. Angilletta, M. Ferrara, M. Tettoni, A. Ianniello, A. De Nicolò, A. D'Avolio, A. Calcagno, G. Di Perri, S. Bonora
Clinica Malattie Infettive, Ospedale Amedeo di Savoia, Università di Torino

SOCIAL AND BEHAVIOURAL SCIENCE, MARGINALIZED GROUPS, COMMUNITY ASPECTS AND COMMUNITY SURVEYS

- P 143 Health construction in MSM people who are living with HIV in Veneto**
M. Costacurta
Università degli Studi di Padova, Padova
- P 144 Prevention during the Apps era. Anlaids is online on Grindr**
S. Negri¹, A. Chinelli³, R. Galipò⁴, M. Longhi⁵, J.D. Pamphili⁴, M. Ramadori⁶, B. Marchini²
¹Anlaids Lombardia, ²Anlaids Onlus, ³Anlaids Liguria, ⁴Anlaids Lazio, ⁵Anlaids Mantova, ⁶Anlaids Umbria
- P 145 ANLAIDS online FORUM is an effective tool to monitor the perception of HIV transmission risk and the HIV-related social stigma in general population**
G.V. Calvino¹, A. Venturelli¹, M. Galli², C. Balotta², B. Marchini¹
¹Anlaids – Associazione Nazionale per la lotta contro l'Aids Onlus, ²Infectious Diseases Unit, Department of Biomedical and Clinical Sciences, University of Milan, Italy
- P 146 Promoting migrant access to sexual and reproductive health services for sexual gender based violence (SGBV) prevention and response (Pro-access). Preliminary data on HIV and HCV prevalence**
K. Ceessay, D. Di Dio, S.B. Dhiab, G. Florida, M.C. Longo, M. Manuli, D. Matheson, G. Petrelli, S. Reale, S. Scalzo, A.A. Sleemankhel, M.G. Di Benedetto, F. Bellissima and L. Nigro for the ProAccess/LILA Volunteer Group
Lega Italiana per la Lotta contro l'AIDS - Catania
- P 147 Hepatitis A awareness among homosexuals and the general population: results of a survey**
M. Properzi, B. Boldrini, A. Chiesa, D. Coletto, N. Gregori, F. Castelli, E. Quiros-Roldan
Departement of Infectious and Tropical Diseases, University of Brescia and ASST Spedali Civili Hospital, Brescia, Italy
- P 148 HIV-related stigma as a multi-layered category: an anthropological inquiry**
A. Gattari
Università Alma Mater Studiorum, Bologna
- P 149 "Massima Sicurezza": Interventions for the prevention of HIV, hepatitis and other infections in the Milan prisons of San Vittore and Bollate**
S. Penon, L. Cosmaro, S. Curridori, D. Savarino, M. Oldrini
Fondazione LILA Milano ONLUS, Milano
- P 150 Positive projections: The Thematic Apperception Test (TAT) and the immunological response in Hiv+ patients**
C. De Guglielmo, A. Masiello, S. Giglio, M. Talamo, S. Leone
A.O.R.N "S.Giuseppe Moscati" Malattie Infettive, Avellino
- P 151 Treatment of HCV in the age of new direct-acting antiviral drugs (DAAs): innovative aspects, management impacts and bioethical implications**
D. Piccioni¹, S. Bertini¹, A. Ferrero¹, C.B. Traversi¹, C. Carcieri¹, G. Cinnirella¹, A. Consoli²
¹Amedeo di Savoia Hospital Pharmacy, ASL City of Turin, ²Department of Addictions, ASL TO 5



- P 152 Young people and HIV: knowledge and attitudes about condom of high school students in the last five years in Italy**
M. Galli^{1,2,5}, L. Oreni¹, M. Pedretti², E. Zambon², T. Ferrario², R. Galipò³, M. Longhi⁴, G. Del Bene^{2,5}, B. Marchini⁵
¹UOC clinicizzata di Malattie Infettive, DIBIC L. Sacco – UNIMI, ²ANLAIDS Sezione Lombardia, ³ANLAIDS Lazio, ⁴ANLAIDS Mantova, ⁵ANLAIDS Onlus - Progetto Scuola
- P 153 Knowledge and sources of information on HIV from a large sample of Italian students in the five-year period 2013-2018**
M. Galli^{1,2,5}, L. Oreni¹, M. Pedretti², E. Zambon², T. Ferrario², R. Galipò³, M. Longhi⁴, G. Del Bene^{2,5}, B. Marchini⁵
¹UOC clinicizzata di Malattie Infettive, DIBIC L. Sacco – UNIMI, ²ANLAIDS Sezione Lombardia, ³ANLAIDS Lazio, ⁴ANLAIDS Mantova, ⁵ANLAIDS Onlus - Progetto Scuola
- P 154 ANLAIDS programme on HIV/AIDS/STI prevention among high school students in Milan metropolitan Area, in collaboration with Department of Biomedical and Clinical Sciences 'L.Sacco' (DIBIC) – UNIMI and SISM of Milan**
M. Pedretti¹, E. Bonomessi¹, G. Del Bene¹, M. Massa¹, E. Zambon¹, E. Torazzi³, M. Galli^{1,2}
¹Anlaids Sezione Lombardia, ²Department of Biomedical and Clinical Sciences 'L.Sacco' (DIBIC)-UNIMI, ³SISM Milano Humimed
- P 155 "EXTERNA" project development: from linkage to care to quality of life for people living with HIV**
A. Antonino¹, G. Fracca², A. Bianchi³, F. Rossi⁴, N. Gianotti⁵, A. Castagna⁶, M. Cernuschi⁷
Associazione Solidarietà AIDS, Centro S. Luigi HSR
- P 156 Chemsex behaviours in HIV risk populations in Padova: a case-control analysis**
V. Vazzoler¹, L. Sassef², L. Fabbris¹, A.M. Cattelan²
¹Dipartimento di Scienze Statistiche, Università di Padova, Padova, ²UOC Malattie infettive e Tropicali - Azienda Ospedaliera e Università di Padova, Padova
- P 157 Ma.S.D.HIV project: survey on sexually transmitted diseases, sexual behaviors and drug abuse in HIV-positive young patients**
V. Rizzo¹, M.A. Carleo¹, V. Penta², V. Iodice², P. Rosario¹, M. D'Abbraccio¹, A. Busto¹, R. Viglietti², V. Sangiovanni², V. Esposito¹
¹UOC Immunodeficienze e Malattie Infettive di genere, Ospedale Cotugno, Napoli, ²UOC Infezioni Sistemiche e dell'immunodepresso, Ospedale Cotugno, Napoli
- P 158 Chemsex and related additional risk factors for HIV positive MSM: preliminary results from the Screening chemsex study**
P. Vinti¹, M. Cernuschi^{1,2}, A. Castagna², S. Bossolasco², S. Nozza², C. Raddato², A. Bianchi¹, M. Lanza¹, E. Messina², V. Spagnuolo², M. Maillard²
¹ASA onlus, Milano, ²IRCCS Ospedale San Raffaele, Milano
- P 159 Therapy adherence, emotional awareness and cardiovascular risk in persons with HIV**
S.A. Sofia¹, C. Iacobello¹, G. Pantò¹, B. Cocopardo², B.M. Celesia²
¹Unit of Infectious Diseases, Cannizzaro Hospital, Catania, ²Unit of Infectious Diseases, University of Catania, ARNAS Garibaldi, Catania
- P 160 HIV related stigma in a cohort of patients chronically treated in eastern Sicily**
L. Vinci, B. Cocopardo, B.M. Celesia
Unit of Infectious Diseases. University of Catania. ARNAS Garibaldi Catania
- P 161 Survey on human papillomavirus (HPV) knowledge and perception in a sample of MSM population**
A. Marcandalli
C.I.G. - Arcigay Milano, Milano
- P 162 HIV Auto-test and PrEP in Milan's pharmacies: a survey**
D. Calzavara, D. Deserti, S. Betti, M. Corbetta, D. Papagna, M. Pilloni
CIG - Arcigay Milano
- P 163 Risk of developing body dysmorphic disorders in HIV-infected individuals assessed by self-reported questionnaires. The VIGOR Study**
F. De Zottis¹, G. Passavanti¹, M.M. Plazzi¹, A. Giannetti¹, R. Bellagamba¹, S. Cicalini¹, G.M. Corbelli², A. Antinori¹, A. Ammassari¹
¹Istituto Nazionale per le Malattie Infettive Lazzaro Spallanzani IRCCS, Roma, ²PLUS Onlus, Bologna
- P 164 What do Italian people think about PrEP for HIV prevention in 2018/2019? A network analysis approach to social representation: a new survey**
A. Toscano¹, A. Bignardi², L. Gozzi²
¹Polo Universitario di Milano - Università degli Studi eCampus, ²Centro Studi Airone, Taranto, ³Arcigay "Matthew Shepard", Modena
- P 165 Peer Education -SISM**
E. Clemente, D. Rosini
SISM - Segretariato Italiano Studenti in Medicina, Anlaids

11° CONGRESSO NAZIONALE



**Italian Conference on
AIDS and Antiviral Research**

Promosso da



5-7 GIUGNO 2019
UNIVERSITÀ DEGLI STUDI DI MILANO

Presidenza del Congresso
Antonella Castagna
Antonella d'Arminio Monforte
Massimo Puoti
Giuliano Rizzardini

GENERAL INFORMATION





GENERAL INFORMATION

Conference Venue

Università degli Studi di Milano

Via Festa del Perdono, 7 - 20122 Milan

www.unimi.it



How to reach the Conference Venue

Public transportation



By tram

Line 12, 19, 24: Missori stop

By bus

Line 65, 94: Ospedale Policlinico stop

By underground

Line M1 (red): Duomo stop

Line M3 (yellow): Missori stop



Car

Milan is served by a very extensive highway system: to the west from the A8 (from Como to Varese), the A4 (from Turin), the A7 (from Genoa), the A1 (from Bologna). To the east, the A1 and the A4 to Bergamo



Airport

10 km from Linate airport

50 Km from Malpensa airport



Railway Station

From Milan Central Station take underground M3 (yellow), direction S. Donato, Missori stop

From Cadorna Station take underground M1 (red), direction Sesto 1° Maggio, Duomo stop





Official languages

Italian and English. No simultaneous translation provided.

Pre-conference advanced Courses and Congress dates

Pre-conference advanced Courses: Wednesday, June 5 from 13.30 to 16.00

Conference: from Wednesday, June 5 at 16.00 to Friday, June 7 at 17.15

Conference Secretariat opening times

Wednesday, June 5	Thursday, June 6	Friday, June 7
from 10.00 to 20.45	from 08.00 to 18.00	from 08.00 to 17.15

Lunches (Porticato San Nazaro)

Wednesday, June 5	Thursday, June 6	Friday, June 7
only for Courses participants from 12.30 to 13.30	from 12.30 to 14.30	from 12.30 to 14.30

Exhibition Area opening times

Wednesday, June 5	Thursday, June 6	Friday, June 7
from 13.30 to 20.45	from 09.00 to 18.00	from 09.00 to 17.15



GENERAL INFORMATION

Instructions for Speakers

It is not possible to bring presentations directly to the lecture hall. All presentations have to be handed over at the Slide Center Room at least **2 hours before the session**. At the Slide Center Room, Speakers will have the possibility of:

- Reviewing power-point presentations
- Last minute changes of power-point presentations
- Being supported by technical staff
- Uploading power-point presentation in the dedicated session conference room

All Speakers are requested to start their presentations with a Disclosure of Potential Conflicts of Interest slide.

Oral Communication Sessions

Selected abstract will be presented in Oral Communication Sessions. Authors of the selected abstract are requested to attend their sessions and **provide max 8/10 (Microsoft Power Point) slides** resuming their abstract. Time allowed for **presentation: 10 minutes followed by 2 minutes for discussion**.

All Speakers are requested to start their presentations with a Disclosure of Potential Conflicts of Interest slide.

Poster Discussion Sessions

Selected abstract will be presented in Oral Discussion Sessions. Authors of the selected abstract are requested to attend their sessions and **provide max 5 (Microsoft Power Point) slides** resuming their poster. Time allowed for **presentation: 5 minutes followed by 3 minutes for discussion**.

All Speakers are requested to start their presentations with a Disclosure of Potential Conflicts of Interest slide.

Authors can set up their posters according to the number received from the Organizing Secretariat on **June 5 from h. 10.00 and remove them on June 7 at the end of the Congress.**

Poster Exhibition

ICAR Poster exhibition will take place within a dedicated area of the Congress Center. Dimensions should not exceed 70x100 cm. Authors can set up their posters according to the number received from the Organizing Secretariat on **June 5 from h. 10.00 and remove them on June 7 at the end of the Congress.**



OFFICIAL
 EVENTS

Quick test for HIV and HCV

At Piazza S. Francesca Romana:

(next to Buenos Aires – V.le Regina Giovanna cross) on:

- **Saturday, June 1 from 15.00 to 20.00**

At University of Milan (Cortile d’Onore):

- **Wednesday, June 5 from 13.00 to 17.00**
- **Thursday, June 6 from 09.00 to 13.00 and from 14.00 to 17.00**
- **Friday, June 7 from 09.00 to 15.30**



Healthcare personnel from IRCCS Ospedale San Raffaele, ASST Santi Paolo e Carlo - Ospedale San Paolo, ASST Grande Ospedale Metropolitano Niguarda and ASST Fatebenefratelli Sacco - Ospedale Luigi Sacco will perform free rapid testing for HIV and HCV at the request of citizens in a confidential and anonymous way. The test is noninvasive, requires few minutes and is highly reliable.

*Con la sponsorizzazione non condizionante di Gilead Sciences
 In collaborazione con Meridian Bioscience e Cepheid*

RaccontART HIV

Wednesday June 5, Conference venue

- **Aula 201, from 13.30 to 16.00**
 Presentation of the finalist works
- **Aula Magna, from 17.30**
 Winners' Awards

The art competition launched by ICAR to students who are invited to present their views on HIV/AIDS through various forms of expression. During the Conference Opening Session the winners will be awarded by the Jury composed of leading representatives of the national cultural world, ICAR Scientific Coordinators and Patients' Community. *See pages 20 and 23*

Realizzato con il contributo di Janssen





SPECIAL AWARDS

The work of young researchers and community representatives continues to be widely recognized by ICAR, not only through Scholarships, but also with special prizes. The 11th edition of ICAR awards as follows:



ICAR-CROI Awards 2019

The absolute winners among the young Italian investigators who presented their work at CROI in Seattle 2019:

- 1 Award** of € 1.000,00 for the best work in **Clinical**
- 1 Award** of € 1.000,00 for the best work in **Basic Science**

Winners will be announced during the ICAR-CROI Awards 2019 session in Aula Magna on Wednesday June 5 from 17.00.



ICAR 2019 Scientific Committee Awards

The 11th ICAR Chairs and Scientific Secretariat will recognize the "Scientific Committee Awards": the ICAR awards to the best abstracts:

- 3 Awards** of € 1.000,00 each one for **Clinical (1 Award), Basic Science (1 Award) and Social Science (1 Award)**.

Winners will be announced during the ICAR 2019 Special Awards Session in Aula Magna on Friday June 7 from 16.45.



SIMIT Special Awards

The 11th ICAR Chairs and Scientific Secretariat wish to thank SIMIT for the Special Awards addressed to Young Investigators:

- 5 Awards** of € 2.000,00 each for the best abstracts accepted as Oral Communications in **Clinical HIV (3 Awards), Clinical HCV (1 Award), Virology and Immunopathogenesis (1 Award)**, presented by young Investigators (under 45 aa), regularly registered to SIMIT for years 2018 and 2019.

Abstracts will be selected at the Congress Venue by a dedicated SIMIT Commission and winners will be announced during the ICAR 2019 Special Awards Session in Aula Magna on Friday June 7 from 16.45.



ICAR FOR PARTICIPANTS



ICAR 2019 App – The news of the 11th ICAR!

Realizzato con il contributo di Janssen

Designed to facilitate participation in ICAR 2019 and to respond to request for effective and high-performance digital tools and supports. Two simple steps to access:

1. **Download the ICAR App for free** from the main markets (Apple Store and Google Play)
"Minimum system requirements required for the App: Android 6.0 and iOS 10"
2. **Login App:** enter your personal login credentials (username e password) sent to you by the Organizing Secretariat Effetti

Menu Functions

HOME: Simple and immediate with a usability designed specifically for the Conference. Each Menu item corresponds to a precise and useful feature.

MY BUSINESS CARD: The most innovative App's function is My Business Card: the electronic QR Code contains User's information (name, surname, e-mail and profession). Users show their QR code, instead of giving their own business paper card.

MY AGENDA: Users can customize their own Agenda using this function. ICAR 2019 App will create the list of favorite selected sessions in a chronological order.

ICAR COMMITTEES: The complete list of ICAR 2019 Committees

FACULTY: The complete list of ICAR 2019 Faculty

KEYNOTE SPEAKERS: Pictures and Curriculum of the Keynote Lectures' Speakers

PROGRAMME AT A GLANCE: Users discover the Programme, rooms and timetable in a quick and practical way

SCIENTIFIC PROGRAMME: Complete Scientific Programme day by day with detailed information about each session (title, speaker, time, room). Users can also select favorite Lectures, clicking on the calendar icon: those will be saved in My Agenda

ABSTRACTS: All abstracts accepted, broken down by type of presentation (Oral, Poster Discussion, Exhibition) and the Abstract Reviewers. From June 5, the Abstract Repository at your fingertips with keyword search, Authors names, Abstract IDs, etc.

ICAR-CROI AWARDS: The winners of the ICAR-CROI Awards 2019 with their Mentors

RACCONTART HIV: To access the Art Contest, consult the works in competition, learn about participating schools, and much more

QUICK TEST FOR HIV AND HCV: Where, when and at what times: all the appointments of the Quick test for HIV and HCV

ICAR SOCIAL: Direct links to ICAR 2019 Social Network Pages. Stay connected and post contents, pictures, stories! #ICAR2019

GENERAL INFORMATION: A menu item for the most useful and important links: Congress Venue, Transportation, Pharmacies and much more ...

MESSAGES: A useful function to receive Messages from the Organizing Secretariat in real time

NOTES: Users have the possibility to take notes during Scientific Sessions and send them to their own e-mail addresses

Realizzato con il contributo di Janssen



ICAR FOR PARTICIPANTS



Community Village

A specific area of the Congress Venue dedicated to the Community Village: a meeting point for all the participants to visit the booths of HIV/AIDS and Hepatitis patient associations and meet the Community activists. *See page 86*



Nice to ICAR you

The Secretary Meeting point where all registered participants can ask for ICAR T-shirt.



Poster-4-you

A free service for selected posters' Authors to create and print their own posters and pick them up at the Poster exhibition area inside the Congress Venue.

ICAR Poster-4-you USB Pendrive can be requested showing the coupon at the Gilead Sciences booth.

Con la sponsorizzazione non condizionante di Gilead Sciences



Abstract USB Pendrive

All registered participants can ask for the **ICAR Abstract USB Pendrive** showing the coupon at ViiV Healthcare booth: it contains all accepted abstracts.

Con il supporto incondizionato di ViiV Healthcare



Website and Web Repository

After the Congress, the ICAR official website (www.icar2019.it) will publish the ICAR 2019 web repository with abstracts, presentations, oral communications, accepted posters, podcasts and photo gallery.

Social Media

 www.facebook.com/ICARcongress

 www.twitter.com/ICARcongress



CME
ACCREDITATION

Conference



The 11th ICAR Conference has been accredited to the Italian Ministry of Health for 14,7 CME Credits.

Every single day has been accredited for the following professionals:

Id ECM Number	Credits	Professionals
Wednesday, June 5 150-248085	2,8	Medical Doctor (all disciplines) Healthcare Assistant, Biologist, Pharmacist, Nurse, Medical laboratory technician, Psychologist
Thursday, June 6 150-248089	6,3	
Friday, June 7 150-248090	5,6	

Pre-conference advanced Courses

The 11th ICAR advanced Courses have been accredited to the Italian Ministry of Health for each single course:

Id ECM Number	Credits	Professionals
Viral reservoir as obstacle to cure 150-260113	2	Medical Doctor Infectious and Tropical Diseases; Hygiene, Epidemiology and Public Health; Microbiology and Virology; Allergology and Clinical Immunology; Internal Medicine; Gastroenterology Biologist, Medical laboratory technician
Ageing with HIV infection: new scenarios and new challenges 150-260118	2	Medical Doctor Infectious and Tropical Diseases; Geriatrics; Hygiene, Epidemiology and Public Health; Microbiology and Virology; Allergology and Clinical Immunology; Internal Medicine; Gastroenterology; Pharmacology Biologist, Hospital Pharmacist
Prevention and treatment of sexually transmitted diseases (STDs) 150-260135	2	Medical Doctor Infectious and Tropical Diseases; Dermatology; Hygiene, Epidemiology and Public Health; Microbiology and Virology; Allergology and Clinical Immunology; Internal Medicine; Gastroenterology; Pharmacology, Psychiatry Biologist, Healthcare Assistant, Hospital Pharmacist, Professional educator, Psychologist
HIV and chronic viral hepatitis: the strategic role of the nurse 150-260142	2	Nurse, Biologist, Professional educator, Psychologist, Healthcare Assistant, Medical Doctor Infectious and Tropical Diseases; Gastroenterology; Hygiene, Epidemiology and Public Health; Internal Medicine, Psychiatry



CME ACCREDITATION

Obtaining CME credits

Participants

To obtain credits, registered participants are required to:

- Wear the identification badge during working sessions
- Provide their signature and write entrance/exit times before and after attending working sessions
- Complete assessment and satisfaction questionnaires for each day

Speakers

Speakers will be given 1 credit for each half-hour of consecutive teaching.

Speakers, moderators and discussants can decide to obtain credits as participants (see Participants).

Attendance Tracking

Attendance will be tracked through participants' signature at the start/end of each day, and through assessment and satisfaction questionnaires.

CME Certificates

Credits will be given only if a participant attends 90% of the working sessions and provides correct answers to at least 75% of the questions included in the final assessment questionnaire. The Provider will send CME certificates to the participants after the Conference.



Pre-conference advanced Courses

Free of charge (registrations available on a “first come, first served” basis).

Registration includes: congress kit (delegate bag, badge, certificate of attendance), CME registration and materials, working brunch and coffee breaks during the day of the course.

Conference

Conference Registration Fees (22% VAT not included)

Physicians	€ 700,00
Physicians < 35 years of age, Biologist, Biotechnologist, Pharmacist, Nurse, Psychologist	€ 310,00
Students/PhD and Post-graduate medical trainees	Free
Members of HIV/AIDS Community	Free

The registration fee includes: congress kit (delegate bag, badge, certificate of attendance), Opening Session and Welcome Cocktail on June 5, coffee breaks and lunches on June 6 and 7, CME registration, Conference USB/abstract and poster.

Daily Conference registration fees (22% VAT not included)

Physicians	€ 300,00
Physicians < 35 years of age, Biologist, Biotechnologist, Pharmacist, Nurse, Psychologist	€ 150,00
Students/PhD and Post-graduate medical trainees	Free
Members of HIV/AIDS Community	Free

The registration fee includes: attendance to the sessions of the day, congress kit (delegate bag, badge, certificate of attendance), Conference USB/abstract and poster, coffee break and lunch for the day, certificate of attendance for the sessions of the day.

11° CONGRESSO NAZIONALE



**Italian Conference on
AIDS and Antiviral Research**

Promosso da




5-7 GIUGNO 2019
UNIVERSITÀ DEGLI STUDI DI MILANO

Presidenza del Congresso
Antonella Castagna
Antonella d'Arminio Monforte
Massimo Puoti
Giuliano Rizzardini



CONGRESS
MAP



CONGRESS
 MAP





PIANO RIBASSATO
VILLAGGIO COMMUNITY
AULA 113
HOSPITALITY SUITE MSD
HOSPITALITY SUITE COMMUNITY















- A**
- B**
- C**

PIANO TERRA ESTERNO
 SEGRETERIA ORGANIZZATIVA
 TEST RAPIDO
 AREA POSTER
 NICE TO ICAR YOU
 PIAZZA ICAR
 AREA LUNCH/COFFEE BREAK



PIANO TERRA
 AREA ESPOSITIVA
 CENTRO SLIDE
 GUARDAROBA
 AULA MAGNA
 HOSPITALITY SUITE GILEAD




ia Festa del Perdono, 7

D 	G 	L 	O 
E 	H 	M 	P 
F 	I 	N 	Q 


PIANO 1
AREA ESPOSITIVA
AULA 211
AULA 201
AREA POSTER
SALA MALLIANI
UFFICIO STAMPA





PIANO 1
AULA CROCIERA

**AULA
CROCIERA
PIANO 1**



THANKS TO THE SPONSORS

The Chairs, the Scientific Secretariat and CME Provider wish to thank the following Companies for the support given to the Congress, as unrestricted educational grants:

PLATINUM



GOLD



SILVER



OTHERS





Congress Venue
Università degli Studi di Milano
 Via Festa del Perdono, 7 - 20122 Milan, I

Provider and Organizing Secretariat
Effetti srl

Via G.B. Giorgini, 16 - 20151 Milan, I
 Tel. +39 02 3343281
 Fax +39 02 38002105
 icar2019@effetti.it
 @ICARcongress



Download the ICAR App for free from the main markets (Apple Store and Google Play)

"Minimum system requirements required for the App: Android 6.0 and iOS 10"



www.icar2019.it

Seguici su:   #ICAR2019